<SEC-DOCUMENT>0001493152-25-028431.txt : 20251219
<SEC-HEADER>0001493152-25-028431.hdr.sgml : 20251219
<ACCEPTANCE-DATETIME>20251219061524
ACCESSION NUMBER:		0001493152-25-028431
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20251219
DATE AS OF CHANGE:		20251219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001335105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				202903526
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278874
		FILM NUMBER:		251584907

	BUSINESS ADDRESS:	
		STREET 1:		433 PLAZA REAL
		STREET 2:		SUITE 275
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432
		BUSINESS PHONE:		310 203 2902

	MAIL ADDRESS:	
		STREET 1:		433 PLAZA REAL
		STREET 2:		SUITE 275
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRKP 7 INC
		DATE OF NAME CHANGE:	20050803
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
pursuant to Rule 424(b)(5)</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Statement No. 333-278874</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
Prospectus Dated May 2, 2024)</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_001.jpg" ALT=""></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"></P>



<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>526,342
Shares of Common Stock, Pre-Funded Warrants to Purchase up to 525,000 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Warrants to Purchase up to 1,051,342 Shares of Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to 525,000 Shares of Common Stock Underlying the Pre-Funded Warrants</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to 1,051,342 Shares of Common Stock Underlying the Common Warrants</B></FONT></P>
<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are offering 526,342 shares of our common stock, par value $0.0001 per share (&ldquo;Common Stock&rdquo;), pre-funded warrants (the &ldquo;Pre-Funded
Warrants&rdquo;) to purchase up to 525,000 shares of our Common Stock, and accompanying common warrants to purchase up to 1,051,342 shares
of common stock (the &ldquo;Common Warrants&rdquo;, and together with the Pre-funded Warrants, the &ldquo;Warrants&rdquo;) (and the common
stock issuable from time to time upon exercise of such Warrants) at (i) a combined offering price of $4.09 per share of common stock
and accompanying Common Warrant to purchase common stock for each share of Common Stock purchased, and (ii) a combined offering price
of $4.08999 per Pre-funded Warrant to purchase one share of Common Stock and accompanying Common Warrant to purchase one share of Common
Stock for each Pre-funded Warrant purchased, in each case in this offering pursuant to this prospectus supplement, the accompanying prospectus,
and a securities purchase agreement entered into on December 18, 2025 (the &ldquo;Purchase Agreement&rdquo;), between the Company and
certain accredited investors thereto (the &ldquo;Purchasers&rdquo;). Each Pre-Funded Warrant will have an exercise price of $0.00001,
will be immediately exercisable, and is valid and exercisable until all Pre-Funded Warrants are exercised in full. Each Common Warrant
will have an exercise price of $3.96, will be exercisable immediately and expire 60 months after the initial issuance date. This prospectus
supplement also relates to the offering of the shares of Common Stock issuable upon exercise of such Pre-Funded Warrants and Common Warrants,
respectively.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on the Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;. The last sale price of our Common Stock on December
17, 2025, as reported by the Nasdaq Capital Market, was $3.96 per share. There is no established public trading market for the Pre-funded
Warrants or the Common Warrants, and we do not expect a market to develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2025, the aggregate market value of our outstanding Common Stock held by non-affiliates was $35,514,491 based on 7,476,735
shares of outstanding Common Stock, of which 11,000 shares were held by affiliates, and a per share price of $4.75 based on the closing
sale price of our Common Stock on November 12, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in a public primary offering with a value exceeding
more than one-third of our public float in any 12-month period so long as our public float remains below $75,000,000. During the prior
12 calendar month period that ends on and includes the date of this prospectus supplement, we sold securities pursuant to General Instruction
I.B.6. of Form S-3 aggregating $2,550,003 (excluding this offering).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in any of our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-18 of this prospectus supplement
and page 4 of the accompanying prospectus and in other documents that are incorporated by reference.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have retained Spartan Capital Securities, LLC (&ldquo;Spartan&rdquo; or the &ldquo;Placement Agent&rdquo;) to act as our exclusive placement
agent in connection with the securities offered by this prospectus supplement and the accompanying prospectus. Spartan is not purchasing
or selling any of these securities nor is it required to sell any specific number or dollar amount of securities, but has agreed to use
its reasonable best efforts to sell the securities offered by this prospectus supplement and the accompanying prospectus and the Placement
Agent is not required to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay Spartan
a cash fee equal to 6.0% of the aggregate gross proceeds raised in this offering, as set forth in the table below.</FONT></P>
<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Share</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
                                            Pre-Funded</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant</FONT></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public offering price</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.09</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.08999</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,299,988.78</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent fees<SUP>(2)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.2454</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.2454</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">257,999.33</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds, before expenses, to us</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.8446</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.8446</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,041,989.45</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    proceeds from the assumed exercise of the Pre-Funded Warrants in cash.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have also agreed to reimburse the Placement Agent for the fees and disbursements of its legal counsel in the amount of $85,000. See
    &ldquo;Plan of Distribution&rdquo; beginning on page S-25 of this prospectus supplement for additional information regarding the
    compensation we will pay the Placement Agent.</FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery
of the securities offered pursuant to this prospectus supplement and the accompanying prospectus is expected to be made on or about December
19, 2025, subject to the satisfaction of certain closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>
<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"></P>



<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Spartan
Capital Securities, LLC</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is December 18, 2025.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_001">About
    This Prospectus Supplement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_002">Cautionary
    Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-<FONT STYLE="font-size: 10pt">1</FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_003">Prospectus
    Supplement Summary</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_004">The
    Offering</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_005">Risk
    Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_006">Dividend
    Policy</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_007">Dilution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_008">Use
    of Proceeds</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_009">Description
    of Securities</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_010">Plan
    of Distribution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-25</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_011">Legal
    Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_012">Experts</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_013">Where
    You Can Find More Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-27</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#me_014">Incorporation
    of Documents By Reference</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-27</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_001">ABOUT
    THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_002">NOTE
    ABOUT FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_003">PROSPECTUS
    SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_004">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_005">THE
    SECURITIES WE MAY OFFER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_006">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_007">DESCRIPTION
    OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_008">DESCRIPTION
    OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_009">DESCRIPTION
    OF WARRANTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_010">DESCRIPTION
    OF RIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_011">DESCRIPTION
    OF UNITS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_012">LEGAL
    OWNERSHIP OF SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_013">PLAN
    OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_014">LEGAL
    MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_015">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_016">WHERE
    YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_017">INFORMATION
    INCORPORATED BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should rely only upon the information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus
and any related free writing prospectus required to be filed with the Securities and Exchange Commission. We have not, and Spartan has
not, authorized any person to provide you with different or additional information. If anyone provides you with different or additional
information, you should not rely upon it. We are not, and Spartan is not, making an offer to sell these securities in any jurisdiction
where such offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement, the accompanying
prospectus, any applicable free writing prospectus and the documents incorporated by reference herein or therein is accurate only as
of the respective dates of these documents or such other dates as may be specified therein. Our business, financial condition, liquidity,
results of operations and prospects may have changed since those dates.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_001"></A>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus relate to the sale of our securities registered for sale under our Registration
Statement on Form S-3 (File No. 333-278874) (the &ldquo;Registration Statement&rdquo;), which the Securities and Exchange Commission
(the &ldquo;Commission&rdquo; or the &ldquo;SEC&rdquo;) declared effective on May 2, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus form part of a registration statement that we filed with the Securities and Exchange
Commission, or the SEC. This document is in two parts. The first part is this prospectus supplement, which describes the specific terms
of this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by
reference herein or therein. The second part, the accompanying prospectus, provides more general information. Generally, when we refer
to this prospectus, we are referring to both parts of this document combined. If the description of this offering varies between this
prospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus supplement, which supersedes
the information in the accompanying prospectus. This prospectus supplement contains information about the securities offered in this
offering and may add, update or change information in the accompanying prospectus. Before you invest in any of the securities offered
under this prospectus supplement, you should carefully read both this prospectus supplement and the accompanying prospectus together
with the additional information described under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
of Certain Information by Reference.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering to sell, and seeking offers to buy, securities only in jurisdictions where offers and sales are permitted. The distribution
of this prospectus supplement and the accompanying prospectus and the offering of the securities in certain jurisdictions may be restricted
by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must
inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus
supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not
constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by
this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person
to make such an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus,
the documents incorporated by reference into this prospectus supplement or the accompanying prospectus, and in any free writing prospectus
that we may authorize for use in connection with this offering. We have not, and the Placement Agent has not, authorized any other person
to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on
it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
in this prospectus supplement and the accompanying prospectus to the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;Lixte&rdquo;
or the &ldquo;Company&rdquo; or other similar terms mean Lixte Biotechnology Holdings, Inc. and its consolidated subsidiaries, unless
we state otherwise or the context indicates otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_002"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying
prospectus and any free writing prospectus that we may authorize for use in connection with this offering contain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section 21E of the
Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). All statements, other than statements of historical fact,
that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements
regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and
future products and product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have identified some of these forward-looking statements with words such as &ldquo;believe&rdquo;, &ldquo;may&rdquo;, &ldquo;will&rdquo;,
&ldquo;should&rdquo;, &ldquo;could&rdquo;, &ldquo;expect&rdquo;, &ldquo;intend&rdquo;, &ldquo;plan&rdquo;, &ldquo;predict&rdquo;, &ldquo;anticipate&rdquo;,
&ldquo;estimate&rdquo;, &ldquo;continue&rdquo; or other words and terms of similar meaning and the use of future dates. These forward-looking
statements are based on current expectations about future events affecting us and are subject to uncertainties and factors relating to
our operations and business environment, all of which are difficult to predict and many of which are beyond our control and could cause
our actual results to differ materially from those matters expressed or implied by our forward-looking statements. Forward-looking statements
are only predictions or statements of current plans and can be affected by inaccurate assumptions we might make or by known or unknown
risks and uncertainties, including the risks described under the &ldquo;Risk Factors&rdquo; sections that are contained in this prospectus
supplement on page S-18, in the accompanying prospectus and in our filings with the SEC that are incorporated by reference into this
prospectus supplement and the accompanying prospectus, including, without limitation, the &ldquo;Risk Factors&rdquo; sections of our
most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Such risks and uncertainties are not exclusive and
further information concerning us and our business, including factors that potentially could materially affect our financial results
or condition, may emerge from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks of which you should be aware of before making an investment decision. Some of these risks include
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are engaged in early-stage research and as such might not be successful in our efforts to develop a portfolio of commercially viable
    products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses
    for the foreseeable future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    need significant additional financing to fund our operations and complete the development and, if approved, the commercialization
    of our lead product candidate, LB-100. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate
    our product development programs or commercialization efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently have no source of revenues. We might never generate revenues or achieve profitability;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to use net operating losses to offset future taxable income might be subject to limitations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical-stage
    biopharmaceutical companies with product candidates in clinical development face a wide range of challenging activities which might
    entail substantial risk;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might find it difficult to enroll patients in our clinical trials which could delay or prevent the start of clinical trials for our
    product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our lead product candidate
    in clinical trials, and any other product candidates that might advance into clinical trials, might not have favorable results in
    later clinical trials or receive regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    drug development involves a lengthy and expensive process with an uncertain outcome;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    is a risk that one or more of our clinical trials could be placed on hold by regulatory authorities due to serious adverse events
    (SAEs) related to our drug candidate or to another company&rsquo;s drug used in combination in one of our clinical trials. It is
    possible that the SAEs could be attributable to our drug candidate and could include, but not be limited to, unexpected severe side
    effects, treatment-related deaths, or long-term health complications. A dose given could result in non-tolerable adverse events defined
    as dose-limiting toxicity (DLT). When two DLTs occur at the same dose-level that dose-level is considered too high and unsafe. Further
    treatment is only allowed at lower dose-levels that have previously been found safe.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with operating in foreign countries could materially adversely affect our product development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects
    or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label
    or result in significant negative consequences following any regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product development program might not uncover all possible adverse events that patients who take our lead product candidate may experience.
    The number of subjects exposed to our lead product candidate and the average exposure time in the clinical development program might
    be inadequate to detect rare adverse events or chance findings that might only be detected once the product is administered to more
    patients and for greater periods of time;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    future success is dependent on the regulatory approval of our lead product candidate;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    lead product candidate and future product candidates could fail to receive regulatory approval from the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to obtain regulatory approval in international jurisdictions would prevent our lead product candidate from being marketed abroad;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if our current primary product candidate receives regulatory approval, it might still face future development and regulatory difficulties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on certain key scientific personnel for our success who do not work full time for us. The loss of any such personnel could
    adversely affect our business, financial condition and results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to rely heavily on third parties for the conduct of clinical trials of our product candidates. If these clinical trials are
    not successful, or if we or our collaborators are not able to obtain the necessary regulatory approvals, we will not be able to commercialize
    our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    interruptions could adversely affect future operations, revenues, and financial conditions, and might increase our costs and expenses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to find third party collaborators to assist or share in the costs of product development could materially harm our business,
    financial condition or results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims by third parties asserting that our employees, consultants, collaborators contractors or we have misappropriated
    their intellectual property, or claiming ownership of what we regard as our own intellectual property;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    cannot be certain we will be able to obtain patent protection to protect our product candidates and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not obtain patent term extension in the United States under the Hatch-Waxman Act or in foreign countries under similar legislation,
    our business might be materially harmed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with our obligations in agreements under which we have licensed or, might license, intellectual property rights
    from third parties, or if we otherwise experience disruptions to our business relationships with our licensors, we could lose rights
    that are important to our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us
    from commercializing or increase the costs of commercializing our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade
    secrets of one or more third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    intellectual property might not be sufficient to protect our intended products from competition, which might negatively affect our
    business as well as limit our partnership or acquisition appeal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are not able to protect and control our unpatented trade secrets, know-how and other technological innovation, we might suffer
    competitive harm;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might incur substantial costs prosecuting our patent applications, maintaining our patents and patent applications, enforcing our
    patents, defending against third party patent infringement suits, seeking invalidation of third party patents or in-licensing third
    party intellectual property, as a result of litigation or other proceedings relating to patent and other intellectual property rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to protect our intellectual property rights, our competitors might develop and market products with similar or identical
    features that might reduce demand for our potential products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    commercial success depends upon attaining significant market acceptance of our current product candidate and future product candidates,
    if approved, among physicians, patients, healthcare payors and cancer treatment centers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are able to commercialize our lead product candidate or any future product candidates, the products might not receive coverage
    or adequate reimbursement from third party payors in the United States and in other countries in which we seek to commercialize our
    intended products, which could harm our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
    legislative measures aimed at reducing healthcare costs might have a material adverse effect on our business and results of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
    controls might be imposed in foreign markets, which might adversely affect our future profitability;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    relationships with customers and third party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare
    laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished
    profits and future earnings. If we or they are unable to comply with these provisions, we might become subject to civil and criminal
    investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    employees might engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
    which could cause significant liability for us and harm our reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that
    we might develop;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face substantial competition, which might result in others discovering, developing or commercializing products before or more successfully
    than we do;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    disruptions of information technology systems, computer system failures or breaches of information and cyber security could adversely
    affect our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might need to grow the size of our organization in the future, and we might experience difficulties in managing this growth;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inadequate
    funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other
    personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those
    agencies from performing normal business functions on which the operation of our business might rely, which could negatively impact
    our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unstable
    market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may
    have serious adverse consequences on our business, financial condition and stock price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a &ldquo;smaller reporting company&rdquo; and we have elected to comply with certain reduced reporting and disclosure requirements
    which could make its common stock less attractive to investors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    price of our common stock might fluctuate substantially;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    sale or perceived sale of a substantial number of shares of our common stock might cause the price of our common stock to decline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    and economic conditions might negatively impact our business, financial condition and share price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business,
    our stock price and trading volume might decline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    sales and issuances of our common stock could result in additional dilution of the percentage ownership of our stockholders and could
    cause our share price to fall;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be at risk of securities class action litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Certificate of Incorporation and our Amended and Restated Bylaws, and Delaware law might have anti-takeover effects that could discourage,
    delay or prevent a change in control, which might cause our stock price to decline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be
    required to devote substantial time to compliance matters; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with the rules under Sarbanes-Oxley related to accounting controls and procedures in the future, or, if we discover
    material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
    and raising capital could be more difficult.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to maintain compliance with the continued listing requirements of the Nasdaq Capital Market.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
forward-looking statement is based on information available to us as of the date of the document in which the forward-looking statement
is contained. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise, except as otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
forward-looking statements that are made by us in this prospectus supplement, in the accompanying prospectus, in the documents incorporated
by reference into this prospectus supplement and the accompanying prospectus and in any free writing prospectus that we may authorize
for use in connection with this offering are qualified by these cautionary statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are not guarantees of future performance, and actual results may differ materially due to risks and uncertainties, including
those discussed under &ldquo;Risk Factors&rdquo; and in our filings with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_003"></A>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary highlights selected information about us, this offering and information contained elsewhere in or incorporated by reference
into this prospectus supplement or the accompanying prospectus. This summary does not contain all the information that may be important
to you. Before purchasing any of the Common Stock that we are offering, you should carefully read in their entirety this prospectus supplement
and the accompanying prospectus, including the documents incorporated by reference into this prospectus supplement and the accompanying
prospectus, and any free writing prospectus that we may authorize for use in this offering. In particular, you should carefully review
the &ldquo;Risk Factors&rdquo; sections that are contained in this prospectus supplement on page S-18, in the accompanying prospectus
and in our filings with the SEC that are incorporated by reference into this prospectus supplement and the accompanying prospectus, including,
without limitation, the &ldquo;Risk Factors&rdquo; sections of our most recently filed Annual Report on Form 10-K and Quarterly Report
on Form 10-Q.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing
cancer therapies. Our product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which are used to enhance cytotoxic
agents, radiation, immune checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant
therapeutic potential for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor,
referred to as LB-100, which has been shown to have clinical anti-cancer activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the mechanism by which LB-100 affects cancer cell growth is different from cancer agents currently approved for clinical
use. LB-100 is currently being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable (MSS) Colon
Cancer, and Advanced Soft Tissue Sarcoma. LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma,
and medulloblastoma, all cancers of neural tissue. LB-100 has also been shown to enhance the effectiveness of commonly used anti-cancer
drugs in animal models of melanoma, breast cancer and sarcoma. The enhancement of anti-cancer activity of these anti-cancer drugs occurs
at doses of LB-100 that do not significantly increase toxicity in animals. It is therefore hoped that, when combined with standard anti-cancer
regimens against many tumor types, LB-100 will improve therapeutic benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment
at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, we have allocated resources
to expand the breadth and depth of its patent portfolio. Our approach has been to operate with a minimum of overhead, moving compounds
forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain milestones are reached.
Our longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical companies with
major programs in cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
activities are subject to significant risks and uncertainties, including the need for additional capital. We have not yet commenced any
revenue-generating operations, do not have positive cash flows from operations, rely on stock-based compensation for a substantial portion
of employee and consultant compensation, and are dependent on periodic access to equity capital to fund its operating requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2025, the Company, entered into a Share Exchange Agreement with Orbit Capital Inc., a Cayman Islands corporation (&ldquo;Orbit
Capital&rdquo;) and Liora Technologies Europe Ltd., a corporation organized under the laws of England and Wales (&ldquo;Liora&rdquo;)
which is wholly-owned by Orbit Capital. Pursuant to the Share Exchange Agreement, the Company purchased from Orbit Capital all of the
issued and outstanding ordinary shares of Liora in exchange for the consideration set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liora
was formed on October 7, 2025, and, on November 11, 2025, acquired certain assets from Advanced Oncotherapy PLC pursuant to an asset
purchase agreement. These assets include intellectual property and goodwill, technology, hardware, software, digital assets and all of
the other assets, property or rights relating to the LIGHT (Linac Image Guided Hadron Therapy), a proton-based radiotherapy solution.
Liora&rsquo;s equipment and operations are located at the Daresbury Laboratory in Warrington, United Kingdom pursuant to a lease agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the closing, the Company agreed to pay the following consideration to Orbit Capital: (i) 2,700 shares of the Company&rsquo;s Series C
Preferred Stock, $1,000 stated value per share, which are non-voting and are convertible into an aggregate of 2,700,000 shares of the
Company&rsquo;s common stock, subject to a 19.99% conversion limitation until the Company obtains shareholder approval; (ii) pay 10.56
Bitcoin and 300 Ethereum; (iii) pay $440,000 in cash; and (iv) enter into a royalty agreement with Orbit Capital that entitles the Orbit
Capital to receive a royalty equal to ten percent (10%) of net revenues generated from the operation, use, licensing, monetization or
sale of and the LIGHT equipment, up to a maximum aggregate royalty payment of $45,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Share Exchange was consummated on November 24, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Royalty Agreement was subsequently terminated on December 16, 2025.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
cancer patients are treated with either chemotherapy or immunotherapy or both. These therapies often have limited benefit and there is
a high unmet medical need to enhance their effects. In many preclinical models we have shown that LB-100 enhances the effect of both
chemotherapy and Immunotherapy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LB-100,
a small molecule potent inhibitor of PP2A, was designed and developed by us. Numerous preclinical studies have documented that LB-100
potentiates most if not all anti-cancer drugs that damage DNA. LB-100 is not associated with any increase in cytotoxicity when given
with cytotoxic drugs. This synergy involves transient interruption of several DNA damage repair pathways by LB-100 and an increase in
cell division rate. LB-100 has FDA Investigational New Drug status in the US and Investigational Medicinal Product Dossier approval in
the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its initial Phase 1 clinical trial, LB-100 given alone daily for 3 days was non-toxic, except for a transient increase in serum creatinine
believed to be caused by inhibition of PP2A in the renal tubules. In the Phase 1 clinical trial, the Maximum Tolerated Dose (&ldquo;MTD&rdquo;)
was 2.33mg/m2 daily for 3 days every 3 weeks. Of the 25 patients with heavily-treated advanced solid tumors with measurable disease,
3 patients had stable disease for 2 cycles, 3 patients had stable disease for 4 cycles, and 3 patients had stable disease for 6 cycles.
One patient with pancreatic cancer had a partial response after 12 cycles lasting 534 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
doses of LB-100 have now been shown to enhance immune checkpoint inhibition (&ldquo;ICI&rdquo;) by several different mechanisms affecting
the tumor compartment and immune T-cell compartment. LB-100 increases CD8+T-cell infiltration and CD8-Treg ratio, CD8+T-cell proliferation,
and cytokine production induces microsatellite instability, neoantigen production and immune responsiveness, converting immunologically
&ldquo;cold&rdquo; to &ldquo;hot&rdquo; cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="form424b5_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ovarian
clear cell carcinoma patients with inactivating mutations in PPP2R1A, a gene coding for a scaffold component of PP2A, and treated with
immune checkpoint inhibitors, were recently found to have markedly longer survival than patients without the mutation in their cancers.
Retrospective reviews of patients with a variety of cancers treated with ICI or chemotherapy show much longer survival of ICI-treated
patients with a PPP2R1A mutation in their tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_004.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the observations in ovarian clear cell carcinoma, we have initiated a clinical trial in this disease combining LB-100 with a monoclonal
antibody blocking PD-1, a protein found on T-cells (NCT06065462).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
these preclinical and clinical observations, it is likely that LB-100 may be a general way to enhance immunotherapy responses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_005.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research on the LB-100 series was initiated in 2006 under a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) with
the National Institute of Neurologic Disorders and Stroke or NINDS of the National Institutes of Health or NIH dated March 22, 2006 that
was subsequently extended through a series of amendments until it terminated on April 1, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also designed and developed the LB-200 series, which consists of histone deacetylase inhibitors (HDACi). LB-200 has not advanced
to the clinical stage and would require additional capital to fund further development. Accordingly, because of our focus on the clinical
development of LB-100 and analogs for cancer therapy as described below in more detail, we have decided not to actively pursue the preclinical
development of our LB-200 series of compounds at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Trial Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spanish
Sarcoma Group Collaboration Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 31, 2019, we entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group
(Grupo Espa&ntilde;ol de Investigaci&oacute;n en Sarcomas or &ldquo;GEIS&rdquo;), Madrid, Spain, to carry out a study entitled &ldquo;Randomized
phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma&rdquo;. The purpose of
this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined with doxorubicin in soft tissue
sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (&ldquo;ASTS&rdquo;). Doxorubicin
alone has been the mainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding cytotoxic
compounds to or substituting other cytotoxic compounds for doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor
activity of doxorubicin without apparent increases in toxicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEIS
has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative
studies in ASTS. We agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as well as to
provide funding for the clinical trial. The goal is to enter approximately 150 to 170 patients in this clinical trial over a period of
two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended Phase 2 dose
of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase 2 portion of
the study assumes a median progression-free survival (&ldquo;PFS&rdquo;), no evidence of disease progression or death from any cause)
of 4.5 months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a
statistically significant decrease in relative risk of progression or death by adding LB-100. There is a planned interim analysis of
the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, we announced that the Spanish Agency for Medicines and Health Products (Agencia Espa&ntilde;ola de Medicamentos y Productos
Sanitarios or &ldquo;AEMPS&rdquo;) had authorized a Phase 1b/randomized Phase 2 study of LB-100, our lead clinical compound, plus doxorubicin,
versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS). Consequently, this clinical
trial commenced during the quarter ended June 30, 2023 and to be completed and a report prepared by December 31, 2026. In April 2023,
GEIS completed its first site initiation visit in preparation for the clinical trial at Fundaci&oacute;n Jim&eacute;nez D&iacute;az University
Hospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment phase of the Phase 1b portion of the protocol
was completed during the quarter ended September 30, 2024. We expect to have data on toxicity and preliminary efficacy from this portion
of the clinical trial during the quarter ending December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the focus on the combination of LB-100 with immunotherapy in ovarian clear cell carcinoma and colorectal cancer and the availability
of capital resources, we entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved us of the
financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration Agreement of approximately
$3,095,000. As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
Research Support Agreement Relating to Small Cell Lung Cancer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had executed a Clinical Research Support Agreement with the City of Hope National Medical Center to carry out a Phase 1b clinical trial
of LB-100 combined with an FDA-approved standard regiment for treatment of untreated extensive-stage disease small cell lung cancer.
The clinical trial was initiated on March 9, 2021. However, due to the lack of patient accrual, the Company provided notice to the City
of Hope National Medical Center of our intent to terminate the Clinical Research Support Agreement effective as of July 8, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MD
Anderson Cancer Center Clinical Trial</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2023, we announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to
a human programmed death receptor-1 (&ldquo;PD-1&rdquo;) blocking antibody of GSK plc (&ldquo;GSK&rdquo;), dostarlimab-gxly, may enhance
the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (&ldquo;OCCC&rdquo;). The clinical trial is being
sponsored by The University of Texas MD Anderson Cancer Center (&ldquo;MD Anderson&rdquo;) and is being conducted at The University of
Texas &ndash; MD Anderson Cancer Center. We are providing LB-100 and GSK is providing dostarlimab-gxly and financial support for the
clinical trial. On January 29, 2024, we announced the entry of the first patient into this clinical trial. We currently expect that this
clinical trial will be completed by December 31, 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2025, we announced that we had added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern
University as a second site in a clinical trial combining the Company&rsquo;s proprietary compound LB-100 with GSK&rsquo;s dostarlimab
to treat ovarian clear cell cancer. Patient recruitment is underway, and the first patient has been dosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands
Cancer Institute Clinical Trial</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 10, 2024, we entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (&ldquo;NKI&rdquo;) to conduct a Phase
1b clinical trial of the Company&rsquo;s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary
molecule of F. Hoffman-La Roche Ltd. (&ldquo;Roche&rdquo;), for patients with microsatellite stable metastatic colon cancer. Under the
agreement, we will provide our lead clinical compound, LB-100, and under a separate agreement between NKI and Roche, Roche will provide
atezolizumab and financial support for the clinical trial. We have no obligation to and will not provide any reimbursement of clinical
trial costs. Pursuant to the agreement and the protocol set forth in the agreement, the clinical trial will be conducted by NKI at NKI&rsquo;s
site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and NKI will be responsible for the recruitment of patients. The
agreement provides for the protection of the respective intellectual property rights of each of Lixte, NKI and Roche.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment
of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can
enhance the body&rsquo;s immune response against cancer and hinder tumor growth and spread. LB-100 has been found to improve the effectiveness
of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell surfaces. Blocking PP2A increases stress signals
in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment efficacy for metastatic
colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended
Phase 2 dose (RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate
the preliminary efficacy, safety, tolerability, and pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical
trial opened in August 2024 with the enrollment of the first patient. Patient accrual is expected to take up to 24 months, with a maximum
of 37 patients with advanced colorectal cancer to be enrolled in this study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shelf life of the batch of LB-100 being utilized in this clinical trial was scheduled to expire on December 25, 2025, but has been extended
for a final time for a period of 12 months through December 25, 2026, after which date no new patients can be recruited into this clinical
trial and no patients can be treated with the current batch of LB-100. Although we do not currently intend to commission the production
of a new batch of LB-100 for this clinical trial, we believe that it is likely that we will be able to recruit enough patients in sufficient
time into this clinical trial to be able to reach an evaluable outcome for all end points in this clinical trial by December 25, 2026.
The expiration of the shelf life of this batch of LB-100 represents an effective termination date of this clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious
Adverse Events (&ldquo;SAEs&rdquo;) observed in the clinical trial that was launched in August 2024. The Investigational Review Board
(IRB) of the Netherlands Cancer Institute has requested additional information with respect to these SAEs and the study has been paused
for enrollment until the IRB&rsquo;s questions have been, as more fully discussed below at &ldquo;Risks Related to the Development and
Regulatory Approval of Our Product Candidates - <I>A clinical trial hold due to serious adverse events could delay or halt the development
of our product candidate&rdquo;.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Cancer Institute Pharmacologic Clinical Trial</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic clinical trial. This study was being conducted
and funded by the NCI under a Cooperative Research and Development Agreement, with the Company being required to provide the LB-100 clinical
compound.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
malignant brain tumors (gliomas) are very challenging to treat. Radiation combined with the chemotherapeutic drug temozolomide has been
the mainstay of therapy of the most aggressive gliomas (glioblastoma multiforme or GBM) for decades, with little further benefit gained
by the addition of one or more anti-cancer drugs, but without major advances in overall survival for the majority of patients. In animal
models of GBM, the Company&rsquo;s novel protein phosphatase inhibitor, LB-100, has been found to enhance the effectiveness of radiation,
temozolomide chemotherapy treatments and immunotherapy, raising the possibility that LB-100 may improve outcomes of standard GBM treatment
in the clinic. Although LB-100 has proven safe in patients at doses associated with apparent anti-tumor activity against several human
cancers arising outside the brain, the ability of LB-100 to penetrate tumor tissue arising in the brain was not known. Many drugs potentially
useful for GBM treatment do not enter the brain in amounts necessary for anti-cancer action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove
one or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100
present and to determine whether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its
molecular target. As a result of the innovative design of the NCI study, it was believed that data from a few patients would be sufficient
to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding LB-100 to the standard treatment
regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.
Results of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative
methods of drug delivery will be required to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme
and other aggressive brain tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
and License Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Institute of Health</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 23, 2024, we entered into a Patent License Agreement (the &ldquo;License Agreement&rdquo;) with the National Institute of Neurological
Disorders and Stroke (&ldquo;NINDS&rdquo;) and the National Cancer Institute (&ldquo;NCI&rdquo;), each an institute or center of the
National Institute of Health (&ldquo;NIH&rdquo;). Pursuant to the License Agreement, we have licensed exclusively NIH&rsquo;s intellectual
property rights claimed for a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) subject invention co-developed with
the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer
drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis, until the expiration
of the last-to-expire valid claim of the jointly owned licensed patent rights in each such country in the licensed territory, unless
sooner terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement contemplates that we will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive
cancer centers) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be
the subject of various regulatory filings for marketing approval in applicable countries in the licensed territories. Subject to the
receipt of marketing approval, we would be expected to commercialize the licensed products in markets where regulatory approval has been
obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Significant Agreements and Contracts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands
Cancer Institute</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2021, we entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (&ldquo;NKI&rdquo;),
one of the world&rsquo;s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center,
for a term of three years. The Development Collaboration Agreement was subsequently modified by Amendment No. 1 thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<BR>
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Development Collaboration Agreement is a preclinical study intended to identify the most promising drugs to be combined with LB-100,
and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying
the identified combinations. We agreed to fund the preclinical study, at an approximate cost of 391,000 Euros and provide a sufficient
supply of LB-100 to conduct the preclinical study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, we entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional research
activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added 500,000
Euros to the operating budget being funded by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, we entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment No. 2
and provided for a new study term of one year and starts upon the dosing of the first patient in the clinical trial at a project cost
of 100,000 Euros.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of June 15, 2022, Dr. Ren&eacute; Bernards was appointed to our Board of Directors as an independent director. Dr. Bernards is a leader
in the field of molecular carcinogenesis and is employed by NKI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property includes proprietary know-how, proprietary methodologies and extensive clinical validation data and publications.
To provide legal protection of our intellectual property, we rely on a combination of patents, licenses, trade secrets, trademarks, confidentiality
and non-disclosure clauses and agreements, and other forms of intellectual property protection to define and protect our rights to our
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are expected to be covered by our patents. These patents now cover sole rights to the composition and synthesis of our LB-100
series of drugs, which is the Company&rsquo;s lead clinical compound in development. Lixte has filed patent applications covering the
treatment of cancer with LB-100. Lixte has also filed joint patent applications with the NIH and the Netherlands Cancer Institute for
the treatment of cancer using LB-100 in combination with other drugs like immune checkpoint inhibitors and WEE1 inhibitors (a class of
drugs that target and inhibit the WEE1 kinase enzyme that plays a crucial role in regulating cell division).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
applications for the LB-100 series (oxabicycloheptanes and oxabicycloheptenes) have been filed in the United States and internationally
under the Patent Cooperation Treaty. Patents for composition of matter and for several uses of the LB-100 series have been issued in
the United States, Mexico, Australia, Japan, China, Hong Kong, Canada, and by the European Patent Office</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development
of our business, including seeking, maintaining, and defending its patent rights, which are owned solely by our wholly-owned Delaware
subsidiary, Lixte Biotechnology, Inc., except in several instances jointly with one of many of our collaborators. We also rely on trade
secrets relating to its proprietary pipeline of product candidates and on know-how and continuing technological innovation to develop
and strengthen its pipeline. We intend to rely on regulatory protection afforded by regulatory agencies through data exclusivity, market
exclusivity, and patent term extensions, where available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in large part on its ability to obtain and maintain patent and other proprietary protection for commercially important
technology, inventions and know-how related to its business; defend and enforce its patents; preserve the confidentiality of its trade
secrets; and operate without infringing valid and enforceable patents or proprietary rights of third parties. Our ability to stop third
parties from making, using, selling, offering to sell, or importing our technology may depend on the extent to which we have rights under
valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, enforcement of these rights may
depend on cooperation of the joint owners of our jointly owned patents and patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to both our solely and jointly owned intellectual property, we cannot be sure that patents will be granted on any of its pending
patent applications or on any patent applications filed solely or jointly by us in the future; we cannot be sure that any of our existing
patents or any patents that may be granted to us in the future will be commercially useful in protecting our intended commercial products
or therapeutic methods; and we cannot be sure that an agency or court would determine that the our solely or jointly owned patents are
valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a history of operating losses since inception. Because we are currently engaged in various early-stage clinical trials, it is expected
that it will take a significant amount of time and resources to develop any product or intellectual property capable of generating sustainable
revenues. Accordingly, our business is unlikely to generate any sustainable operating revenues in the next several years and may never
do so. Even if we are able to generate revenues through licensing our technology, product sales or other commercial activities, there
can be no assurance that we will be able to achieve and maintain positive earnings and operating cash flows. As discussed further in
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources&rdquo;
included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is incorporated herein by reference, our
auditor has included a &ldquo;going concern&rdquo; explanatory paragraph in its report on our consolidated financial statements for the
fiscal year ended December 31, 2024, expressing substantial doubt about our ability to continue as a going concern for the next twelve
months. Our consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty. If
we cannot secure the financing needed to continue as a viable business, our shareholders may lose some or all of their investment in
us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated as a Delaware Corporation on May 24, 2005 under the name SRKP7, Inc. On June 30, 2006, pursuant to a share exchange
agreement, we acquired all of the outstanding shares of Lixte Biotechnology, Inc. which then became a wholly owned subsidiary. On December
7, 2006, we changed our name to Lixte Biotechnology Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 26, 2023, Bastiaan van der Baan, a director of the Company since June 17, 2022, replaced our founder, John S. Kovach, as President
and Chief Executive Officer. Dr. Kovach passed away on October 5, 2023. Effective October 6, 2023, Mr. van der Baan was appointed as
Chairman of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed below, effective June 16, 2025, Mr. van der Baan resigned as Chairman of the Board of Directors and Chief Executive Officer,
but remained as President and as a member of the Board of Directors, and was appointed as the Company&rsquo;s Chief Scientific Officer,
and Geordan Pursglove was appointed as Chairman of the Board of Directors and Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock and public warrants are traded on the Nasdaq Capital Market under the symbols &ldquo;LIXT&rdquo;. On June 2, 2023, we effected
a one-for-ten reverse split of our outstanding shares of common stock in order to remain in compliance with the $1.00 minimum closing
bid price requirement of the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
principal address is 433 Plaza Real, Suite 275, Boca Raton, FL 33432. Our telephone number is (631) 830-7092. We maintain a website at
<U>https://lixte.com</U>. The information contained on our website is not, and should not be interpreted to be, incorporated into this
prospectus.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Management and Director Changes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to and effective as of the consummation of the $5,050,000 private placement on July 2, 2025, there have been several changes with respect
to our executive management and the Board of Directors as described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bastiaan
van der Baan. </B>Effective June 16, 2025, Bastiaan van der Baan resigned as Chairman of the Board of Directors and as Chief Executive
Officer, but remained as President and as a member of the Board of Directors, and was appointed as Chief Scientific Officer. Mr. van
der Baan&rsquo;s principal responsibility as President will be related to the clinical development of our LB-100 lead compound. His responsibility
as Chief Scientific Officer (CSO) will be for shaping and executing the scientific vision and research and development strategy of the
Company, with a focus on discovering and developing innovative cancer therapeutics. The CSO leads all research functions, oversees preclinical
and translational programs, supervises the Chief Medical Officer, and ensures alignment with clinical and regulatory development goals.
The CSO provides scientific leadership to internal teams and external partners, supports fundraising and business development, and serves
as a key member of executive management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with such resignation, the stock option that Mr. van der Baan was previously granted on September 26, 2023 to acquire 250,000
shares of common stock was deemed fully vested effective with Mr. van der Baan&rsquo;s resignation as described herein, and the time
period for Mr. van der Baan to exercise his stock option at any time in the future that he is no longer providing his services to the
Company as a consultant, employee or otherwise was increased from ninety (90) days to one (1) year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the previously described changes in Mr. van der Baan&rsquo;s management duties and the modifications to the terms of the stock option,
Mr. van der Baan&rsquo;s three (3) year employment agreement dated September 26, 2023 will remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company does not complete a successful financing that enables it to maintain its listing on the Nasdaq Small Cap Market by July 3,
2025, the amendment to Mr. van der Baan&rsquo;s employment agreement as described herein will be automatically terminated retroactive
to the amendment date and Mr. van der Baan will be reinstated as Chairman of the Board of Directors and Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Geordan
Pursglove.</B> Effective June 16, 2025, Geordan Pursglove was appointed as our new Chairman of the Board of Directors and Chief Executive
Officer. His responsibilities include the oversight of our business operations and strategic planning, and he will be the primary contact
between our executive team and the Board of Directors. He will also be the principal spokesperson of the Company and have final say on
all corporate matters, subject only to the authority of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an employment agreement with Mr. Pursglove for a term of three (3) years effective June 16, 2025. Mr. Pursglove will
receive an annual salary of $240,000, which may be increased from time to time in the sole discretion of the Board of Directors. At his
election, his compensation will be payable in cash and/or restricted shares, or a combination thereof. He is also eligible to receive
an annual bonus as determined in the sole discretion of the Board of Directors in the form of cash or equity, or a combination thereof.
Mr. Pursglove will not receive any additional compensation for serving as the Chairman of the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of the end of the first trading day for the Company&rsquo;s common stock immediately following the consummation of this offering,
which was July 3, 2025, as an inducement for Mr. Pursglove to join our Company, as a signing bonus, he was granted a stock option to
purchase 350,000 shares of our common stock at an exercise price equal to the closing price on the Nasdaq Stock Market on such date of
$2.83 per share, which is exercisable for a term of five (5) years, provides for cashless exercise, and will vest 50% on the grant date,
25% on September 30, 2025, and 25% on December 31, 2025, subject to continued service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock option grant was not issued under the Company&rsquo;s 2020 Stock Incentive Plan. The stock option agreement provided for certain
registration rights (including on Form S-8) and for accelerated vesting upon the occurrence of certain events, including early termination
of the employment agreement that is not the result of the voluntary termination, gross negligence or willful misconduct of Mr. Pursglove,
a sale or change in control of the Company, or a sale, licensing or other disposition of all or substantially all of the assets of the
Company, as defined in such stock option agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company does not complete a successful financing that enables it to maintain its listing on the Nasdaq Capital Market by July 3,
2025, the employment agreement with Mr. Pursglove as described herein will be deemed automatically terminated retroactively as of June
16, 2025 and the stock option grant will be cancelled, and Mr. Pursglove will promptly resign from the Board of Directors. In such event,
Mr. van der Baan will be reinstated as Chairman of the Board of Directors and Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to joining the Company, Mr. Pursglove served as President, Chief Executive Officer and Chairman of the Board of Directors at Beyond Commerce,
Inc. He was also President of Service 800, Inc., a leading phone and online customer satisfaction survey service that provides the most
actionable customer feedback, to the most recognizable Fortune 500 companies globally, in which he led operations, scaled revenue, and
oversaw the company&rsquo;s strategic vision. Mr. Pursglove held a board position at SemiCab Holdings, an emerging leader in the global
logistics and distribution industry that was part of Algorhythm Holdings (NASDAQ: RIME). Currently Mr. Pursglove serves as the managing
director of The 2GP Group LLC. During his time as the Managing Director of The 2GP Group, Mr. Pursglove has built multiple businesses
in Sports, Sales, Marketing and Logistics. Mr. Pursglove has over a decade of experience in M&amp;A, public markets space, capital raising,
funding, growth, scaling businesses and driving innovation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Associated with Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Development and Regulatory Approval of Our Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
clinical trial hold due to serious adverse events could delay or halt the development of our product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of these trials could
be placed on hold by regulatory authorities due to serious adverse events (SAEs) related to our drug candidate or to another company&rsquo;s
drug used in combination in one of our clinical trials. It is possible that the SAEs could be attributable to our drug candidate and
could include, but not be limited to, unexpected severe side effects, treatment-related deaths, or long-term health complications. A
dose given could result in non-tolerable adverse events defined as dose-limiting toxicity (DLT). When two DLTs occur at the same dose-level
that dose-level is considered too high and unsafe. Further treatment is only allowed at lower dose-levels that have previously been found
safe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an SAE or a pattern of SAEs is observed during the course of a clinical trial involving our drug candidate, the U.S. Food and Drug Administration
(FDA), European Medicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring us to pause or discontinue
further enrollment and dosing in our clinical trial. It is also possible that the clinical trial could be terminated. Any of these actions
could delay or halt the development of our drug candidate, increase development costs, and negatively impact our ability to ultimately
achieve regulatory approval. Additionally, if an SAE is confirmed to be drug-related, we may be required to conduct additional studies,
modify the study design, or abandon further development of the drug candidate altogether, which could materially impact our business,
financial condition, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of an SAE and any resulting clinical hold could also harm our reputation with patients, physicians, health institutions, and
investors, diminish our ability to attract clinical trial participants, and damage our ability to interest investors and obtain financing
in the future. There can be no assurances that we will not experience such SAEs in the future or that any related clinical hold will
be lifted in a timely manner, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating
two SAEs observed in the clinical trial that was launched in August 2024. The Institutional Review Board (the &ldquo;IRB&rdquo;) of the
Netherlands Cancer Institute (&ldquo;NKI&rdquo;) has put the colorectal cancer study on hold. The adverse reactions that developed in
the two patients were dyspnea (shortness of breath) due to lung toxicity possibly or probably related to the combination of LB-100 and
atezolizumab in one patient and fever and aphasia possibly or probably related to the combination of LB-100 and atezolizumab in the second
patient. The patient who developed lung toxicity deceased due to the combination of lung metastases of colorectal cancer and dyspnea.
The patient with fever and aphasia fully recovered from the adverse events with supportive medication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the identified adverse events in the two patients in the clinical trial, the IRB requested from the principal investigator of the study
at the NKI information as to whether the adverse events could have been caused by the combination of LB-100 and atezolizumab and information
about the mode of action of the combination of LB-100 and atezolizumab. The principal investigator prepared a response to the IRB detailing
the safety experience with LB-100 given alone and in combination with other cancer drugs, especially doxorubicin and dostarlimab. Doxorubicin
is a well-known chemotherapy, and dostarlimab is a well-known immunotherapy of which the mode of action is closely related to that of
atezolizumab.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reported adverse events in the colorectal cancer study have not been seen in any other patients thus far treated with LB-100 alone or
in combination with other cancer drugs. Through early July 2025, the Company has been informed that a total of 82 patients had received
or were receiving experimental treatment with LB-100.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025, the Company updated the safety overview of LB-100 and delivered the updated version 5.0 of the Investigator&rsquo;s Brochure
(the &ldquo;IB&rdquo;), which contains all of the relevant preclinical, clinical and pharmacologic data with respect to the study of
the LB-100 clinical compound in humans, to the investigators of all ongoing clinical trials. The investigators of the study in colorectal
cancer (NCT06012734) submitted a detailed response to the IRB, including the updated IB. The Company is currently awaiting the outcome
of the IRB review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks of which you should be aware of before making an investment decision. Some of these risks include
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses
    for the foreseeable future.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could
    force us to delay, limit, reduce or terminate our product development or commercialization efforts.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently have no source of revenues. We may never generate revenues or achieve profitability.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to continue to incur significant operating and non-operating expenses, which may make it difficult for us to secure sufficient
    financing and may lead to uncertainty about our ability to continue as a going concern.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are dependent in part on technologies we license, and if we lose the right to license such technologies or we fail to license new
    technologies in the future, our ability to develop new products would be harmed, and if we fail to meet our obligations under our
    current or future license agreements, we may lose the ability to develop our product candidate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to face substantial competition, which may result in others discovering, developing or commercializing products before or
    more successfully than we do.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are currently a clinical-stage biopharmaceutical company with a product candidate in clinical development. If we are unable to successfully
    develop and commercialize our product candidate or experience significant delays in doing so, our business may be materially harmed.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success relies on third-party suppliers and manufacturers. Any failure by such third parties, including, but not limited to, failure
    to successfully perform and comply with regulatory requirements, could negatively impact our business and our ability to develop
    and market our product candidate, and our business could be substantially harmed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    future success is dependent on the regulatory approval of our product candidate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business may be adversely affected by the ongoing coronavirus pandemic.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our cost of expenses.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to find third party collaborators to assist or share in the costs of product development could materially harm our business,
    financial condition, and results of operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with our obligations under our license agreement with licensors, we could lose rights that are important to our
    business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may infringe the intellectual property rights of others, which may prevent or delay our product development efforts.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    intellectual property may not be sufficient to protect our products from competition.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: center; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: center; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48pt; text-align: center; text-indent: -24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_004"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
    Biotechnology Holdings, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock offered by us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">526,342
    shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
    Warrants offered by us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are also offering Pre-Funded Warrants to purchase up to 525,000 shares of Common Stock in lieu of shares of Common Stock to the Purchaser
    whose purchase of shares of Common Stock in this offering would otherwise result in the Purchaser, together with its affiliates and
    certain related parties, beneficially owning more than 4.99% of our outstanding Common Stock immediately following the consummation
    of this offering. Each Pre-Funded Warrant is exercisable for one share of our Common Stock. The purchase price of each Pre-Funded
    Warrant is equal to the price at which the share of Common Stock is being sold to the public, minus $0.00001 per share. The Pre-Funded
    Warrants are exercisable immediately, at an exercise price of $0.00001 per share, and may be exercised at any time until all of the
    Pre-Funded Warrants are exercised in full. This offering also relates to the shares of Common Stock issuable upon exercise of the
    Pre-Funded Warrants sold in this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Warrants offered by us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
                                            Warrants to purchase up to 1,051,342 shares of common stock. Each share of Common Stock or
                                            Pre-funded Warrant to purchase one share is being sold together with one Common Warrant to
                                            purchase one share of Common Stock. Each Common Warrant has an exercise price of $3.96 per
                                            share of Common Stock, will be immediately exercisable and will expire 60 months after the
                                            initial issuance date. The exercise price is subject to customary adjustments for stock splits
                                            and similar recapitalization transactions. The Common Stock or the Pre-funded Warrants, as
                                            the case may be, and the accompanying Common Warrants can only be purchased together in this
                                            offering but will be issued separately and will be immediately separable upon issuance. This
                                            prospectus supplement and the accompanying prospectus also relate to the offering of the
                                            common stock issuable upon exercise of the Common Warrants. See &ldquo;Description of Securities
                                            Offered&rdquo; on page S-23 of this prospectus supplement.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock to be outstanding after the offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,528,077
    shares (as of December 17, 2025), assuming the issuance of 525,000 shares of Common Stock upon the exercise of the Pre-Funded Warrants.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate the net proceeds to us from this offering will be approximately $3,841,989.45, after deducting the placement agent fee and
    estimated offering expenses payable by us. We intend to use the net proceeds from this offering for working capital and general corporate
    purposes, including for further clinical development of our lead compound LB-100. See &ldquo;Use of Proceeds&rdquo;.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    investment in our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-18 for a discussion
    of certain factors that you should consider when evaluating an investment in our securities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
    symbols</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Common Stock is listed on the Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
number of shares of our Common Stock to be outstanding after this offering as shown above is based on 7,476,735 shares of Common Stock
outstanding at December 17, 2025, and excludes any outstanding options and warrants.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, all information in this prospectus supplement assumes the exercises of the Pre-Funded Warrants offered and sold
in this offering and no exercise of outstanding options or warrants, including the Common Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following risk factors, together with the other information presented in this document or included by reference, should be considered
by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
price of our common stock might fluctuate substantially.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consider an investment in our common stock to be risky. Some factors that might cause the market price of our common stock to
fluctuate, in addition to the other risks mentioned in this &ldquo;Risk Factors,&rdquo; are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of our common stock by our stockholders, executives, and directors and our stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of our shares of common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financings to conduct and complete research and development activities including, but not limited to, our clinical
    trials, and other business activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and success of introductions of new products by us or our competitors or any other change in the competitive dynamics of our
    industry, including consolidation among competitors, customers or strategic partners;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">network
    outages or security breaches;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure resources and the necessary personnel to conduct clinical trials on our desired schedule;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement,
    enrollment or results of our clinical trials for our lead product candidate or any future clinical trials we might conduct;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the development status of our lead product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delays or adverse developments or perceived adverse developments with respect to the FDA&rsquo;s review of our planned preclinical
    and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our submission for studies or product approvals or adverse regulatory decisions, including failure to receive regulatory
    approval for our lead product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    safety concerns related to the use of our lead product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures
    to meet external expectations or management guidance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    and events surrounding financing efforts, including debt and equity securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to enter into new markets or develop new products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reputational
    issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing technologies and products or new technologies and products that might emerge;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in general economic, political and market conditions in or any of the regions in which we conduct our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in industry conditions or perceptions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in valuations of similar companies or groups of companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst
    research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures
    and additions of key personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    and litigations related to intellectual properties, proprietary rights, and contractual obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, rules, regulations, or accounting practices and other dynamics; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which might be out of our control.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences
a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition
and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and might expose us to lawsuits that,
even if unsuccessful, could be costly to defend and a distraction to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering and our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
may experience dilution of your ownership interests because of the future issuance of additional shares of Common Stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we will need to issue additional authorized but previously unissued equity securities, resulting in the dilution of the ownership
interests of our stockholders. We may also issue additional Common Stock, warrants or other securities that are convertible into or exercisable
for Common Stock in connection with hiring or retaining employees, future acquisitions, future sales of securities for capital raising
purposes, or for other business purposes. The future issuance of any such additional shares of Common Stock may create downward pressure
on the trading price of the Common Stock. There can be no assurance that we will not be required to issue additional shares, warrants
or other convertible securities in the future in conjunction with any capital raising efforts, including at a price (or exercise prices)
below the offering price of the shares of Common Stock in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management will have broad discretion over the use of the proceeds to us from this offering and may apply it to uses that do not improve
our operating results or the value of our securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the application of the net proceeds from this offering, and investors will be relying solely
on such judgment of our management regarding the application of these proceeds. Although we expect to use the net proceeds from this
offering for working capital and general corporate purposes, including the ongoing clinical development of our lead compound LB-100,
we have not allocated these net proceeds for specific purposes. Investors will not have the opportunity, as part of their investment
decision, to assess whether the proceeds are being used appropriately. Our use of the proceeds may not improve our business prospects
or increase the value of the securities being offered hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>There
is no public market for the Warrants being offered in this offering.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established public trading market for the Pre-Funded Warrants or Common Warrants being offered in this offering, respectively,
and we do not expect a market to develop. In addition, we do not intend to apply to list the Pre-Funded Warrants or Common Warrants on
any securities exchange or nationally recognized trading system. Without an active market, the liquidity of the Pre-Funded Warrants or
Common Warratns will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders
of our Warrants will have no rights as holders of Common Stock until such warrants are exercised.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
you acquire shares of Common Stock upon exercise of your Warrants, you will have no rights with respect to Common Stock issuable upon
exercise of your warrants. Upon exercise of your Warrants, you will be entitled to exercise the rights of a holder of Common Stock only
as to matters for which the record date occurs after the exercise date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Warrants are speculative in nature.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-Funded Warrants offered hereby do not confer any rights of ownership of our Common Stock on their holders, such as voting rights
or the right to receive dividends, but rather merely represent the right to acquire Common Stock at a fixed price. Specifically, commencing
on the date of issuance, holders of the Pre-Funded Warrants may acquire Common Stock issuable upon exercise of such warrants at an exercise
price of $0.00001 per common share. Moreover, following this offering, the market value of the Pre-Funded Warrants is uncertain, and
there can be no assurances that the market value of the Pre-Funded Warrants will equal or exceed their public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants, which have an exercise price of $3.96 per share of common stock, are immediately exercisable, in whole or in part, and
will expire 60 months after the initial issuance date. If our common stock price does not increase to an amount sufficiently above the
exercise price of the Common Warrants during the period during which the Common Warrants are exercisable, you will be unable to recover
any of your investment in the Common Warrants. In such event, the Common Warrants will not have any value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the market price of our common stock will ever equal or exceed the exercise price of the Common Warrants, and
consequently, whether it will ever be profitable for holders of the Common Warrants to exercise such Common Warrants<B><I>.</I></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_006"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s dividend policy is determined by its Board of Directors and will depend upon a number of factors, including the Company&rsquo;s
financial condition and performance, its cash needs and expansion plans, income tax consequences, and the restrictions that applicable
laws and any credit or other contractual arrangements may then impose. The Company has not paid any cash dividends on its common stock
to date and at the current time the Company does not anticipate paying a cash dividend on its common stock in the foreseeable future.
Rather, the Company anticipates that it will retain earnings, if any, for use in the development of its business.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_007"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of our securities in this offering will have a dilutive impact on our stockholders. As a result, our net income/(loss) per share
would decrease in future periods and the market price of our Common Stock could decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our securities in this offering, your ownership interest will be diluted to the extent of the difference between the offering
price per share of our Common Stock and accompanying Common Warrant in this offering and the as adjusted net tangible book value per
share of our Common Stock immediately after this offering. Our net tangible book value as of September 30, 2025, before this offering,
was $4,912,254 or $0.86 per share of Common Stock. Net tangible book value per share represents the amount of total tangible assets (total
assets less intangible assets) less total liabilities, divided by the number of shares of our common stock outstanding as of September
30, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As-adjusted
net tangible book value per share represents our net tangible book value per share after giving effect to the issuance and sale of all
Common Shares and Pre-Funded Warrants offered hereby (and assuming the exercise of the Pre-Funded Warrants), and after deducting Placement
Agent fees and estimated offering expenses payable by us in connection with this offering. The as-adjusted net tangible book value was
calculated on a cash basis and does not consider the potential accounting classifications of the Common Warrants or Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this per share dilution assuming the holders of the Common Warrants do not exercise any of the Common Warrants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Offering price per share and accompanying
    Common Warrant</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.09</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Historical net tangible book value per share as of September 30,2025</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.86</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase in net tangible
    book value per share attributable to this offering</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.44</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">As adjusted net tangible
    book value per share after this offering</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.30</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dilution per share to
    new investors participating in this offering</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.79</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table and calculations set forth above are based on 5,704,200 shares of Common Stock outstanding as of September 30, 2025, and assumes
no exercise of any outstanding stock options or warrants or conversion of the Series B Preferred Stock. To the extent that the Series
B Preferred Stock is converted into common stock, outstanding options or warrants are exercised, new options or other equity grants are
issued under or outside of our equity incentive plans or we otherwise issue additional shares of Common Stock in the future, there will
be further dilution to new investors participating in this offering.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_008"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assuming
all of the shares offered in this offering are sold, we estimate that our net proceeds from this offering will be approximately $3,841,989.45.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering for working capital and general corporate purposes, including for further clinical
development of our lead compound LB-100.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus supplement, the Company cannot specify with certainty all of the particular uses for the net proceeds
to be received upon the completion of this offering. The amounts and timing of its actual expenditures will depend on numerous factors,
including the status of the Company&rsquo;s drug development activities, clinical trial programs, patent expenditures, regulatory and
compliance issues, research and development activities, and other operating expenditures. Accordingly, the Company&rsquo;s management
will have broad discretion in the application of the net proceeds and investors will be relying on the judgment of its management regarding
the application of the proceeds of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_009"></A>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue 100,000,000 shares of Common Stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par
value $0.0001 per share. As of December 17, 2025, we had 7,476,735 shares of common stock outstanding. A description of the common stock
we are offering pursuant to this prospectus supplement is set forth under the heading &ldquo;Description of Capital Stock &ndash; Common
Stock&rdquo;, beginning on page S-23 of the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2023, the Company effected a 1-for-10 reverse split of its issued and outstanding shares of Common Stock. While the Certificate
of Amendment reduced the number of outstanding shares of Common Stock, it did not reduce the number of authorized shares of Common Stock
or preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of Common Stock will be entitled to receive dividends if and when declared by the board of directors from funds legally available
therefore, and, upon liquidation, dissolution or winding-up of our Company, will be entitled to share ratably in all assets remaining
after payment of liabilities. The holders of shares of Common Stock will not have any preemptive rights, but will be entitled to one
vote for each share of Common Stock held of record. Stockholders will not have the right to cumulate their votes for the election of
directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Funded
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;pre-funded&rdquo; refers to the fact that the purchase price of our Common Stock in this offering includes almost the entire
exercise price that will be paid under the Pre-Funded Warrants, except for a nominal remaining exercise price of $0.00001. The purpose
of the Pre-Funded Warrants is to enable the investor that may have restrictions on its ability to beneficially own more than 4.99% of
our outstanding Common Stock following the consummation of this offering the opportunity to make an investment in the Company without
triggering its ownership restrictions, by receiving Pre-Funded Warrants in lieu of our Common Stock which would result in such ownership
of more than 9.99% and receive the ability to exercise its option to purchase the shares underlying the Pre-Funded Warrants at such nominal
price at a later date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercisability</I>.
The holder may exercise the Pre-Funded Warrants immediately and at any time until the Pre-Funded Warrants are exercised in full. The
Pre-Funded Warrants are exercisable, at the option of the holder, in whole or in part, by delivering to us a written exercise notice
accompanied, within one trading day, by payment in full for the number of shares of our Common Stock purchased upon such exercise. The
holder of Pre-Funded Warrants does not have the right to exercise any portion of the Pre-Funded Warrant if the holder would have beneficially
owned in excess of 4.99% of the shares of our Common Stock outstanding immediately after giving effect to such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cashless
Exercise</I>. The holder may exercise its Pre-Funded Warrants on a cashless basis. When exercised on a cashless basis, a portion of the
Pre-Funded Warrants are cancelled in payment of the purchase price payable in respect of the number of shares of our Common Stock purchasable
upon such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
Price</I>. The exercise price of Common Stock purchasable upon exercise of the Pre-Funded Warrants is $0.00001 per share. The exercise
price and the number of shares issuable upon exercise of the Pre-Funded Warrants is subject to appropriate adjustment in the event of
recapitalization events, stock dividends, stock splits, stock combinations or similar events affecting our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transferability</I>.
The Pre-Funded Warrants may be transferred at the option of the holder without obtaining our consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exchange
Listing</I>. We do not plan on making an application to quote the Pre-Funded Warrants on The Nasdaq Capital Market, or any other national
securities exchange or any other trading system. Our Common Stock underlying the Pre-Funded Warrants is quoted on the Nasdaq Capital
Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
as a Stockholder</I>. Except as otherwise provided in the Pre-Funded Warrants, including the right for Pre-Funded Warrant holders to
receive the same dividends and distributions as holders of Common Stock, or by virtue of such holder&rsquo;s ownership of our Common
Stock, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders of our Common Stock, including any voting
rights, until they exercise their Pre-Funded Warrants.</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercisability</I>.
The holder may exercise the Common Warrants immediately and at any time until 60 months after the initial issuance date. The Common are
exercisable, at the option of the holder, in whole or in part, by delivering to us a written exercise notice accompanied, within one
trading day, by payment in full for the number of shares of our Common Stock purchased upon such exercise. The holder of Common does
not have the right to exercise any portion of the Common Warrant if the holder would have beneficially owned in excess of 4.99% of the
shares of our Common Stock outstanding immediately after giving effect to such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cashless
Exercise</I>. At any time when a registration statement covering the issuance or resale of the shares of Common Stock issuable upon exercise
of the Common Warrants is not effective, the holder may exercise its Common Warrants on a cashless basis. When exercised on a cashless
basis, a portion of the Common Warrants are cancelled in payment of the purchase price payable in respect of the number of shares of
our Common Stock purchasable upon such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
Price</I>. The exercise price of Common Stock purchasable upon exercise of the Common Warrants is $3.96 per share. The exercise price
and the number of shares issuable upon exercise of the Common Warrants is subject to appropriate adjustment in the event of recapitalization
events, stock dividends, stock splits, stock combinations or similar events affecting our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transferability</I>.
The Common Warrants may be transferred at the option of the holder without obtaining our consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exchange
Listing</I>. We do not plan on making an application to quote the Common Warrants on The Nasdaq Capital Market, or any other national
securities exchange or any other trading system. Our Common Stock underlying the Common Warrants is quoted on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
as a Stockholder</I>. Except as otherwise provided in the Common Warrants, including the right for Common Warrant holders to receive
the same dividends and distributions as holders of Common Stock, or by virtue of such holder&rsquo;s ownership of our Common Stock, the
holders of the Common Warrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, until
they exercise their Common Warrants.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_010"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spartan
has agreed to act as our exclusive placement agent in connection with this offering subject to the terms and conditions of the Placement
Agent Agreement dated December 18, 2025 (the &ldquo;Placement Agent Agreement&rdquo;). Spartan is not purchasing or selling any of the
shares of Common Stock offered by this prospectus supplement and the accompanying prospectus, nor is it required to arrange the purchase
or sale of any specific number or dollar amount of shares of Common Stock, but has agreed to use its reasonable best efforts to arrange
for the sale of all of the shares of Common Stock offered hereby. Therefore, we may not sell the entire amount of shares of Common Stock
being offered. The terms of this offering were subject to market conditions and negotiations between us, Spartan and prospective investors.
The engagement agreement does not give rise to any commitment by Spartan to purchase or sell any of our shares of Common Stock, and Spartan
will have no authority to bind us by virtue of the engagement agreement. Spartan may engage sub-agents or selected dealers to assist
with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into Purchase Agreements directly with the Purchasers in connection with this offering. We will only sell to such investors
who have entered into the Purchase Agreement with us. The Purchase Agreements contain customary representations, warranties and covenants.
The offering is expected to close on or about December 19, 2025, subject to satisfaction of customary closing conditions.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees
and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged Spartan as our exclusive placement agent in connection with this offering. This offering is being conducted on a reasonable
&ldquo;best efforts&rdquo; basis and the Placement Agent has no obligation to buy any of the securities from us or to arrange for the
purchase or sale of any specific number or dollar amount of securities. We have agreed to pay the Placement Agent a placement fee equal
to 6% of the aggregate gross proceeds as set forth in the table below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Share</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Pre-Funded<BR> Warrant</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public offering price</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.09</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.08999</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,299,988.78</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent fees<SUP>(2)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.2454</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.2454</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">257,999.33</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds, before expenses, to us</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.8446</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.8446</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,041,989.45</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    proceeds from the assumed exercise of the Pre-Funded Warrants in cash.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have also agreed to reimburse the Placement Agent for the fees and disbursements of its legal counsel in the amount of $85,000. See
    &ldquo;Plan of Distribution&rdquo; beginning on page S-25 of this prospectus supplement for additional information regarding the
    compensation we will pay the Placement Agent.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the total expenses payable by us for this offering to be approximately $200,000 (excluding the Placement Agent fee of $257,999.33).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
M</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements
of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and
Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the
Placement Agent acting as principal. Under these rules and regulations, the Placement Agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    not engage in any stabilization activity in connection with our securities; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted
    under the Exchange Act, until it has completed its participation in the distribution.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the Spartan and specified other persons against certain liabilities relating to or arising out of Spartan&rsquo;s
activities under the Placement Agent Agreement and to contribute to payments that the Spartan may be required to make in respect of such
liabilities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
placement agent, in its sole discretion, may release the Common Stock and other securities subject to the lock-up agreements described
above in whole or in part at any time. When determining whether or not to release Common Stock and other securities from lock-up agreements,
the placement agent will consider, among other factors, the holder&rsquo;s reasons for requesting the release, the number of shares of
Common Stock and other securities for which the release is being requested and market conditions at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination
of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price of the securities we are offering was negotiated between us and the investors, in consultation with the placement
agent based on the trading of our Common Stock prior to the offering, among other things. Other factors considered in determining the
public offering price of the securities we are offering include our history and prospects, the stage of development of our business,
our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions
of the securities markets at the time of the offering and such other factors as were deemed relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock is listed on the Nasdaq Capital Market under the symbols &ldquo;LIXT&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
transfer agent and registrar for our common stock is Vstock Transfer.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Activities and Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent and certain of its affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment,
hedging, financing and brokerage activities. The Placement Agent and certain of its affiliates may in the future perform various commercial
and investment banking and financial advisory services for us, for which they will receive customary fees and expenses. However, except
as disclosed in this prospectus supplement, we have no present arrangements with the Placement Agent for any services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus may be made available in electronic format on websites or through other online services maintained by the placement agent
or by an affiliate. Other than this prospectus, the information on the placement agent&rsquo;s website and any information contained
in any other website maintained by the placement agent is not part of this prospectus or the registration statement of which this prospectus
forms a part, has not been approved and/or endorsed by us or the placement agent, and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the placement agent that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may
not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection
with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will
result in compliance with the applicable rules and regulations of that jurisdiction. Persons who come into possession of this prospectus
are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_011"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock offered hereby will be passed upon for us by Sichenzia Ross Ference Carmel LLP, New York, NY.
The Placement Agent is being represented by Kaufman &amp; Canoles, P.C., Richmond, Virginia, in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_012"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weinberg
&amp; Company, P.A., our independent, registered public accounting firm, has audited our consolidated financial statements as of December
31, 2024 and 2023 and for the years then ended included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024,
which is incorporated by reference into this prospectus and elsewhere in the registration statement of which this prospectus is a part.
Our consolidated financial statements are incorporated by reference in reliance on Weinberg &amp; Company P.A.&rsquo;s report, which
includes an explanatory paragraph regarding substantial doubt about the Company&rsquo;s ability to continue as a going concern, given
on their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_013"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and current reports, proxy statements and other information with the SEC, which are available at the SEC&rsquo;s
website at http://www.sec.gov. In addition, we maintain a website that contains information about us at http://www.lixte.com. The information
found on, or otherwise accessible through, our website is not incorporated into, and does not form a part of, this prospectus supplement
or any other report or document we file with or furnish to the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-3 (File No. 333-278874) under the Securities Act with respect to the shares
of common stock offered by this prospectus supplement. When used in this prospectus supplement, the term &ldquo;registration statement&rdquo;
includes amendments to the registration statement as well as the exhibits, schedules, financial statements and notes filed as part of
the registration statement or incorporated by reference therein. This prospectus supplement, which constitutes a part of the registration
statement, omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review
the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the common
stock we are offering by this prospectus supplement. Statements herein concerning any document we filed as an exhibit to the registration
statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings.
You should review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the SEC
at the address listed above or from the SEC&rsquo;s website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="me_014"></A>INCORPORATION
OF DOCUMENTS BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement is part of the registration statement but the registration statement includes and incorporates by reference additional
information and exhibits. The SEC permits us to &ldquo;incorporate by reference&rdquo; the information contained in documents we file
with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including
them in this prospectus supplement. Information that is incorporated by reference is considered to be part of this prospectus supplement
and you should read it with the same care that you read this prospectus supplement. Information that we file later with the SEC will
automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus supplement,
and will be considered to be a part of this prospectus supplement from the date those documents are filed. We have filed with the SEC,
and incorporate by reference in this prospectus supplement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Current Reports on Form 8-K, filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225001069/form8-k.htm" STYLE="-sec-extract: exhibit">January
    6, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225006285/form8-k.htm" STYLE="-sec-extract: exhibit">February
    13, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225007865/form8-k.htm" STYLE="-sec-extract: exhibit">February
    21, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225008203/form8-k.htm" STYLE="-sec-extract: exhibit">February
    25, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225008203/form8-k.htm" STYLE="-sec-extract: exhibit">March
    11, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225009782/form8-k.htm" STYLE="-sec-extract: exhibit">March
    11, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225009786/form8-k.htm" STYLE="-sec-extract: exhibit">March
    14, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225010282/form8-k.htm" STYLE="-sec-extract: exhibit">March
    27, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225001763/form8-k.htm" STYLE="-sec-extract: exhibit">March
    31, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225005466/form8-k.htm" STYLE="-sec-extract: exhibit">April
    18, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225011701/form8-k.htm" STYLE="-sec-extract: exhibit">May
    20, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/form8-k.htm" STYLE="-sec-extract: exhibit">June
    17, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225017653/form8-k.htm" STYLE="-sec-extract: exhibit">July
    3, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225018256/form8-k.htm" STYLE="-sec-extract: exhibit">July
    8, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225018684/form8-k.htm" STYLE="-sec-extract: exhibit">July
    11, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225019900/form8-k.htm" STYLE="-sec-extract: exhibit">July
    16, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225020408/form8-k.htm" STYLE="-sec-extract: exhibit">July
    21, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225023628/form8-k.htm" STYLE="-sec-extract: exhibit">August
    14, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225024680/form8-k.htm" STYLE="-sec-extract: exhibit">August
    19, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225026448/form8-k.htm" STYLE="-sec-extract: exhibit">September
    4, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225027109/form8-k.htm" STYLE="-sec-extract: exhibit">September
    11, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/form8-k.htm" STYLE="-sec-extract: exhibit">November
    25, 2025</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225027219/form8-k.htm" STYLE="-sec-extract: exhibit">December
    11, 2025</A>;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225009575/form10-q.htm" STYLE="-sec-extract: exhibit">May
    12, 2025</A>; our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225022517/form10q.htm" STYLE="-sec-extract: exhibit">August
    7, 2025</A>; our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315225021941/form10-q.htm" STYLE="-sec-extract: exhibit">November
    12, 2025</A> and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000164117225000208/form10-k.htm" STYLE="-sec-extract: exhibit">Form
    10-K</A> for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934,
as amended, prior to the termination of the offering (excluding any information furnished rather than filed) shall be deemed to be incorporated
by reference into this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information
that we have &ldquo;furnished&rdquo; to the SEC pursuant to the Securities Exchange Act of 1934, as amended, shall be incorporated by
reference into this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference in this
prospectus supplement, including exhibits to these documents. You should direct any requests for documents to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lixte
Biotechnology Holdings, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680
East Colorado Boulevard, Suite 180</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pasadena,
California 91101</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:
(631) 830-7092</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
also may access these filings on our website at http://www.lixte.com. We do not incorporate the information on our website into this
prospectus supplement or any supplement to this prospectus and you should not consider any information on, or that can be accessed through,
our website as part of this prospectus supplement or any supplement to this prospectus (other than those filings with the SEC that we
specifically incorporate by reference into this prospectus supplement or any supplement to this prospectus).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus supplement will be deemed
modified, superseded or replaced for purposes of this prospectus supplement to the extent that a statement contained in this prospectus
supplement modifies, supersedes or replaces such statement. Any statement contained herein or in any document incorporated or deemed
to be incorporated by reference shall be deemed to be modified or superseded for purposes of the registration statement of which this
prospectus supplement forms a part to the extent that a statement contained in any other subsequently filed document which also is or
is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not
be deemed to constitute a part of the registration statement of which this prospectus supplement forms a part, except as so modified
or superseded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dated
May 3, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="form424b5_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>$50,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Debt
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may offer and sell up to an aggregate amount of $50,000,000 of any combination of the securities described in this prospectus
in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise
of any securities registered hereunder, including any applicable antidilution provisions. We may sell the securities to or through underwriters
and also to other purchasers or through agents. The names of any underwriters or agents, and any fees, discounts or other compensation
payable to them will be set forth in the applicable prospectus supplement accompanying this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide the specific terms of these offerings in one or more supplements to this prospectus. We may also authorize one or more free
writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing
prospectus may also update or change information contained in this prospectus. You should carefully read this prospectus, the applicable
prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any
of the securities being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;. On April 30, 2024, the last reported sale price
of our common stock on The Nasdaq Capital Market was $2.76 per share. As of April 30, 2024, the aggregate market value of our outstanding
shares of Common Stock held by non-affiliates was $6,049,771 based on 2,249,290 shares of common stock outstanding, of which 2,191,946
shares were held by non-affiliates on such date, and based on a closing sale price of our common stock of $2.76 per share on that date.
Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding
1/3 of our public float in any 12-month period so long as our public float remains below $75,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters, dealers, or
through a combination of these methods on a continuous or delayed basis. See &ldquo;Plan of Distribution&rdquo; in this prospectus. We
may also describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters
or dealers are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their
names and the nature of our arrangements with them in a prospectus supplement. The price to the public of such securities and the net
proceeds we expect to receive from any such sale by us will also be included in a prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves significant risks. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk
Factors&rdquo; beginning on page 4 of this prospectus and in any applicable prospectus supplement and free writing prospectuses we have
authorized for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by
reference into this prospectus or any prospectus supplement or free writing prospectuses.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>The
date of this prospectus is May 3, 2024.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 31; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>TABLE
OF CONTENTS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Page</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_001">ABOUT
    THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_002">NOTE
    ABOUT FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_003">PROSPECTUS
    SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_004">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_005">THE
    SECURITIES WE MAY OFFER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_006">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_007">DESCRIPTION
    OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_008">DESCRIPTION
    OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_009">DESCRIPTION
    OF WARRANTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_010">DESCRIPTION
    OF RIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_011">DESCRIPTION
    OF UNITS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_012">LEGAL
    OWNERSHIP OF SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_013">PLAN
    OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_014">LEGAL
    MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_015">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_016">WHERE
    YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ar_017">INFORMATION
    INCORPORATED BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_001"></A>ABOUT
THIS PROSPECTUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) using
a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may, from time to time, offer and sell, either
individually or in combination, in one or more offerings, up to a total dollar amount of $50,000,000 of shares of our common stock (&ldquo;Common
Stock&rdquo;), preferred stock (&ldquo;Preferred Stock&rdquo;), various series of debt securities, rights to purchase shares of our Common
Stock or Preferred Stock, and/or warrants to purchase any such securities, <FONT STYLE="background-color: white">either individually
or as units comprised of a combination of one or more of the other securities</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus,
we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We may also authorize
one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus
supplement and any related free writing prospectus that we may authorize to be provided to you may also update or change any of the information
contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. We urge you to read carefully
this prospectus, any applicable prospectus supplement and any related free writing prospectuses we have authorized for use in connection
with a specific offering, together with the information incorporated herein by reference as described under the heading &ldquo;Information
Incorporated by Reference&rdquo;, before buying any of the securities being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement,
along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering.
We have not authorized anyone to provide you with information in addition to or different from that contained in this prospectus, any
applicable prospectus supplement and any related free writing prospectus. We take no responsibility for and can provide no assurances
as to the reliability of, any information not contained in this prospectus, any applicable prospectus supplement or any related free
writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities offered hereby,
but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus,
any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document
and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless
of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale
of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
in this prospectus to the terms &ldquo;Lixte&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo; or the &ldquo;Company&rdquo;
or other similar terms refer, collectively, to Lixte Biotechnology Holdings, Inc. and its consolidated subsidiary, unless we state otherwise
or the context indicates otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we refer to &ldquo;you&rdquo;, we mean the potential holders of the applicable series of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_002"></A>NOTE
ABOUT FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and the information incorporated herein by reference includes forward-looking statements within the meaning of Section 27A
of the Securities Act, as amended (the &ldquo;Securities Act&rdquo;), and Section 21E of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;). For this purpose, any statements contained herein, other than statements of historical fact, may be
forward-looking statements under the provisions of the Private Securities Litigation Reform Act of 1995, including any statements about
our future performance, business, financial condition, strategic transactions (including mergers, acquisitions and management services
agreements), sources of revenue, operating results, plans, objectives, expectations and intentions; any statements regarding future economic
conditions; and any statements of belief or assumptions including underlying any of the foregoing. In this prospectus and the information
incorporated herein by reference, words such as &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;estimate&rdquo;, and variations
of such words or similar expressions are used to identify these forward-looking statements. Actual results may differ materially from
those indicated by such forward-looking statements as a result of various important factors. These risks are described in greater detail
in the section entitled &ldquo;Risk Factors&rdquo; of this prospectus. Many of these factors that will determine actual results are beyond
our ability to control or predict. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, actual
results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by
these forward-looking statements. In addition, any forward-looking statements in this prospectus represent our views only as of the date
of this prospectus and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events
and developments will cause its views to change. However, while we may elect to update these forward-looking statements publicly at some
point in the future, we specifically disclaim any obligation to do so, except as may be required by law, whether as a result of new information,
future events or otherwise. Our forward-looking statements generally do not reflect the potential impact of any future acquisitions,
mergers, dispositions, joint ventures or investments we may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to the section entitled &ldquo;Risk Factors&rdquo; of this prospectus, and any other risk factors set forth in any accompanying prospectus
supplement and in any information incorporated by reference in this prospectus or any accompanying prospectus supplement to better understand
the risks and uncertainties inherent in our business and underlying any forward-looking statements, as well as any other risk factors
and cautionary statements described in the documents we file from time to time with the SEC, specifically our most recent Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q, Definitive Proxy Statements on Schedule 14A and Current Reports on Form 8-K, including
sections therein titled &ldquo;Risk Factors&rdquo; and &ldquo;Note About Forward-Looking Statements&rdquo;, respectively. See &ldquo;Information
Incorporated by Reference&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_003"></A>PROSPECTUS
SUMMARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights selected information contained elsewhere in this prospectus. This summary is not complete and does not contain all
the information that you should consider before making a decision to invest in our securities. We urge you to carefully read this entire
prospectus and all applicable prospectus supplements, including the more detailed information regarding our Company, the securities being
registered hereby, as well as our consolidated financial statements, the notes to the consolidated financial statements and other information
incorporated by reference from our other filings with the SEC. Investing in our securities involves a high degree of risks. Therefore,
carefully consider the risk factors set forth in Lixte&rsquo;s most recent annual and quarterly filings with the SEC, as well as other
information in this prospectus, all applicable prospectus supplements and the documents incorporated by reference herein or therein,
before purchasing our securities. Each of the risk factors could adversely affect our business, operating results and financial condition,
as well as adversely affect the value of an investment in our securities.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company dedicated to improving patients&rsquo; lives by developing a drug class called Protein
Phosphatase 2A inhibitors. Our corporate office is located in Pasadena, California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product pipeline is primarily focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-ray,
immune checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant therapeutic
potential for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor, referred
to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
activities are subject to significant risks and uncertainties, including the need for additional capital. We have not yet commenced any
revenue-generating operations, do not have positive cash flows from operations, rely on stock-based compensation for a substantial portion
of employee and consultant compensation, and are dependent on periodic infusions of equity capital to fund its operating requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Associated with Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks of which you should be aware of before making an investment decision. Some of these risks include
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are engaged in early-stage research and as such might not be successful in our efforts to develop a portfolio of commercially viable
    products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses
    for the foreseeable future.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    need significant additional financing to fund our operations and complete the development and, if approved, the commercialization
    of our lead product candidate, LB-100. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate
    our product development programs or commercialization efforts.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently have no source of revenues. We might never generate revenues or achieve profitability.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical-stage
    biopharmaceutical companies with product candidates in clinical development face a wide range of challenging activities which might
    entail substantial risk.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might find it difficult to enroll patients in our clinical trials which could delay or prevent the start of clinical trials for our
    product candidate.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    drug development involves a lengthy and expensive process with an uncertain outcome.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with operating in foreign countries could materially adversely affect our product development.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects
    or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label
    or result in significant negative consequences following any regulatory approval.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product development program might not uncover all possible adverse events that patients who take our lead product candidate may experience.
    The number of subjects exposed to our lead product candidate and the average exposure time in the clinical development program might
    be inadequate to detect rare adverse events or chance findings that might only be detected once the product is administered to more
    patients and for greater periods of time.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    future success is dependent on the regulatory approval of our lead product candidate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    lead product candidate and future product candidates could fail to receive regulatory approval from the FDA.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to obtain regulatory approval in international jurisdictions would prevent our lead product candidate from being marketed abroad.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if our current primary product candidate received regulatory approval, it might still face future development and regulatory difficulties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on certain key scientific personnel for our success who do not work full time for us. The loss of any such personnel could
    adversely affect our business, financial condition and results of operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to rely heavily on third parties for the conduct of clinical trials of our product candidates. If these clinical trials are
    not successful, or if we or our collaborators are not able to obtain the necessary regulatory approvals, we will not be able to commercialize
    our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to find third party collaborators to assist or share in the costs of product development could materially harm our business,
    financial condition or results of operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims by third parties asserting that our employees, consultants, collaborators contractors or we have misappropriated
    their intellectual property, or claiming ownership of what we regard as our own intellectual property.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    cannot be certain we will be able to obtain patent protection to protect our product candidates and technology.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not obtain patent term extension in the United States under the Hatch-Waxman Act or in foreign countries under similar legislation,
    our business might be materially harmed.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with our obligations in agreements under which we have licensed or, might license, intellectual property rights
    from third parties, or if we otherwise experience disruptions to our business relationships with our licensors, we could lose rights
    that are important to our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us
    from commercializing or increase the costs of commercializing our product candidates.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade
    secrets of one or more third parties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    intellectual property might not be sufficient to protect our intended products from competition, which might negatively affect our
    business as well as limit our partnership or acquisition appeal.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are not able to protect and control our unpatented trade secrets, know-how and other technological innovation, we might suffer
    competitive harm.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might incur substantial costs prosecuting our patent applications, maintaining our patents and patent applications, enforcing our
    patents, defending against third party patent infringement suits, seeking invalidation of third party patents or in-licensing third
    party intellectual property, as a result of litigation or other proceedings relating to patent and other intellectual property rights.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    commercial success depends upon attaining significant market acceptance of our current product candidate and future product candidates,
    if approved, among physicians, patients, healthcare payors and cancer treatment centers.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are able to commercialize our lead product candidate or any future product candidates, the products might not receive coverage
    or adequate reimbursement from third party payors in the United States and in other countries in which we seek to commercialize our
    intended products, which could harm our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face substantial competition, which might result in others discovering, developing or commercializing products before or more successfully
    than we do.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business might be adversely affected by a recurrence of the Coronavirus pandemic or a pandemic due to the emergence of another virus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    disruptions of information technology systems, computer system failures or breaches of information and cyber security could adversely
    affect our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    might need to grow the size of our organization in the future, and we might experience difficulties in managing this growth.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_004"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves significant risks. Before making an investment decision, with respect to any of our securities, you should
carefully consider the information set forth in this prospectus, including under the heading &ldquo;Risks Associated with our Business&rdquo;
and in any applicable prospectus supplement and in the documents incorporated by reference into this prospectus, including our most recent
Annual Report on Form 10-K, as revised or supplemented by our subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K
on file with the SEC, all of which are incorporated herein by reference, and which may be amended, supplemented or superseded from time
to time by other reports we file with the SEC in the future</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risks included in this prospectus, the applicable prospectus supplement and the documents we have incorporated by reference are not the
only ones we face. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could
have material adverse effects on our future results. The occurrence of any of these risks could materially adversely affect our business,
financial condition, results of operations and prospects. As a result, the value of our securities could decline and you could lose part
or all of your investment therein. Past financial performance may not be a reliable indicator of future performance and historical trends
should not be used to anticipate results or trends in future periods. Conditions that we currently deem to be immaterial may also materially
and adversely affect our business, financial condition, cash flows and results of operation. For more information, see &ldquo;Information
Incorporated by Reference&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_005"></A>THE
SECURITIES WE MAY OFFER</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer shares of Common Stock and Preferred Stock, various series of debt securities, rights to purchase shares of Common Stock and
Preferred Stock, and/or warrants to purchase any such securities, either individually or in combination, up to a total dollar amount
of $50,000,000 from time to time under this prospectus, together with any applicable prospectus supplement and any related free writing
prospectuses, at prices and on terms to be determined by market conditions at the time of any offering. This prospectus provides you
with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we
will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including,
to the extent applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designation
    or classification;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">aggregate
    principal amount or aggregate offering price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maturity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">original
    issue discount, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rates
    and times of payment of interest or dividends, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redemption,
    conversion, exchange or sinking fund terms, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conversion
    or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange
    prices or rates and in the securities or other property receivable upon conversion or exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ranking;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictive
    covenants, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting
    or other rights, if any; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">important
    U.S. federal income tax considerations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may add, update
or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus
supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the
effectiveness of the registration statement of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE BY US OF OUR SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities directly to investors or to or through agents, underwriters or dealers. We and our agents or underwriters, reserve
the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters,
we will include in the applicable prospectus supplement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    names of those agents or underwriters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable
    fees, discounts and commissions to be paid to them;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">details
    regarding over-allotment or other options, if any; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    net proceeds to us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_006"></A>USE
OF PROCEEDS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described in any applicable prospectus supplement or in any related free writing prospectuses we have authorized for use in connection
with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any,
for working capital, research and development costs, capital expenditures, and general corporate purposes, funding future acquisition
of other companies, purchasing other assets or lines of business, repurchasing Common Stock, or for any other purpose we describe in
the applicable prospectus supplement. We have not determined the amounts we plan to spend on any of these areas or the timing of these
expenditures. As a result, our management will have broad discretion regarding the application of the net proceeds from the sale of securities
described in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_007"></A>DESCRIPTION
OF CAPITAL STOCK</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following is a summary description of the Common Stock, which does not purport to be complete and is summarized from, and is qualified
in its entirety by reference to, our Certificate of Incorporation, as amended, and Amended and Restated Bylaws, and Certificate of Designation,
to which you should refer and copies of which are incorporated herein by reference as Exhibits 3.1 - 3.5 and 4.1, respectively, and to
the registration statement on Form S-3 of which this prospectus forms a part. The summary below is also qualified by provisions of applicable
law, including the Delaware General Corporation Law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue up to a total of 100,000,000 shares of common stock, par value $0.0001 per share. Holders of our common stock
are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have
no cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
holders of our common stock have no pre-emptive or conversion rights or other subscription rights. Upon our liquidation, dissolution
or winding-up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation
preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares
of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our
board of directors out of our assets which are legally available. Each outstanding share of our common stock is, and all shares of common
stock to be issued in this offering when they are paid for, will be fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of 33-1/3% of the shares of our common stock outstanding, represented in person or by proxy, are necessary to constitute a quorum
for the transaction of business at any meeting. Except in regards to proposals that require the approval of a majority of the issued
and outstanding shares, if a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes
cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of the election of directors,
which requires a plurality of the votes cast.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock
in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional, or special
rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights,
voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of the common stock.
Our board of directors, without stockholder approval, will be able to issue convertible preferred stock with voting, conversion, or other
rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued
quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the
issuance of preferred stock may have the effect of decreasing the market price of our common stock, and may adversely affect the voting
and other rights of the holders of common stock. At present, we have no plans to issue any shares of preferred stock following this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have designated a total of 350,000 shares as our Series A Convertible Preferred Stock, which are non-voting and not subject to increase
without the written consent of a majority of the holders of such series. The holders of each tranche of 175,000 shares are entitled to
receive a per share dividend equal to 1% of our annual net revenue divided by 175,000, until converted or redeemed. Each share of Series
A Convertible Preferred Stock may be converted, at the option of the holder, into 2.083 shares of common stock (subject to customary
anti-dilution provisions), and are subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction
resulting in gross proceeds to us of at least $21,875,000. Each share has a liquidation preference based on its assumed conversion into
shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will fix the designations, voting powers, rights, preferences and privileges of each series, as well as the qualifications,
limitations or restrictions thereof, of the Preferred Stock of each series that we offer under this prospectus and applicable prospectus
supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which
this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation
that describes the terms of the series of Preferred Stock we are offering before the issuance of that series of Preferred Stock. This
description will include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title and stated value;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares being offered;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    liquidation preference per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purchase price per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    dividend rate per share, dividend period and payment dates and method of calculation for dividends;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    right, if any, to defer payment of dividends and the maximum length of any such deferral period;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    procedures for any auction and remarketing, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions for a sinking fund, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase
    rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    listing of the Preferred Stock on any securities exchange or market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the Preferred Stock will be convertible into Common Stock, and the conversion rate or conversion price, or how they will be calculated,
    and the exchange period;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting
    rights, if any, of the Preferred Stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preemption
    rights, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on transfer, sale or other assignment, if any;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion of any material or special United States federal income tax considerations applicable to the Preferred Stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative ranking and preferences of the Preferred Stock as to dividend rights and rights if we liquidate, dissolve or wind up our
    affairs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    limitations on issuances of any class or series of Preferred Stock ranking senior to or on a parity with the series of Preferred
    Stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other specific terms, rights, preferences, privileges, qualifications or restrictions of the Preferred Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
issuance, the shares of Preferred Stock will be fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Provisions of Delaware Law, our Certificate of Incorporation and our Amended and Restated Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delaware
Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are governed by the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly traded
Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date
of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed
manner. A business combination includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder.
An interested stockholder is a person who, together with affiliates and associates, owns (or within three years, did own) 15% or more
of the corporation&rsquo;s voting stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing
a change in control of our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
of Directors Vacancies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Amended and Restated Bylaws authorize only our board of directors to fill vacant directorships. In addition,
the number of directors constituting our board of directors may be set only by resolution of the majority of the incumbent directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stockholder
Action; Special Meeting of Stockholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Amended and Restated Bylaws provide that our stockholders may take action by written consent. Our Certificate
of Incorporation and Amended and Restated Bylaws further provide that special meetings of our stockholders may be called by a majority
of the board of directors, the Chief Executive Officer, or the Chairman of the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice Requirements for Stockholder Proposals and Director Nominations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate
candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To
be timely, a stockholder&rsquo;s notice must be delivered to the secretary at our principal executive offices not later than the close
of business on the 90<SUP>th</SUP> day nor earlier than the close of business on the 120<SUP>th</SUP> day prior to the first anniversary
of the preceding year&rsquo;s annual meeting; provided, however, that in the event the date of the annual meeting is more than 30 days
before or more than 60 days after such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder
to be timely must be so delivered not earlier than the close of business on the 120<SUP>th</SUP> day prior to such annual meeting and
not later than the close of business on the later of the 90<SUP>th</SUP> day prior to such annual meeting or the 10<SUP>th</SUP> day
following the day on which a public announcement of the date of such meeting is first made by us. These provisions may preclude our stockholders
from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions could discourage a potential acquirer from acquiring Lixte Biotechnology Holdings, Inc. or otherwise attempting to obtain
control and increase the likelihood that its incumbent directors and officers will retain their positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
Agent and Registrar</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Computershare Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nasdaq Capital Market</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;LIXT&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_008"></A>DESCRIPTION
OF DEBT SECURITIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus,
summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell
a particular series of debt securities, we will describe the specific terms of the series in a prospectus supplement. We will also indicate
in the prospectus supplement to what extent the general terms and provisions described in this prospectus apply to a particular series
of debt securities. To the extent the information contained in the prospectus supplement differs from this summary description, you should
rely on the information in the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities
described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise
specified in the prospectus supplement, the debt securities will be our direct, unsecured obligations and may be issued in one or more
series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt securities will be issued under an indenture between us and a trustee named in the prospectus supplement. We have summarized select
portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration
statement of which this prospectus is a part, and you should read the indenture for provisions that may be important to you. Capitalized
terms used in the summary and not defined in this prospectus have the meanings specified in the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or
determined in the manner provided in a resolution of our board of directors, in an officer&rsquo;s certificate or by a supplemental indenture.
The particular terms of each series of debt securities will be described in a prospectus supplement relating to such series (including
any pricing supplement or term sheet).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture would not limit the amount of debt securities that we may issue under it. Debt securities issued under the indenture may be
in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will set forth in a prospectus
supplement (including any pricing supplement or term sheet) relating to any series of debt securities being offered, the aggregate principal
amount and the following terms of the debt securities, if applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title and ranking of the debt securities (including the terms of any subordination provisions);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices (expressed as a percentage of the principal amount) at which we will sell the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    limit on the aggregate principal amount of the debt securities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date or dates on which the principal on a particular series of debt securities is payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any commodity,
    commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from
    which interest will accrue, the date or dates on which interest will commence and be payable and any regular record date for the
    interest payable on any interest payment date;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    place or places where principal of, and interest, if any, on the debt securities will be payable (and the method of such payment),
    where the debt securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands
    to us in respect of the debt securities may be delivered;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    period or periods within which, the price or prices at which and the terms and conditions upon which we may redeem the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous provisions or at the option
    of a holder of debt securities and the period or periods within which, the price or prices at which and the terms and conditions
    upon which the debt securities of a particular series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    dates on which and the price or prices at which we will repurchase debt securities at the option of the holders of debt securities
    and other detailed terms and provisions of these repurchase obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the debt securities will be issued in the form of certificated debt securities or global debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the
    principal amount;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    currency of denomination of the debt securities, which may be U.S. dollars or any foreign currency, and if such currency of denomination
    is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    designation of the currency, currencies or currency units in which payment of principal of, and premium and interest on, the debt
    securities will be made;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    payments of principal of, or premium or interest on, the debt securities will be made in one or more currencies or currency units
    other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these
    payments will be determined;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    manner in which the amounts of payment of principal of, and premium, if any, and interest on, the debt securities will be determined,
    if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity
    index, stock exchange index or financial index;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    provisions relating to any security provided for the debt securities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    addition to, deletion of or change in the events of default described in this prospectus or in the indenture with respect to the
    debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the
    debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    addition to, deletion of or change in the covenants described in this prospectus or in the indenture with respect to the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to the debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions, if any, relating to conversion or exchange of any debt securities of such series, including if applicable, the conversion
    or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment
    of the conversion or exchange price and provisions affecting conversion or exchange;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as it applies to that series,
    including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the
    securities; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including the terms of subordination,
    if any, of such guarantees.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of
acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the material U.S. federal
income tax considerations applicable to any of these debt securities in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we denominate the purchase price of any of the debt securities in a foreign currency or currencies or a foreign currency unit or units,
or if the principal of, and premium, if any, and interest on, any series of debt securities is payable in a foreign currency or currencies
or a foreign currency unit or units, we will provide you with information on the restrictions, elections, general tax considerations,
specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign
currency unit or units in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
and Exchange</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company (&ldquo;DTC&rdquo;
or the &ldquo;Depositary&rdquo;) or a nominee of the Depositary (we will refer to any debt security represented by a global debt security
as a &ldquo;book-entry debt security&rdquo;), or a certificate issued in definitive registered form (we will refer to any debt security
represented by a certificated security as a &ldquo;certificated debt security&rdquo;) as set forth in the applicable prospectus supplement.
Except as set forth under the heading &ldquo;Legal Ownership of Securities&rdquo; below, book-entry debt securities will not be issuable
in certificated form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certificated
Debt Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the terms of the
indenture. No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of
a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may effect the transfer of certificated debt securities and the right to receive the principal of, premium and interest on certificated
debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the
trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Global
Debt Securities and Book-Entry System</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
global debt security representing book-entry debt securities will be deposited with, or on behalf of, the Depositary, and registered
in the name of the Depositary or a nominee of the Depositary. See the section of this prospectus entitled &ldquo;Legal Ownership of Securities&rdquo;
for more information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenants</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Protection in the Event of a Change of Control</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford holders
of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether
or not such transaction results in a change in control) that could adversely affect holders of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidation,
Merger and Sale of Assets</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to,
any person (a &ldquo;successor person&rdquo;) unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are the surviving corporation or the successor person (if other than Lixte Biotechnology Holdings, Inc.) is a corporation organized
    and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities
    and under the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately
    after giving effect to the transaction, no default or event of default, shall have occurred and be continuing; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    other conditions are met.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its properties to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Events
of Default</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;event of default&rdquo; means with respect to any series of debt securities, any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">default
                                            in the payment of any interest upon any debt security of that series when it becomes due
                                            and payable, and continuance of such default for a period of 30 days (unless the entire amount
                                            of the payment is deposited by us with the trustee or with a paying agent prior to the expiration
                                            of the 30-day period);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">default
    in the payment of principal of any debt security of that series at its maturity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">default
    in the performance or breach of any other covenant or warranty by us in the indenture or any debt security (other than a covenant
    or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series),
    which default continues uncured for a period of 60 days after we receive written notice from the trustee or Lixte Biotechnology Holdings,
    Inc. and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities
    of that series as provided in the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    voluntary or involuntary events of bankruptcy, insolvency or reorganization of Lixte Biotechnology Holdings, Inc.; or</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other event of default provided with respect to debt securities of that series that is described in the applicable prospectus supplement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization)
necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of certain events of
default or an acceleration under the indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries
outstanding from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide the trustee written notice of any default or event of default within 30 days of becoming aware of the occurrence of such
default or event of default, which notice will describe in reasonable detail the status of such default or event of default and what
action we are taking or propose to take in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee
or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing
to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if the debt securities
of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued
and unpaid interest, if any, on all debt securities of that series. In the case of an event of default resulting from certain events
of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on
all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the
trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to debt securities
of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders
of a majority in principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all events
of default, other than the non-payment of accelerated principal and interest, if any, with respect to debt securities of that series,
have been cured or waived as provided in the indenture. We refer you to the prospectus supplement relating to any series of debt securities
that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount
securities upon the occurrence of an event of default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture unless
the trustee receives indemnity satisfactory to it against any cost, liability or expense that might be incurred by it in performing such
duty or exercising such right or power. Subject to certain rights of the trustee, the holders of a majority in principal amount of the
outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any
remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that
series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the
indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
    holder has previously given to the trustee written notice of a continuing event of default with respect to debt securities of that
    series; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holders of not less than 25% in principal amount of the outstanding debt securities of that series have made written request, and
    offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee
    has not received from the holders of not less than a majority in principal amount of the outstanding debt securities of that series
    a direction inconsistent with that request and has failed to institute the proceeding within 60 days.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment
of the principal of, and premium and any interest on, that debt security on or after the due dates expressed in that debt security and
to institute suit for the enforcement of payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with
the indenture. If a default or event of default occurs and is continuing with respect to the securities of any series and if it is known
to a responsible officer of the trustee, the trustee shall mail to each holder of the securities of that series notice of a default or
event of default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such default
or event of default. The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of any
default or event of default (except in payment on any debt securities of that series) with respect to debt securities of that series
if the trustee determines in good faith that withholding notice is in the interest of the holders of those debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modification
and Waiver</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder
of any debt security:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    cure any ambiguity, defect or inconsistency;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    comply with covenants in the indenture described above under the heading &ldquo;Consolidation, Merger and Sale of Assets&rdquo;;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide for uncertificated securities in addition to or in place of certificated securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add guarantees with respect to debt securities of any series or secure debt securities of any series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    surrender any of our rights or powers under the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add covenants or events of default for the benefit of the holders of debt securities of any series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    comply with the applicable procedures of the Depositary;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    make any change that does not adversely affect the rights of any holder of debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted by the
    indenture;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    effect the appointment of a successor trustee with respect to the debt securities of any series and to add to or change any of the
    provisions of the indenture to provide for or facilitate administration by more than one trustee; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act
    of 1939.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding
debt securities of each series affected by the modification or amendment. We may not make any modification or amendment without the consent
of the holders of each affected debt security then outstanding if that amendment would:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the amount of debt securities whose holders must consent to an amendment, supplement or waiver;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the rate of or extend the time for payment of interest (including default interest) on any debt security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of, or postpone the date fixed
    for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    the principal amount of discount securities payable upon acceleration of maturity;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">waive
    a default or event of default in the payment of the principal of, or premium or interest on, any debt security (except a rescission
    of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the outstanding
    debt securities of that series and a waiver of the payment default that resulted from such acceleration);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    the principal of, or premium or interest on, any debt security payable in a currency other than that stated in the debt security;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    any change to certain provisions of the indenture relating to, among other things, the right of the holders of debt securities to
    receive payment of the principal of, and premium and interest on, those debt securities and to institute suit for the enforcement
    of any such payment and to waivers or amendments; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">waive
    a redemption payment with respect to any debt security.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series
may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. The holders
of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all of the debt securities
of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment
of the principal of, or any interest on, any debt security of that series; provided, however, that the holders of a majority in principal
amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment
default that resulted from the acceleration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defeasance
of the Debt Securities and Certain Covenants in Certain Circumstances</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Defeasance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged from
any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon
the deposit with the trustee, in trust, of cash and/or U.S. government obligations or, in the case of debt securities denominated in
a single currency other than U.S. dollars, cash and/or government obligations of the government that issued or caused to be issued such
currency, that, through the payment of interest and principal in accordance with their terms, will provide cash in an amount sufficient
in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment
of principal of, premium and interest on, and any mandatory sinking fund payments in respect of, the debt securities of that series on
the stated maturity of those payments in accordance with the terms of the indenture and those debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received
from, or there has been published by, the U.S. Internal Revenue Service a ruling or, since the date of execution of the indenture, there
has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such opinion shall
confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes
as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amounts and in the same
manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Defeasance
of Certain Covenants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon compliance with certain
conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may omit to comply with the covenant described under the heading &ldquo;Consolidation, Merger and Sale of Assets&rdquo; and certain
    other covenants set forth in the indenture, as well as any additional covenants that may be set forth in the applicable prospectus
    supplement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    omission to comply with those covenants will not constitute a default or an event of default with respect to the debt securities
    of that series (a &ldquo;covenant defeasance&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
conditions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">depositing
    with the trustee cash and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other
    than U.S. dollars, cash and/or government obligations of the government that issued or caused to be issued such currency, that, through
    the payment of interest and principal in accordance with their terms, will provide cash in an amount sufficient in the opinion of
    a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal
    of, premium and interest on, and any mandatory sinking fund payments in respect of, the debt securities of that series on the stated
    maturity of those payments in accordance with the terms of the indenture and those debt securities; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delivering
    to the trustee an opinion of counsel to the effect that we have received from, or there has been published by, the U.S. Internal
    Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal
    income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the debt securities
    of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related
    covenant defeasance and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times
    as would have been the case if the deposit and related covenant defeasance had not occurred.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Personal Liability of Directors, Officers, Employees or Stockholders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our past, present or future directors, officers, employees or stockholders, as such, will have any liability for any of our obligations
under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation.
By accepting a debt security, each holder waives and releases all such liability. This waiver and release is part of the consideration
for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities under U.S. federal securities
laws, and it is the view of the SEC that such a waiver is against public policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
Law</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the debt securities,
will be governed by the laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably
waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or
relating to the indenture, the debt securities or the transactions contemplated thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture provides that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated
thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the
State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt securities (by their acceptance
of the debt securities) irrevocably submit to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. The
indenture further provides that service of any process, summons, notice or document by mail (to the extent allowed under any applicable
statute or rule of court) to such party&rsquo;s address set forth in the indenture will be effective service of process for any suit,
action or other proceeding brought in any such court. The indenture further provides that we, the trustee and the holders of the debt
securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of
any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or
claim any such suit, action or other proceeding has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_009"></A>DESCRIPTION
OF WARRANTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue warrants for the purchase of shares of Common Stock or Preferred Stock or for the purchase of debt securities. We may issue
warrants independently or together with other securities, and the warrants may be attached to or separate from any offered securities.
If a series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant
agent, we will so specify in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of the material terms of the warrants and warrant agreements is subject to, and qualified in its entirety by reference
to, all of the provisions of the warrants and any warrant agreement applicable to a particular series of warrants. The terms of any warrants
offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement
and any related free writing prospectus, as well as the complete warrants and any warrant agreements that contain the terms of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms of any issue of warrants will be described in the prospectus supplement relating to the issue. Those terms may include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares of Common Stock or Preferred Stock purchasable upon the exercise of warrants to purchase such shares and the price
    at which such number of shares may be purchased upon exercise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    summary of the terms (including, without limitation, liquidation, dividend, conversion and voting rights) of the series of Preferred
    Stock purchasable upon exercise of warrants to purchase Preferred Stock as set forth in the certificate of designations for such
    series of Preferred Stock;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date, if any, on and after which the warrants and the related debt securities, Preferred Stock or Common Stock will be separately
    transferable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms of any rights to redeem or call the warrants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the right to exercise the warrants will commence and the date on which the right will expire;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    material U.S. federal income tax consequences applicable to the warrants; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    additional material terms of the warrants, including terms, procedures, and limitations relating to the exchange, exercise and settlement
    of the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of equity warrants will not be entitled:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    vote, consent or received dividends;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">receive
    notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">exercise
    any rights as stockholders of Lixte Biotechnology Holdings, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of Preferred Stock or Common
Stock at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify
in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the
expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised
warrants will become void. A holder of warrant certificates may exchange them for new warrant certificates of different denominations,
present them for registration of transfer and exercise them at the corporate trust office of the warrant agent or any other office indicated
in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised, the holder of the warrants will
not have any rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive payments of
principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants
to purchase Common Stock or Preferred Stock are exercised, the holders of the warrants will not have any rights of holders of the underlying
Common Stock or Preferred Stock, including any rights to receive dividends or payments upon any liquidation, dissolution or winding up
on the Common Stock or Preferred Stock, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ar_010"></A>DESCRIPTION
OF RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue rights to our stockholders to purchase shares of our common stock, preferred stock or the other securities described in this
prospectus. We may offer rights separately or together with one or more additional rights, debt securities, preferred stock, common stock
or warrants, or any combination of those securities in the form of units, as described in the applicable prospectus supplement. Each
series of rights will be issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights
agent. The rights agent will act solely as our agent in connection with the certificates relating to the rights of the series of certificates
and will not assume any obligation or relationship of agency or trust for or with any holders of rights certificates or beneficial owners
of rights. The following description sets forth certain general terms and provisions of the rights to which any prospectus supplement
may relate. The particular terms of the rights to which any prospectus supplement may relate and the extent, if any, to which the general
provisions may apply to the rights so offered will be described in the applicable prospectus supplement. To the extent that any particular
terms of the rights, rights agreement or rights certificates described in a prospectus supplement differ from any of the terms described
below, then the terms described below will be deemed to have been superseded by that prospectus supplement. We encourage you to read
the applicable rights agreement and rights certificate for additional information before you decide whether to purchase any of our rights.
We will provide in a prospectus supplement the following terms of the rights being issued:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date of determining the stockholders entitled to the rights distribution;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    aggregate number of shares of common stock, preferred stock or other securities purchasable upon exercise of the rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise price;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    aggregate number of rights issued;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the rights are transferrable and the date, if any, on and after which the rights may be separately transferred;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the right to exercise the rights will commence, and the date on which the right to exercise the rights will expire;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    method by which holders of rights will be entitled to exercise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    conditions to the completion of the offering, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    withdrawal, termination and cancellation rights, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    there are any backstop or standby purchaser or purchasers and the terms of their commitment, if any;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    stockholders are entitled to oversubscription rights, if any;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    applicable material U.S. federal income tax considerations; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the rights, including terms, procedures and limitations relating to the distribution, exchange and exercise of the
    rights, as applicable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
right will entitle the holder of rights to purchase for cash the principal amount of shares of common stock, preferred stock or other
securities at the exercise price provided in the applicable prospectus supplement. Rights may be exercised at any time up to the close
of business on the expiration date for the rights provided in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
may exercise rights as described in the applicable prospectus supplement. Upon receipt of payment and the rights certificate properly
completed and duly executed at the corporate trust office of the rights agent or any other office indicated in the prospectus supplement,
we will, as soon as practicable, forward the shares of common stock, preferred stock or other securities, as applicable, purchasable
upon exercise of the rights. If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed
securities directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such
methods, including pursuant to standby arrangements, as described in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Rights
Agent</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights agent for any rights we offer will be set forth in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_011"></A>DESCRIPTION
OF UNITS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We
may evidence each series of units by unit certificates that we will issue under a separate unit agreement. We may enter into unit agreements
with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit
agent in the applicable prospectus supplement relating to a particular series of units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description, together with the additional information included in any applicable prospectus supplement, summarizes the general
features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus
that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that
contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file each
unit agreement as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from
another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without
limitation, the following, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title of the series of units;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identification
    and description of the separate constituent securities comprising the units;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices at which the units will be issued;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date, if any, on and after which the constituent securities comprising the units will be separately transferable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    material U.S. federal income tax considerations applicable to the units; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other material terms of the units and their constituent securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_012"></A>LEGAL
OWNERSHIP OF SECURITIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary
or warrant agent maintain for this purpose as the &ldquo;holders&rdquo; of those securities. These persons are the legal holders of the
securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered
in their own names, as &ldquo;indirect holders&rdquo; of those securities. As discussed below, indirect holders are not legal holders,
and investors in securities issued in book-entry form or in street name will be indirect holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Book-Entry
Holders </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be
represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf
of other financial institutions that participate in the depositary&rsquo;s book-entry system. These participating institutions, which
are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will
be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize
only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary
passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial
owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are
not obligated to do so under the terms of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, investors in book-entry securities will not own securities directly. Instead, they will own beneficial interests in a global
security, through a bank, broker or other financial institution that participates in the depositary&rsquo;s book-entry system or holds
an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not holders,
of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Street
Name Holders </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate a global security or issue securities in non-global form. In these cases, investors may choose to hold their securities
in their own names or in &ldquo;street name&rdquo;. Securities held by an investor in street name would be registered in the name of
a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those
securities through an account he or she maintains at that institution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names
the securities are registered as the holders of those securities, and we will make all payments on those securities to them. These institutions
pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their
customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders,
not holders, of those securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
Holders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the
legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street
name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has
no choice because we are issuing the securities only in global form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that
holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but
does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences
of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we
would seek approval only from the holders, and not the indirect holders, of the securities. Whether or how the holders contact the indirect
holders is the responsibility of the holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
Considerations for Indirect Holders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check
with your own institution to find out:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    performance of third-party service providers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
    it handles securities payments and notices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    it imposes fees or charges;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
    it would handle a request for the holders&rsquo; consent, if ever required;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the
    future;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
    it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect
    their interests; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the securities are in book-entry form, how the depositary&rsquo;s rules and procedures will affect these matters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
Securities</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities
represented by the same global securities will have the same terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial
institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless
we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary,
unless special termination situations arise. We describe those situations below under the section entitled &ldquo;Special Situations
When a Global Security Will Be Terminated&rdquo; in this prospectus. As a result of these arrangements, the depositary, or its nominee,
will be the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to own
only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other
financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose
security is represented by a global security will not be a holder of the security, but only an indirect holder of a beneficial interest
in the global security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security
will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may
issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry
clearing system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
Considerations for Global Securities</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights of an indirect holder relating to a global security will be governed by the account rules of the investor&rsquo;s financial institution
and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of
securities and instead deal only with the depositary that holds the global security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are issued only in the form of a global security, an investor should be aware of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her
    interest in the securities, except in the special situations described below;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection
    of his or her legal rights relating to the securities, as described above;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required
    by law to own their securities in non-book-entry form;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the
    securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    depositary&rsquo;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating
    to an investor&rsquo;s interest in a global security;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    and any applicable trustee have no responsibility for any aspect of the depositary&rsquo;s actions or for its records of ownership
    interests in a global security, nor do we or any applicable trustee supervise the depositary in any way;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its
    book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    institutions that participate in the depositary&rsquo;s book-entry system, and through which an investor holds its interest in a
    global security, may also have their own policies affecting payments, notices and other matters relating to the securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for
the actions of any intermediary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
Situations When a Global Security Will Be Terminated</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be the responsibility
of the investor. Investors must consult their own banks or brokers to learn how to have their interests in securities transferred to
their own names so that they will be direct holders. We have described the rights of holders and street name investors above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations
occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security
    and we do not appoint another institution to act as depositary within 90 days;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we notify any applicable trustee that we wish to terminate that global security; or</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular
series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or
any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_013"></A>PLAN
OF DISTRIBUTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities offered by this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions,
block trades or a combination of these methods or through underwriters or dealers, through agents and/or directly to one or more purchasers.
The securities may be distributed from time to time in one or more transactions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a fixed price or prices, which may be changed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    market prices prevailing at the time of sale;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    prices related to such prevailing market prices; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    negotiated prices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
time that we sell securities offered by this prospectus, we will provide a prospectus supplement or supplements that will describe the
method of distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the
securities and the proceeds to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offers
to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers
to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal.
The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed
with the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter
will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the purchasers of securities
for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter
may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions
from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus
supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal, and may then resell
the securities at varying prices to be determined by the dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions
or commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters,
dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities
Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to
be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities,
including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse
those persons for certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Common Stock issued by us under this prospectus will be listed on The Nasdaq Capital Market, but any other securities may or may not
be listed on a national securities exchange. To facilitate the offering of securities, certain persons participating in the offering
may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments
or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to
them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market
or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities
by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers
participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions.
The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might
otherwise prevail in the open market. These transactions may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
indicated in the applicable prospectus supplement, underwriters or other persons acting as agents may be authorized to solicit offers
by institutions or other suitable purchasers to purchase the securities at the public offering price set forth in the prospectus supplement
pursuant to delayed delivery contracts providing for payment and delivery on the date or dates stated in the prospectus supplement. These
purchasers may include, among others, commercial and savings banks, insurance companies, pension funds, investment companies and educational
and charitable institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In
addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties
in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the
third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.
If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related
open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings
of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in
the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial
institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement.
Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection
with a concurrent offering of other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for
which they receive compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_014"></A>LEGAL
MATTERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TroyGould
PC, Los Angeles, California, has issued an opinion regarding certain legal matters relating to the issuance of the securities offered
by this prospectus on behalf of Lixte Biotechnology Holdings, Inc. Additional legal matters may be passed upon for us, or any underwriters,
dealers or agents, by counsel that we will name in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_015"></A>EXPERTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Lixte Biotechnology Holdings, Inc. appearing in Lixte Biotechnology Holdings, Inc.&rsquo;s Annual
Report on Form 10-K for the fiscal year ended December 31, 2023 have been audited by Weinberg &amp; Company, P.A., an independent registered
public accounting firm, as stated in their report thereon, which includes an explanatory paragraph as to the Company&rsquo;s ability
to continue as a going concern. Such financial statements have been incorporated herein by reference in reliance on such report given
on the authority of such firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_016"></A>WHERE
YOU CAN FIND MORE INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website at http://www.sec.gov
that contains reports, proxy and information statements and other information regarding us and other issuers that file electronically
with the SEC. This prospectus is only part of a registration statement on Form S-3 that we have filed with the SEC under the Securities
Act, and therefore omits certain information contained in the registration statement. We have also filed exhibits and schedules with
the registration statement that are excluded from this prospectus, and you should refer to the applicable exhibit or schedule for a complete
description of any statement referring to any contract or other document. You may access the registration statement of which this prospectus
forms a part by visiting http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain a website at www.lixte.com, through which you can access our SEC filings free of charge. The information set forth on our
website is not part of this prospectus. The reference to our website address does not constitute incorporation by reference of the information
contained on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ar_017"></A>INFORMATION
INCORPORATED BY REFERENCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rules of the SEC allow us to &ldquo;incorporate by reference&rdquo; into this prospectus information that we have filed with the SEC
under the Commission File No. 001-39717. This means we can disclose important information to you without actually including the specific
information in this prospectus by referring you to SEC filings that contain that information. The information incorporated by reference
is considered to be a part of this prospectus, provided that it will be automatically updated and superseded by information that we file
later with the SEC. This prospectus incorporates by reference the documents listed below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224010427/form10-k.htm" STYLE="-sec-extract: exhibit">Form
    10-K</A> for the fiscal year ended December 31, 2023, as filed with the SEC on March 19, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form 8-K, as filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315224010934/form8-k.htm" STYLE="-sec-extract: exhibit">March
    22, 2024</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1335105/000149315224011582/form8-k.htm" STYLE="-sec-extract: exhibit">March
    28, 2024</A>;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of the Common Stock incorporated by reference to our Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1335105/000149315220021857/form8-a12b.htm" STYLE="-sec-extract: exhibit">Form
    8-A</A> that was filed with the SEC on November 17, 2020, including any amendment or report filed for the purpose of updating such
    description; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the
    date of this prospectus and prior to the termination or completion of the offering of securities under this prospectus shall be deemed
    to be incorporated by reference in this prospectus and to be a part hereof from the date of filing such reports and other documents.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, we are not incorporating by reference any documents, portions of documents, exhibits or other information that is deemed
to have been furnished to, rather than filed with, the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus shall
be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or
any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the
statement. Any statements so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of
this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written
or oral request of any such person, a copy of any or all of the documents that has been or may be incorporated by reference into this
prospectus (excluding certain exhibits to the documents) at no cost. Any such request to us may be made by writing or telephoning our
Investor Relations department at the following address and telephone number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680
East Colorado Boulevard, Suite 180</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pasadena,
California 91101</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(631)
830-7092</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also access these documents on our website, www.lixte.com. The information contained on, or that can be accessed through, our website
is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="form424b5_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>526,342
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-Funded
Warrants to Purchase up to 525,000 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
Warrants to Purchase up to 1,051,342 Shares of Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Up
to 525,000 Shares of Common Stock Underlying the Pre-Funded Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Up
to 1,051,342 Shares of Common Stock Underlying the Common Warrants</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>LIXTE
BIOTECHNOLOGY HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Spartan
Capital Securities, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is December 18, 2025.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 60; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !' 1,# 2(  A$! Q$!_\0
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M/T(/\J_D<_X/-O\ E%/\*_\ L^+X7_\ JE_VE:_"C]./\NNO]O3_ ()-\_\
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MJA#,'+7$("FWECAG#$N-I@FFBBF!QY<LL<;[6=00#^#C_@^+_P"1,_X)M_\
M8R_M8_\ IE^ 5?Y[%?Z$_P#P?%_\B9_P3;_[&7]K'_TR_ *O\]B@#_?XII=
MK,74*@8NQ8!5"\L6).%"CELXQWQ3J\?^+7Q5\ _!?X=^-OBO\5O%6D^"/A[\
M-/#FK^,_%GB[7YH8-+\-:%X<BG>ZUB\OI/)M%N+M4_<6<TL;3$%8D=T=" ?S
M_P#_  =!>(_V/]*_X)=_%#1_VIM,CU?QWXBUK3;#]DK3K-K&W\;6?[1=GIMZ
MWAG7_#K22_VEIO@K0]*_M=_'+2PK8WGA.]US1KUEUSQ=X-:X_P G*&*0$@QN
M#MD;!1@=L8<R-C'W4$4I<]%$4FXC8V/V._X+$?\ !4SQO_P5(_:W\1?%>_DF
M\-?!#P1%XB\"?LZ_#N6>?[+X;^'<\WVK^V-9M3,@F\:?$:8GQ'XUU.51=Q27
MJ:!I1(\(>'H[CC?^"<G_  2:_:<_X*8Z/^T=K7[/NDF;3OV=OALWCV\GN+>Y
MD'CCQQ-%<2^!_A+X1N(4Q;^,OB#%I'B-M)ED1X/#4>D6)UA(X=7MS< 'T-_P
M;V?&G]D;X%?\%/\ X$>._P!KG2K:[\--+J/A;X4^,KW7(;;PK\)_C3XA7R?"
M'Q0\:Z?JT4-B?"&G[_$>CP:CJ31:=\/=>\0Z;X\\2S6>B:1]L7_7_CFAN "L
ML;AE1P5D5@4D0R1LI4X*R1@R(PX9 S*2H)K_  .=0LM8T34[[3[^RO\ 1=8T
M?5+Z"^TR>*XTW4](U'3)7@U*QD$Z1W-K>Z=+')%>VSHEQ9RQ.DT:21L!_IK?
M\&OW_!8M_P!K[X)VG[$'[0?B*:Y_:C^ ?AQH?AUXEU_4H8=4^.WP1TF633H9
MWBOY?M>H>-_A.$B\.ZY:VZ3ZA<>%FT+Q-=@0'QO=60!_7V"#T(/T(/\ *EJI
M!+&7:,2(7!92@==X90I92N<@J""PQD C/6K>0>AS0!_D3_\ !TW\O_!;_P#:
MX+?*/['_ &<^O'_-L7PB'?WX^M9'_!KV0?\ @NI^PU@@_-^T[W]?V2/C^1^G
M-;/_  =2_P#*;W]KC_L#_LZ?^LR_"&L+_@UX_P"4Z?[#'U_:;_\ 61?C_0!_
MKYTW8OI^I_QIU% '^13_ ,'4@/\ P_$_:VX/_(N?LY=O^K8_A'7\\WV*\VEO
MLEUM"R,6^SR[0L0G,K$[,!8A:W)D.<(+><MCRI-O]#O_  =1?\IQ?VM_?P[^
MSICW_P",9/A%T]>A_*D_X-@?LMS_ ,%K_P!DV.::WL)&T7]H&2VE7[$S?:%_
M9L^(KZ2D%QJ5MJ$+W$+(-4@^UV()U*W#*IF4[0#^=JBO]^SRT_YY0_\ @.G_
M ,=H\M/^>4/_ (#I_P#': /!_P!EF:)OV9_V>5!!:+X&_":&51C=%-9>#M$M
M;R*0=4EL[F.2&ZC8!K>:-XY0CHRCZ#!!Z$'Z$'^5<VD=M:,[Q;!*WV".(-);
MI.SA&DBT]%A"V]E 88PP1557#2.=R[6K>A!&<@CKU!'IZT 3T444 50IPN5;
M@D]#GN?UP*YCQ!I%MXBTS4=#U6S-SIVJ6=WI=]$8F9)M/U7-A<0\*5PMK(7D
M[*@+$$ UV-08(Z@C\*N%1TZCJ)+FMIOIY_\ #D5:5&O2Q%&O2A5IXE6E&>T=
M-+=[;Z_H?DC\7OV$=0TQ)=7^%CG58,$GPMJ#21ZI%R?^0!K#K]GLP< _Z;N'
M^T3@GX"U/3=1\.37.G>(=/O=!U"R!^VV.LVL^EWEIP/^/JVOHX)[?_MJB5_3
M"QC*@ED8 \,K D<\\#KG\,'."*\*^+W[/_P[^->DC3_%.DS++:\Z;J]F8K;4
M=-8@9:Q=?GXP!LO%92>5!ZU^W< ^.F.RG$_4^+*.)S6@[)XG$2KJ5/?WEAES
M86HMKQDH36KBZE^5?R!XH_12R'/&\Y\/Y4,CXLW4<?&ACL/)?X\9+VT?+1JU
MM5:Y^!?ASX[>.?A]/+)X#\07.A)J6"\,0-S:7GH8+&Y+KI_L51>Q[UYEK7BC
MQ'XDU&[U7Q!XBOM=UO4N#J5_*TFJW@'_ #[ER;.P^B!/?'2OLWXS?L-?%'X=
M3M?>"M,O?B1HNH7@AEFT:-DUJ&$Y'FZOIL<<MQ>1C!^?3XPH!!) //N/P._X
M)[^>EGXA^,UV5*@;O!VF?-;29SQKU^@)O&&,XL]JX/#9XK^A)^)/A'E&7/B#
M!1PM?-I1C:+PE&-:3U:C)PIJHK;*,E'E=^9H_ LK\)?%^MG/^JF+GC985-MQ
MG7Q"H+N^9S]GK;76[M]W\D/_  4+_P"">G[6?[?_ .T'^S]X!_9@^%FL>+4M
M/!'B&RU_QEJ+W&C_  U^',$NK:/)!>^,/&D]O_PCVFO-&DDD/@[P_J%SXAD2
M-VBMV57*_OO_ ,$K?^#<SX#_ +!/B3PE\?OC%XAU+]H#]J7PG>KK'AK5X;>\
MT;X4_#364TE($3X>>'E":AK.J1SZA>1Q_$#QO]E4^6YTWP%X1VD-_1AX9\(Z
M#X2LHM,\/Z7::1IP!_T2PMK6ULY21C_2%51=AL$C+C!Z'(SGM87!4D$9([$'
MKCT_'G^M?QOQMQ;4XMS^6/A".%IN[5"E*4X?-S2:OV5[+K<_T#\..$/]2>$\
M'DU>4\55P<;1Q6(A"%>>K^*--RIK=_"[O4MU_(W_ ,'F_P __!*OX6QI\TC?
MMQ_"F-47YG:1O@Q^T 515&6+L&7:H!8[A@'(K^N2O"/C+\ ?@A^T7X8T_P $
M?'_X+_"SXW^"+'4(M:L/!7Q>^'/A#XD>%+3Q#:6=_9Z9KG_".>,+#6-*6^L]
M,OM2T];J21946]:)!$;BODC[P_P@-C_W6_[Y/^%=?)=Q2N'-P&C=D,)-Q([P
M)%:O %NI&M;*=+C3-.\FQTI;+3UTQ70);1$HT<G^U]_PZ<_X)=_](U_V!O\
MQ#K]FW_YV%'_  Z<_P""7?\ TC7_ &!O_$.OV;?_ )V% '^)3OD_N'_P#L?\
M:_KI_P"#-$23_P#!3_X[!6+B+]@KXA;'BD\A;>S@_:)_9722:&X1[:>/R='G
M>W^U+;)J1.H7:NPW2;_[\_\ ATW_ ,$MO^D;?[ W_B&W[-__ ,[.O2/@Q^P]
M^QQ^SMXMO?'?[/G[(G[,_P "?&ESI%UX>N_%WP?^ 7PR^&?B:_\ #UY=VU[J
M6@7/B+P=X9T/4[K3;O5M(L+\P/&;:7[#IDQBD9;=D /XZ?\ @^'(G\'?\$VT
MA/G/_P ))^U>=L7[QL/I/P C0[4R</)(D:G&&=T499@#_GN>3+_SRD_[X;_"
MO]UGXT_LE_LT_M+2^'D_:/\ V<?@9^T%;^"YM3F\%+\<?A#\/?BXOA$>(!9_
MVXOA:#Q]X8U2'PPU[_8>BBYDTH3/.EI;1R^:D,!C\7_X=3?\$O\ _I&M^P5_
MXAY^SM_\PU 'Z!U_G%_\'6'_  6$C^,/C[4/^";G[._C!;_X5_#S6['4OVE?
M%VAO,L'C?XK:$PUG0_@UINHV4DL&H>#_  )?1VOB;Q3+'-+%>?$JXT6QO?*M
M?AQ;17O^CI7YX3?\$J/^"96H7<EY>_\ !.#]A&>YNGFFN6N_V0?V?+K??7+(
M^I27=_=?#0W][<7;*Q_M-G8S,2=QR=X!_C)? GX$?$K]ICXQ?#CX"?"+PWJ'
MB7XF?%[QA9^#?!^C:>KI:WVOZCJ++/<WSE6&GZ1H6DLVJZM.ZA-,TN-]1NVB
MM5=V_P!E;_@F'_P3\^''_!,_]C_X>?LS_#R&'4-6TNUB\3?%GQL@O5D^*7QF
M\2Z7:+\0O'EW;O!%=V^GW=[966E^&=&E4KH?@S0_#FD*XU2+4#+ZK\-/^"?W
M[#WP3\56'CSX)_L8?LM_!SQUI=C=6NG>/OA1^SQ\)?A]XZM8=3LFTNZM[+Q5
MX9\+Z1XFT^X^S!1+>Q:VC/'N665DD./LOR5_SG_&@#_-1_X.L?\ @D0W[/?Q
M6/\ P4._9_\ ""V/P0^/GB6'3OCQX;T:W58? 'Q]U*2*YF\;ZA8VD<D%OX-^
M+%Q9Z@U])$;:PTWXF1:I<;XX/&>A6LW\J'[.W[1/Q3_98^.'PQ_:%^"WBM/"
M'Q0^$7B/3/%WA'5K6YD>TENK9UEU'3]9@#HE_I>OZ-OT;6-'9=L^@O)H4R-K
M# 5_N"_$;X3> OC'X2USP#\6OA]X0^)OP_\ $UI!IWBOP+\1_#.@^,_!GBO1
M['4/[6T[3-:\)>(='\0>'M8T^VN3A8]2T.WU%7BBE#B959OEG_ATW_P2V_Z1
MK?L _P#B''[.7_SLJ .3_P""77_!0_X4_P#!3#]DGP/^T9X!N]/T?6KG[-X7
M^+7PZ74+2YU+X=_%1+*QO/$_A:Y,<[W46GZS?:G9:UX3NKZ.!M;\+:AIVJZ<
M)=/O8+EOTM0$ Y&.?\*^6?@M^R9^S7^S;#XC@_9W_9R^"OP)A\8M8?\ "86W
MP5^#_@+X21^+IM#M+VUL9O$2>!O"ND6.M7GVK4=:MH-4OXK5HM,U>\:*0VZ:
M;,/JF@#_ "*?^#J,A_\ @MW^UTR'>JZ/^SEN9?F4;_V8_A ZY(R!N1E=<GYE
M8,,@@UB_\&O4<B?\%TOV%V>-T5C^TWM9E95;'[(OQ]SM) !QO7IG[R_WAG_4
M9^)__!/+]A'XS^/]:^)WQE_8M_95^,/Q#\10:;;:UX\^*_[/'PH^)GC'45T'
M1;#P]HBWGBKQAX!USQ'<16&B6&FV-N'UU4MX;.." 8@8J?#3_@GI^P?\$_'6
MB?$WX+_L1?LF?"'XC>'%OCH?C_X5_LZ_!KX=>-]#.MZ1J&@:W'I7BKP?X(T;
MQ#:QWVBZCJ5C=K!KF+J"^:"=98I,  ^UZ*** /\ (O\ ^#J$B3_@N)^UHZ'>
MJ>'OV=@[)\RJ4_9E^$>\,1D*4WIN!(*[ESC<,_@%;ZB+2</$4NT(G-U;7%U<
M6=K*US%;QZBK1:;>V!,=XL^I:8PL+R-YM,F9%")^\;_;\^)__!/C]A7XV>.-
M7^)GQJ_8J_91^,WC[Q"FEV^L^//BM^SS\)OB)XXU%-/L[#0=,^V^)O&/@36?
M$LZZ?H-EI]G&TNM&.UBM!$D4"0F4<+_PZ@_X);_](U?V O\ Q#C]G/\ ^==0
M!_B4>;-_>D_[_P G_P 9I/.E_OO_ .!$G_QFO]M[_AT]_P $M/\ I&M^P)_X
MAI^SI_\ .RI/^'3O_!+?_I&K^P#_ .(<?LZ?_.PH _DE_P"#(Z".YT3_ (*0
MREEBWZG^RD[6L444,-K =,_:)BDFL[R%;.('49((EU=M,*[7TRP2?8&R/[X*
M^:/@M^R1^S'^S,?$<?[-?[-WP)_9\@\7G2QXS7X'_"'X=_"5?&"^'DN_[#'B
M:W\!^&=*B\2FR.M:P+9]3V/;K=W,47EI-,S_ $O0 4444 %,?H/K_0T44 9D
M4,00[&;;WR.<]#W[_H<=N*56A0\.XP3D8/7I115X6I/$0FZKNU*VR[=;I_H&
M'P]+&I8G$1<JUK<\92@[)V2]UI"8$D?*(47L0<_SI&2(18P0F>@QG/(^GM_G
M-%%9SP].==49<[I7;Y.>7+?O:^YY\*LHY<\Q2A]<Y?X_)'F?O.-GIM9=R5(5
M)R221]?ZG^7OGWN1PK&,?Y^OMW[444ZD8TTY0BHNSU2UT/2JSE*?))WC;;Y,
MFJ'R5_SG_&BB@DFHHHH **** "BBB@ HHHH **** "BBB@ HHHH *;L7T_4_
AXT44 .HHHH *;L7T_4_XT44 .HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b5_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "W NX# 2(  A$! Q$!_\0
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MHHH **** "BBB@ HHHH **** "BBF;QZ']/\: 'T444 %%%% !1110 4444
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M;PF@J4950!!M=6R[Y*1T/#WAJ#Q7IGQ'\(^-[NY\4ZA\*]7U/2=,\4WETO\
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M3IWP..GU^/;WQG/K_P"S[\18K_5K8^(/"WAWQ3X:\0WFEW2MMU30XFC;5D.
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M4EB"6QD$9P<D'^4N/?!3..'$\YR>3JY(I7^RIQC)MI.UDU&[L[*35EK)7?\
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ML[V756#_ &P^-O"NN7LO[2W_  2KLK'Q)KCZ?JW[,OQ/O[NRO=8)776'PO\
M#JKK.M *?[=\090.3@[69G. :]G_ &L=3U&T_;2_X)U6.GZQJ-G9ZIXL^,PU
M;3+.Y:R6]T\>"- ^;6D!5I%1C]W*LVTKQD5V/Q2_8R_X37X;_L^Z;X2^)^N?
M#/XU?LOV>FR?";XTZ'HRZC+:ZDFA+X>UO1M=\$RR1P^(/#_C+P_$Z^,/#4DL
M<;Q!#O 1F#O@_P#LF>/;3XV:3^TK^TI\8%^-/Q8\)>&M4\'_  WTO0/!I^&W
MPU^&VFZZJ)KSZ3X?;Q-XH?7_ !%XF'E"7Q/(ZR^7&8 BE4%<K^J[KL]//6VO
MW'0?FY\%/C#\4?V7?B]^T]^T!XS\6Z_X[_9)\=_MN?$KX<?%_2M0FUN\D_9J
MU2VTSPWH^A?$O1&4@M\-9618O'\9^3PA!(_C-P4D8&_XK^._Q$\ ?#']NR[^
M&WCJ[T3Q!\7/^"@7@;X,^$/B5)K*ZGI/PS\!_%7P;\.\^,_!>M*2C2?\(\VM
MGP,5!"^-->\-[6 (S^K'P@_9E\-_#/P_\=O!^O7=KX_\,?'7XP^/?BAX@TK5
M]'4V(TSQUH^AQ/X/"G"Z\@BT92)%<LT<C*44X5_G3X*?\$S/@Q\+O@%^T?\
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M^#.AW_B#Q!XI\:P:;XJU'71I]G9?;K0%-"TM0W_$GTALEMA9@[,&$C'YG/+
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M_:2_93ETCP-\13J?[0WP9.+(:!K^L#_A9OA+3!G_ ) >N$,/$/5L*P(Y)QD
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M5BO]*3^8PJO5BB@!B=#]?Z"GT44 %%%% !1110 4444 %%%% !1110 4444
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M^]GD$[ACC!)X^X?!7PX\*?#W3%TSPMH=OI=OS@6N1Z]LXZ'OD\@YZ8[I@6!
M.">^,]\]*_U4\%/H9<(>'RRK.>,6L_SU)I75XJ36ETM7H[O_ #2/XPX_\?>(
M^*_]BR>_#^2)*W*USM::7TM>VW776S:/XH/V\/\ @A]^T+\&-4\0?%KX$ZYK
M?[0_@"[S>ZQ::M_Q,OB_88/_ )<&.O8COUQ7X/WD-Q!?W^E7T%SINKZ7_H6L
M:3JUG_Q,[#5>G7\?KWK_ %.(HN,0_9@/RS^ (QV_^O7YH_MK_P#!*7]F;]M"
MQNM5UOP_;?#OXKJ&_LGXF^"K---U8'@HNM[0BZ^H&[[^&R1DXZ?Z/\%<78/A
MS!O)Y92N5:\VNBTWO>]M7=:='&Z=_P"7\[R19LUB[Z[V>[\_P_KI_GVU8K]!
M_P!M'_@F'^U!^Q1JES?^(_"A\??"<7N-'^+'@FR;4=,_LP$@_P!N:%Q_PC_B
M'(X/W2.5)!!/YX>=!-%]H@GMKG'_ #Z]NG^)XZ\?6OV[+,RP>;?[;@G??9[M
M?DT^G?L? 8G+<9E+ZK\?+^O^&"B88B'G]N+P#_F']L_E_P#KKT'X8_"3XC_&
M?7K?1/ 'A74M;N.EY>$8TRP_[CG'X@_D*_8[X#_\$_?AS\-_L^N?%6XM?B1X
MPM<7O]D\?\(-H)P<#^P^"<X_+GIS7\N^.GTO/"WP'PG_  M9O_K!GC_KY_<S
M]C\+_ +COQ,O_P!"3S\_N7;_ "WO^9'P-_9*^+?QXE@OM+TD>&O!_'VSQ9JW
M_$MTS/0_V'VS]/R%?J1_P[Q^ ,/P^N/"L\^N?\)3]C^V_P#"PK2\_P")D-4_
M[ ?';CTZCC%?=L<$4<-O86\5M::?:Y^QVEL!I^F6 XZ G;R,]<XS[9I9+<6R
MS39^[9:H!USQQQ@G'OZ^M?XC^+7[0WQI\0N+UC<FSC^P,EO:W_!/]%>"?HK<
M"\*<._4<YB\_SFU^9[-WV2WTZMI+:U[MK\#_ -IS_@GG^TE^S5H.D^/M<\+7
M/C?X0>)[,:UX<^)G@FR_M'&EX!'_  G&A_\ ,O\ B+!ZCC(/.0:^(89H)8?/
M@N/H0,>Q]NY'/O7^E3^SGI&G:W^S]X)T[5K*TU#2=0\+V]G>:9JUFE[I]ZA9
M\J^DR H5PI)#<*,]"RD?D/\ MP?\$&/@Y\:'U;X@?LS7.F_!7XCW@-]=>%Q9
MJ?AGX@U-<?,=#3*Z"6&"6C&S)^4 #-?[Q^#_ (I_V[PAPACN*5;.)<)0C&:O
M)<TXJRFDKP]Y\B?O1NTVX[K_ #-XRX3>'X@SC"Y-9)5*M/MK3FXWU;W2OT\E
MT7\:U%>O_M!_L[?&_P#98\8S^"?C[\.M:\ ZN;P&RU>ZM/\ BF-?!Y&MZ'KH
MX(_/)]J\8A\^;H?M/(^N>O?V'/\ D#^@,*\%FV"6-6J=G=-._6Z:Z=K-^5S\
MPQ&&^J?[[YJ^WY%BO:/AC^SK\=_C9I=SKGPK^'.M^-M'TS6/L5Y=VE[HW^@:
MIQ_GKTYKP^?C'OC/O_G%?MA_P2JT'5-7^$OQWOK?PK\+O%VH:#_IOPK\/?$W
MQ)HWASPUKWBC_F._VYK9_P"*G_/W]L<V9XG%X3"?[%;IZ6_K^NIT9;AOS>WW
M?\/J?CMH.L>/_@SX[M]<\':YKGPW^(_@/6/L7]K>'[S^S?$V@ZH?^@YWY_'C
MN,5_4U_P2Y_X+2_$KXP_%+P!^R]^TGX83Q/XP\8D:3X-^,/A=3IVH7[H<@^-
MM!((C;KAU7*N=Y#G@_RR^-O[4F\6^,/[<M]-TW7_ /A)-5_MC2=)O/[2\,V&
MJG6N=%T,\_\ %._Y'M]S_P#!* C_ (>-_LP?]C=JWYG1/$ _GFO!XHRS!YKD
MLL?BTN>,)N#LKIJ$FDGOK)1NKV?5.VGIY)F6,PF,L]G9->7IUZ^A_HE0=_Q_
MI5BJ]6*_GL_43(6/"-&.?NX_[ZW>OID=:^2OVS1M^ ?C,#M 03]-9@[>Y.:^
MNDD+/&<8W[\_\!!QV']*\W^)OP[TCXI>$M6\'Z\+H:7J*;7%G=/9.0=IQN09
M'*YR0>>V<@_!>(N3XKB/@;B[)LM45/.N&:U*BVTKRE"48V3ZRIMZ=7YGM</Y
MAALJXAR;-L5=*G5ISDK;J+3E;:VMM^E^Z1_.A::O?:=::A]BOKBW_M.S%G>9
MN^AYY&> 1SR.GUK6\*:_#X=U.#5?[/.HVXM-4LOL@((/]MZ.0>W0[?R/&",U
M^MT'_!/_ .#_ ).;FY\1"X(_Z"C'."<YPYQVX)'/?--'_!/[X/ DR7'B@*,<
MC56)YX_Y[$]<#I7^0N&^@]]('"8O*<9@WP?>-MVU;=NVFM_PZG]RXKZ27A;B
M\)FF#Q>2U;3NO=IQ:>B2YGSIQ26S\[:+?\K-.\4^&]'N9QI?@[[/8:EI'B;1
MM8M/[7_YAFN$,#T/<'..Q/2JU[XL$.A#0_"NE'PW8?VN=8NR=6;4M2OP2"1G
M&.2!U/4?6OUEE_8"^#9&?M'B1?KJK'&?Q[?ID>].7_@G_P#!=N!<^*R>^-6*
M_EEF%>S#Z&?T@*F!640EP?D4&O=E"2<7KK:2NFO1V//?C]X0*?UO^R.+5/1M
M-)OW=KIS3NKZ.S:OU/R'TWQ3=V=AX@L;<XN-<U;2M9750"-1L-2T36O[='&
MI''R]1P<8R*V[OQW;S0ZQ?Z5X<M_#GB?Q.,^(]6M+UB3@8_XDG).@^O.<G!^
M\,U^J_\ P[]^# ^]/XKQ[:N3_P"S<5+_ ,.^O@MDC[3XL]O^)LV3^&>U89;]
M##Z1V%P?U-9OPC9=W=J^]VDN[Z:AB?'[P?Q.+>->4<6IOMRJ^BM9.=K+E6W9
M:=_RJO?'<,QO[F#P]IVFZ]KMF;+6=?LPN#D #/RYP/3.23[5^E7_  3N\H_#
M[Q=;0C*'QC?\Y[C1M%;I][^%>_TSWZ<?\$^O@VW*W7BAA_V%''\Y,_I7T7\'
M/@=X5^">CZAHOA3[5]GU2\-[=?:K@R$-@C('XD?0XS7[[]'#Z.'B]X>>([XE
MXRS>,LF2=HW2:;VNM+.^SDO5GY=XL^+/ O%O"/\ 8G#&3U:,E4C-N<6N:V\5
M><URM;I62[:MGL\?WX/H?ZU?JO!W_'^E6*_TH/YA"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,F(AAG9LQT^;=USG_/O7RI\5OV4OAW\7
M?$__  E_B6XUFUU#[%I]B&TO4WL1_9R8PK;'3'S%AUY/ ]_K9E1@5$N >VPG
MOGZ]:B,*E,%\@?Q8/KZ9'TKYCBSA3ASC; +*.)LGAG64U'S.G4]])K2[UCS7
MMT>C[G;D^=9QP_4EB\GS2=+-E'E56,^623U:5DW'UWT6B/@O_AWU\&O^@AXR
M_P#"@?\ ^/5!_P .]O@W_P __C'_ ,&Q_P#BZ^^_*_V?U_\ KT>5_L_K_P#7
MK\H_XEH\"/\ HW'"7S@_TL?6+Q9\1E_S6'%OSQ/_ -J?!7_#O3X.?]!?QC_X
M4#__ !RC_AWO\&?^@EXI_P#!\W_Q=?=_EC^Y^J_X5-Y7^S^O_P!>D_HP^!2_
MYMOPI\J3_P""+_B+/B*]N,.+?_!]OT/@3_AWI\&_^@CXQ_\ !^?_ (Y1_P .
M]/@W_P!!'QC_ .#\_P#QROOKRQ_=/ZU!Y7^S^O\ ]>C_ (EI\%O^C<\)?^"V
MOS2*_P"(L^(J_P":QXN?I7;^_P!U'PCIG[ _PETW5-/U:'4/%AN-,U;3KZR(
MUZ4#*'!R"QX!.=N<O@X/-?=%K8K;)L[>G/3()[DC)/KR?RJZBEC_ *TGV$>/
M7N14H01YVM@>NWZ=B37WG!7ASP;P"I4^#^%J61*:<9*'NW35FK<TNC:/G<XX
MCSCB&SSK-:F=R2LG5M)I-I]_[JOZ%E.A^O\ 04^BBOT,\<**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!DGW&^E49O\ 53_3^IJ])]QOI5:7_5/_
M +III7_'\%<YL1M\OT9_.S\?"#\9OB/COXB0CV!"_GGC\O>O2?V:M1TJRNK^
MQG^(NH^&[@:P?L?@K[9_9NF:[DG_ )C9!ZYQD?I7FWQ\ 'QF^(^.WB) /< +
M^6./S]J]"^ \/@?^Q=0_X2JW\)7-Q=:Q]BUC_A(='UG4O^)7D_Y)]" *_N3B
M!7\)\A_Z]47LGM3I/9I]NUUT:=F?Y'Y=]<_XB_G%N[W]6>/?$>:]U'QUXP_M
M6R_LW4/[6&+3KP!_T'![8X_K7$PVD]Y=064$'VFXN[S[%9\_\Q3OP!V_EWKI
M_&X-GXR\009MN;S_ $06EF/[,_LL?\@+UY_'M^-9_A6;_BL?"$Y&<^,-+[_@
M>G7U_P :^YPF(^I<'+%I)<L8I*SM[L5%6O=I6BM-6K=6G?\ +LRR[^UN._J6
M,_Z*Y]?^&/O+X*?L-WNL&#Q%\6KV"WMU"FT\+:0,(=Q88UHG[[ J0P7E<C/;
M/Z:>$/!/A_P;81:1X8TG3M)L+8*$CLD\I% +#Y5)))(/+,2?E'IQT6FVB+;Q
M+&1Y$=N2<9Y.XN /F/89SGK6H&1%/9%QSR?O'TY/4U_!?$7%6<<0XV4\=5E4
MUM&%E&$59:)1]Z4KW3<FV^B6Q_KQX=>&'"7 ^4Y6L!E$(YM[-7J-7GS+5O72
M,4K-VM?2^EQ?^60^I_FM?F?_ ,%$?^0#X!_[#.I_^F,5^F=?F9_P41_Y /@'
M_L,ZG_Z8Q7\9?3$=_H]^(?\ A3^])G]4^!G_ "=3A'_$_P C\PJ***_YXC_6
MDJS3"",3#C.<#/IC_$]?K]/JCX$_L_>,/B_:P7T$_P#8OAD76Z\U,7@.JG.[
M;C."22I YZ@\]*^5Y2+A@0 <9[\<^_&?N\__ *Z_:7]BB'SO@5HH_<!C/=#Y
M<$X$\QX/3USR./IBOZN^B%X2\.>+'BD\%Q*N;)N'E=1NES.ZLFWM>^KV1_/_
M -)#CC..".!:>,R5I9U4K1IIV^%2C-W2V;YH))/2[>Z33]3^%O[//@/X8VN=
M+L1=ZL3NNM2U,F_E:_(P6W&0 8# X&WTR&(Q[L(F8'*Y!_V@,\_Y]*L0H#G'
M8>GKZ\#G_ UQGC3Q=9>$;&QN)K3[5<:IK.F:)I%JN ;W4]9<[5'7&"&W<9)S
MCCI_O5PQP9PWP;@I8+AG*:.20LM(*_\ X%:<HN[77OW1_F-G68XS,\6\;G&:
MSG)MMRG)WUZ7=DHJ]DDK+K=[]N9H/]1-^O\ +(_D/\*\]^)NF>*=8^'WB_2O
M VN?\(YXON]&U,:-XA%ID:?J?4'GH<]P2> ?I\:^,?B]\;?"_P"U5\(_@\[Z
M=_8_Q9^&_P 3O$]I:_V+GPUHGB?P%K/A^5-'UK75RY_X2CP^VO;,@,LH8H,X
M8I\<_$?[6'QJL;_X2_LP:CX3^"NL:3XBTO0_BC\8?B!HJ^-'\*:8=%77"?A;
MX(! \1^(V8C_ )&M8XUW99>$=?J# ^A_V<+_ ,1:UX".M>(_$%OK4VN>(O$E
M]H]N;L:EJ&@Z7_;4RKH>K:V) =<EC.&>3RQE'159C_JOH:OA&76/'W[*W@CP
M?X"MK+5/C199U0'Q9=^7X<U5E4R:YK1US^P4=?[><EGC8 %P1T 9:^P?!^H7
M6I:%H^JW?%QJ=FFKFTNK,:=J$8U<[U4H#A/O') 5B-H8C"8 -&\T/3=6TN?2
M-6L;&_TJ[A:TN]*O+42:==6&<E#ID@>(\D*-RD84$ @J*_$W]I+_ ((-_LB?
M&'QW-\3/!!\2?![7KE3=ZUX,\&79C^&_BZ1"%/\ ;OA_8J88Y)9&"[^%3:>/
MW4(#8/;G\:@E(FB.,\=/8'GT]ZX\5+%8O!YGA-5SW25]&FN9:;7T=G\KL$K8
MKZWU6]_+S_X/F?S*:Q\%[7]G*X@^&B>%_#7A73]+L_\ B3Z3X=_Y!E_IG'_$
MX(.2K8(R& (STSBJTERSVY992<>X'1@._48[8^E?3'_!18RVGQNT2XMI_LP7
MP-I@/!)/_$U1B?RX[\ 5\5Z?XD!$ F@X&>G?'4?Y!QVSBO\ G%^DAEF-RCQ>
MXNR?^U7Q!!22NUI>R?*VNMG?YK17U_U]\&\/+.?#7A'.?[+BIR@TG#5*493A
MSQ4F]&XVUO9W5W9'<TEU_J_^W+4O_0120WD%Y&3!V _4\>QQ]?T%++")HS #
M_P ?0^Q?GDY_7^8[5^'X=?[8_/\ R/T3$O\ V7TM]W?YG[V?LN?\D$^'7_8L
M:3_[-7T++&'+$]MN.OO_ (_YZ5\Z_LL3>?\  7X;3=[CPOI!Y]0LA']?Z=J^
MCF_C_P" U_T[>&"?_$..#T^O#%+[G"DORN?XJ\4/_C+>*U_U$UD_G.?^9Y'\
M8/@7\)OCSX*U#X?_ !@\"^'?'_@_4K8))I'B*Q:^3!3.Y'= ='VX S$0",YP
M5*U_*O\ MT?\$!/%_P /X=>^)/[&OB%O&OA*W+ZS=?!+QK<R/XBL"@5C_P (
M7X@52NLOM<8BN#$Y;<L8?:6K^PT1$YP?Y?XBN/\ 'L(_X0KQAU_Y%#Q-[=='
M?&?H5ZX^M?J^39WCLKQ:G3EHGK%J\91NDUWB]6U)--/2S5T_ELRR["8O"M->
M:^?S_K5G^6SY_GS3]OLMY]BO/^PIH7_(=T7C@^W'UXXK]L/^"57@_5O%7PJ^
M.'D>"/@%XU\0Z7B]^#^E?'BR\&'X9_\ "><#7?\ A.-< /Q._P"1<_Y$@^$Q
M_P (6.N>F/YJ-2\8:WX4^(/Q!_LN?[5;_P#"R/$][_9-WQ_S&M?ZXZ\\<>QK
M^A'_ ():WGBKXV?L^^(/!OPS_P"$D^$WCBU^,']M:QXW\)_#?X:?%G4_B7I?
M]BZ!_P 47_8?Q _Y%_P[X3_Y&C_A*?37_4\?T%G:OD^4XSNFNOZ--?)KR9^;
MY;;Z[^7]?YGY>^+O[5A\9>./^$C@TW3?$%KXDU3^U])\/6?]F^&=!U7^VN-%
MT/\ ZEWU]*^Z/^"3L./^"CG[+//3Q'JF?_!+X@/^>GI7Q!\1_MUE\1OB#8ZK
M/<ZEK%KXPU2QO-7N]'T;3?M^J?\ 8#\/_P#(O^GUYYZ5]O\ _!)?_E(Y^S!/
MG_F8]5[=/^)+X@X_SQZ"EFG_ "36=6_E?_I$CFPO^^/T_4_T2?\ EK_G^]5B
MJ_\ RU_S_>JQ7\SG[&5Z39+ZC]/\*LUROB/Q5H?@_0M9\4>(=1M]-T/P]I6J
M:WJ]Y= 1I9:7H8DDUC4G*@DI'&06  R"K DN4H Z'9+ZC]/\*7R/?]?_ *U?
MGW\&O^"G/[%W[07C/0/ /PC^,EEXO\3^*(+^]\.6MMHVOV.G:C919)*:O)H:
MQ1@@*5(<,7PTCMM4U]X?VM8^=Y/VBU\[[%]NV_:?^8=NQYGU_#&/FS0!I[)?
M4?I_A1LE]1^G^%?.W[/G[3OP>_:I\ 'XE_!/Q'_PE?@UO$OBKP6][-;2:5*?
M$W@?6/[$U_1O[)UD02(RS%L,NW='@MAV(KW9M5L?,:W6?S[C9]J%G; M?8./
MX RY[CMD<9Q0!I[)?4?I_A1LE]1^G^%5#JMB)883<VWG70!L5%RO^F<?P%1S
MCT(;V'J3:C!#+;PSSV\%S<D_8[8W2YO..B_(..>,!@>^0,4 6]DOJ/T_PHV2
M^H_3_"JAU2#S+>#?;_:KD?+;_:D+@?@ISGT &?>O$/VBOVD?A-^S#\'_ !A\
M<?C/XC7PI\.? =IH][XDU1K1M0U'3QKNMZ'X>T@C2$ D,C:YX@T>->3L=@2
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MF7XG#2O^"T?[7?AJY_:Q\$_'7X*?MD>!O%/[-^C>![OXE>&_#GB\KX,^#O\
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MP_K?PE_MH^(?#G_",_#[Q&WB5Q$/"G_%&L[-L (8;O$?V.O!?C[XF?%GX$>
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MD*NV'0$$?<TW@OPI/K,'BZ3PYHL_B:UL18V?B*XT@'Q1'IXPODC6S&VOK@
MCS,YX"<[Z\X^/UK\*S\$_B=+\<-,\-ZU\)[;P=JW_">:7XSTX^)/#6H>&8])
M!F77=%97374<C8RMB1MQ,;AU#  \P^(W[0,SW.G:9\)='@^(64U&\UC4K.U7
MQ%IVGJ-%5] 5S$>/#_BABR?\),DKQ%2V"RN17T_H5U>ZAI>D7NIV1TS4[JTT
M^]U;2MPS8:E)I"-+I.".?++9(.>F,_,,_/O[*$OPR/P/\#:5\-E\-G0_"VD:
M5X*N1X>!DTG^U_#^C)I&LZ9I&LE5_MPPRQ?(P=AEE9F!("?4_P!E7SO-S^'/
MI_GO0!8_@_X#_2HIO]2?H/Y5+_!_P'^E13?ZD_0?RH _!K_@I%_R6_P[_P!B
M./\ TZQ5\%U]Y?\ !1S_ )+CX>_[$=?_ $ZQU\&U_P [GTH_^3U<7?\ ;OY1
M/]B/HZ_\F?X1_P 53_T[5+\5U-:C%E/GGH1]./\ /Y^O4V6NB7R()P,?;=+/
MYG./P_ET]N.8D D?YYJ@"/M5N>G^FZ8">O3V_2OP##89_6]^O>^OE\S]ES'+
M8XO"NR7-;5V2;7KZ?@?T=_LFG?\ L^_"X]/^*/T#]=+(_K^5?3M?+O[(?_)N
MGPK_ .Q)\+?^FI:^H!]YO^ _RK_IC\,M>!.#?[O"]'YZT?\ ,_PPXP_Y*SBO
M_L+Q#^^I-V-!_NG\/YBN*\=_\B7XR_[%;Q%_Z:)J[5_NG\/YBN+\<?\ (G>,
M?^Q5\1_^FB6OOJ'^\R](_P#MA\SB/ACZW_%'^0;XPASXW\<3_P#4^>*/3MXT
M\0?7_.<5^U/_  2H\7:+\,O@-\4;CQ%H?P5\%3?'_P =Z7^S]X%^,?Q,^+_C
M+X<>./'?B?7=&77!\&?A:?#ZD^'?F*KXV\59 W>(O"P.217XK>,/^1X\;S_Z
M,<>//%'X9\::_P"V?\G/)K]2/^";_C&>RT'P_P"!]<^._P"P9X<\+7/[0G@/
M6O ?PR_:Z\-_$KQ)\3? ?CS_ ) .N_$WX'_\( 1X8_X2(_VYH0_X1;Q;_P C
MI_P@/AC_ )$T5_5>>V_U:RB][)IZ<W2S^SJ]MM;Z)IIV?Y=AO][^3_)=_P ?
MZ9\#>)/&WBKX>_$OX@>%?$?ARYT3^P?&&J:+>>"+O6/^$DU/PE_U!?[</_(P
M?IGBOUH_X(Y^*]"\5?\ !1#]F&XTN^MA<?\ "7ZH3: >FB^(,X/T[_SK\A_V
MBM-OM!_:,^.^E7WBK4O&VH:7\5/%%E>>-]5L]&_M/QY_U&O_ -??K7W1_P $
M2?('_!5+]DG&/]*\2>*._P#U)?B#'^.?ZYKFS[_DFLZ])?\ I+_JU]=M-SFR
MS_?/N_0_T^?^6O\ G^]5BL^'_EV_X'6A7\O'[$%?-_[3EC?ZE^SA\?M,T[3[
MC6]3NOA!\3;2UTO20O\ :.H3-X?UU=$TF(<XW[VC/0GYACYB6^D*SYH?^F_I
MUQ[^F<_Y- '\>O\ P3(\>^-? ?P2\$?!WQ#XH_:RNO$UK^S=\3?!>C? ?Q%^
MQMI'AKX:^!/'IT?Q#KNC?V)\;O+/B<;4"LAW-YC$JPB"AVZ?]EC]F[XX?!6U
M_P""0/Q_TVX_:?U/XV?%GXV>.?!O[4Z^+O%WC+Q+IMY\,M9\&^/Y/[(\=:*S
M,OA_P[X1.A1MX%^12C(6W,64)_6W-#_TW]/Z_GZ?K1Y/7]]TXXQ_H/'4<C&"
M,<X''''- '\6OP3_ &5_BM\)?V7?A-^U!X&TK]H_PC^T=I7_  5-^QVGAVUN
M]9/AJR^!.O\ QI&@ZWHH^%F\^&%^'?BKPWK3>*&#1D.70JXV.#U7Q(\2_M)G
M]O71OB/\.?@3^T/\)O'_ (8_;C\+>&/%]K]L^)?C?2]?^ VO:U_86N>-=<US
M_A)/^%8_\*[\6?\ 0K?\(>1X+^AK^QZ.. "$PS_O@OV//TY((QU&,YYZ_@'>
M3^[\G/\ /IG^>: /XS?B?^SO^T-!^SK^W]^UKX<_X:S'[4WP<_;O:]_9OTG2
M?$GC'/\ P@P^-'@ J/ W@<N/#/B#P]XM42$@(V0I)9-H#_1WQ,\.:@?V\/VC
MC^V3X _;S\:?$[7/VA? UW^P[K_[,]SKO_"H['X$+HV@IH1T%M"*>&?#_B ,
M->/QM?Q:C"52KH=K*S?U236<_P#SWZ_AC_)Z?IS5@6@/^N(/N.<]>H__ %=^
M: /XV)O ?[9FI?MS>,-*^+?B/X_?#;]I"Z_:T_MOX5_$WP1X/^)?C;P-?_LY
MC_D!:+_;G_"2'X8>'_AT/#@'A?QO_P 4?Z>M>"_MT_#CXM^,?!'[<_@WXW?!
MW]M?X@?MW>,?VD--UCX6:OX(M-:U3]FB_P#V=4\;> 5\"C0V\/\ B0^&&^'@
M\.!@_A8G_A-O^$V'/0U_<S]D( ,$_P!1=?-_(9/J?_UU/%:3+UG/X<__ %NO
M7U[CO0!^-W_!3:S^*UW^RY^S#;_#.Q\<G7[7]I#]EX^([;X?_P!J_P!HV'A8
MZWH1UT:SL ?Y<A3YF#C;@L2YK\9_CE^SC\=_$G@O_@H-^T%8ZI^U]HOQI\"_
MMJ^!=(_9[/A[Q%XSTU= ^%VM-X=T#7=9\$>">FO^'CX<?6\+U8!B.%-?V8^4
M?^>Q_3_&EEB!Y'_ZO\]C^!H _D _:$^!7QV_9RF_X*E?"7X V_[2OB'X;^,O
M^";?PU^)?@ZWU/Q+XN\1K#^T<GC'2?#^O'P/K;.Q/B9/#B?\)!*(_G#M)E4C
M$BKV9_X)\:A!^UE\'OA+-KO[7FI? CXC?L#ZE\6OC#]M^*/C3^R]=_:)T+2@
M-$&N:WN!\/\ B3R\@>&,[=V'VE/E/]8GD"4?O\7 [>WX=,<_K1Y4WI^@_P *
M /Y'O@;\1OVG_@=X<_X))?M(_'?P=^U%XU\ ?#'P=^T;\&/C=:>'/#FM>-/'
M=AXHU[6=?\/?"=O''@E3NU\X70POBL$$;?E.5&/(_AG\.?VDOC9\/_V!/!OQ
M$T?]K#X?Z)\1/^"M_P"V-?\ QALGO/&/AOQSX>^#6O'Q'KO@&3Q!K8P^@>&6
M*Z-X7Y901K4@1MP:O[/?*F]/T'^%$,4PY/ZX_+^I_7G% '\?OBKX7_M7> _@
MQ^UK\&/!%A^U%J?[+7P9_P""E7AE=7T#2=7UK4?B_??L:MX,\.Z_XAT3X5:Y
MX@+>)M?\.'Q)K6M$!B3QP>&SXO\ &#]FKXS_ !P_8X_;%F^&WPF_:IUK]D+P
MA^U3^SG\2_V5?AE\3KWQCI?Q?L_ N@(S_M):QX?T+Q"3XH/A[:KOX(7Q66*H
M&).%8U_;5]D_Z;?K_P#7I!"81^YGQ[<'/7ZCZ9H _EEU?]EWX>_M?_MW?LS7
MVF>%OVE]'_9:_P"'6/BB]\(7FJ7/C/P/XDO_ !+H?QK/]@^"OBIK1E;Q/_PD
MB1:Z/$S>&-^&8>&75 "(J^-_%,?[:NK_ +.7[#.H_'?3/VA_$G[.?@.Q^._@
M+XDJ=(\9ZEXYL/'6AZT4^$^M_%+0_ 'B3PCXF\0 >'4QX*\4)PI(9@&D!;^V
M'[-*1D'=_P!?/S?RSCWSV_*H/L@\WSO^7GK]J^R?KC_/]* /Y3?#/[-?Q_\
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M4_E@O_!7W]E'4/B#K'P_\/6'QF\9Z?IWB'Q3\/K3XK>$OA#XT\0_!#Q3\4O
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M-?M1_P $Q]!^*GQ"_9E\8#P;^T+<_"7PO\)OC!X8T;Q)]D^#_P 2_&W]O?\
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M\"?A5XNM/A!HFF_$OPGIGCG1SX?/C+6_'&XGQ!XC3P\NTY&,D ;CG'JOP_\
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MD[@H+!5K^=7_ (*4_P#!TK\$/@1<Z]\*OV&M+T?]H7XK6@U.QO?B7J<C:?\
M"'PEJ8(P?,.V3Q$1MY = QRKE@03_P!+/A3'F\..#[;KA6$GMIRW=_ZZV/\
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M^?G;S/1OAS\4O'OPHUG^U/ ?B&?3Y^1>Z3>@-IFH9R. 0>Q[=C[\_J_\&/\
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M_P# SZ 48?V3G/B?+F;5UP=3G%J,G;2I+5.RO>--REK%\ZM**_@3Q9^F&O\
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M: /@7PO^T%^T+\2/B1I-Y\---\&W-S??L^/XF\8>"_%7B/61X<T[Q[HWC1M
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M4'#\-?M*^(_%_B*X\4Z5_;9T_P"(O_"!7OA#2=6O/^);X#U37/AC_;V3CCQ
M?7&!WQ7Z">*O@9\'_&.E^'M$\4_#7PIK>D>#O^1;L[S2%*Z$=H _L8!<H1CD
M1LJYY())SIS_  P^'MUJ0UB^\&^';K51<6+?VE=:/#]O)_LI=%C8N8]ZD19B
MP&,>TDM\ZK)0!^2?PN_:B^+/PH\+>!O"-UHEU\4OB#J?PTU3]HWQQJA'C#Q*
MNM:;KWC-_#[^$/ H;Q$?[ D=-&*%G+^"E\8Z]X:5%42S>;]):K^UY\3%N?&X
MN/#O@'P9;Z5X[\*_#WP?;:SJ^K^)?%&O^*M<T,ZYKVDMHGAY5R_A8'#G@<<
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M3\%?B[\#;;P9\4/%/PR.@_&/PY_PCNJZ^?#^P#6]% YDT&0$G<%W90@D%E!
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M8_R:(QV%/+PN2-Q +'(!EKLOA_\ "#X?_"Y=6'@CP[!H8U4!KQ59[RQ;:<X
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M+^4XS\X+#@A:HZ;\$?ACH6NV?B:P\&:=:ZMIFH>.M:MM3M599$U'Q]SXV(3
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M#!AX@93H9*G&.Q4X!KK?BQ^T_P"(? WQ+\6_#OPI\'=3\?W7P[^&R_%KQCK
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M +%%%% !1110!3C[_A_6I***YPK]/E^I8HHHKH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *TL0/^>G^>Q_
M T11 ?YZ_P">Y_ 444 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b5_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_003.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (* D # 2(  A$! Q$!_\0
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M]NE &O\ :HO^>Z?D?_B:?YO^U^G_ -:LC[8W]Y/^^%_^*IGVR7^[#_WTW^%
M&MEO[Z_F/\*FWMZ_H/\ "L19'?HR#KU]NW /7\O4BI_/&[9DY^@Q_P#J[YZ4
M ;.>,GCZ\4M9RSB7 <XQGH0.1UZ_CW'.!UZ"S;UR"<XSL(7=CZ=/;K_2@#1H
MIBR*_3/X_P#ZSU[?XT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJO'<+)T21?=E Z_P#
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M@4]>G?\ R>.M94EZSC*K(W/3"YYZ\%AP?<__ %\NYN2C;2X+<G .>IQT]_\
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MCB.5MWD.RK/_  <&6]WJG[ WA%M$N4OK*P^,7@274KK3IEN;>"&+P"@>.]2
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M[6^^2?D"UVUOZ_DTG^!+113$</T!_''MZ$^M6 ^BBB@ HHHH **** "BBB@
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MD[/[+G%+5+_EX[=;7/E[6/B)X_\ ',MU>^'_ !!-X)\,0W(MM!>TMXKG5=2
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MUZ'X]53H5OJ]:,J==-ITIQDIIQ?+)6Y6KJ6C7-=/2Q?HHHKTQ!1110 4444
M%%%% !1110 S8/[B?I_\34?DC^ZGY#_"IZ0Y[8S[UC5HPK)<Z;MM_P %._\
MP *VQ?3]3_C2>6G]T5-L/J/U_P *-A]1^O\ A4>R?_/JA_X#'_Y "'RT_NBI
MO+']U/UI_P _^S^M'S_[/ZTU0BO^75#_ ,%K_P"1 APO]Q?R/^--\N+T_3_[
M*I=A]1^O^%&P^H_7_"L%0J+_ )<87Y4X+\X,!GD+_=7]:/(7^ZOZU-\_^S^M
M'S_[/ZUM["/_ #ZP_P#X*C_\@!6\M/[HIWDI_L?G4FP^H_7_  J3 ]!^0I>Q
M?_/K#_\ @N/_ ,@!P_C&ZET/PSXDUFQCBDN](T36]8M?-)"BZMK0W;9PK80I
MA4X^]P0HPPY/X+>+-3^(7PG^'OC+6K:UCU+Q3X7M/$&IPVY?[/\ ;KE8VPI*
MH2@#'=E0 PQR!FNQ\<Q_:/!/C*-1S/X5\0P+N!'S3Z+(J$XS@ X+$!B,' ->
M9?LOE?\ A0/PKM@,M;>%+*S)P-H-N"& (_A/&W(!P.0,8K6$:=!6ITGZI?+N
MK]_.[ Z+XJ?!WPW\5=!M=+U<S:9JNDG[3X9\4:7++%K?AC50K!;^PG#Q&=<E
M=]I.RP.%((!*LGE/P]^*GB;PQK]O\(/CM/9V7C"2 Q^$/&J :?X>^)NF[1&U
MQL $6G>(MH(DTAA'=L<D)N,A?ZS8$C ]?\:\X\?_  R\(_$7PW-X9\5::EU:
M23"]M+J,JFI:/JP#[-;TG4=@N;35T+%DNXV3!QE""X?4#NH)B#MDW9W&,DC&
MV0#/E_-AB?\ IHH: X.)2<9OU\9>%_'?BCX)ZY:_#KXUW\FI^$K^0:/\//B_
M<B%+:^@^4+X;\92[XY=)U()&%2_DBGM\+AKS #)]?6\W#DEG"-L+*K,N[&<!
ML ;1C+2,1$.[C- %^BD# D@=N_:EH **** "BBB@"M+TG^B?RK(O._\ P&M>
M7I/]$_E61>?=W=CCZ\9S0!R;(S7BQO@K)>?+@G(YXW' [8'0]^3FO1W0G[A
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MCPS??'[X$_#GXD:AX/BEL-!U+6=%0ZG9Z4Z&"/3H]2@%O=KI<=LS*-%D>XL
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M!>3QC?:=XX\%ZQ_P@_Q9\-K_ ,2'Q? AFBO;<9/]@^)H5BSJGAW)^:TEAGE
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLK7_ !:_,^CX7IXBMC_84IRG0M\<7[OXVZ7OH?4?QANX="F\-_"709Y#X?\
M!FFZ5>ZM(J(&UOQ3KI_XF5S?LC'S)/#8YTY9,NIRLGE@ GR R/%*S+L:WXVR
MKN9),?W5">;UR/FB3\CD]#XHO/[1\7^+[^/S7EO_ !7K$P\X ,GGX$L9R_$<
M?_+  MC'.WI7R5\</V@?^%9S1^&_"L5KJ/B^>#SM6N;K9]GT@=?+,:,[+)["
M'!QC=Q7Y+PWE+Q4E2Y)3FGJK*4VVVVW:RUOWZ6TL?:9QB)45^^_=?XM+>EN;
M\;GTTMM*ZEPI"CO(&B;KC_5RA)/_ !SL>_%1R(8G5'P&?[G4J_\ NN!Y?YL*
M_'_6_BI\3?$-Y]OU/QMK;WG:XM[AK8<^MO&1%Z]__K>A?#_]I;XC^#[J.+5[
MA?%7AUL_;['4%_TN'&?^/"4$AL]/WTL73'2OM/\ 4#&+"\KE4Y[?#UO_ .!]
M^M_,^>7%-)Z+E?\ 7IWU_P"!H?J'51D5H&MQ&H29Q++EBQ27UA)4'T.25.<C
M&,51T#7],\3:)8>(='G^TZ9J%B+Z&8;<IGI:3!795O/^F:.\?_36M+'S;,C(
M&>O'T]<^V*^*K4J>%C]0Q$O8R5ERSNGMV49==;J6][V5CZ/"U:=1.<9Q</YU
M>WWVO_Y+]YRW[4GC_P ?>'_@]X!^+NA1:=?2^&];7X=?$*'4(]UZUL3_ ,4M
MJ%Q)&)@UJ_6ZGEFCE3($4-QW\0^%/[3?A[QQ=6OA_P 6P1>%?%5TWEVJ*4-G
M?R_\\I+AI%;S,#&/+//>OH;XB:/:Z]^SC^TIX?NT%RH\ Z=XTBC#LS#4O"9S
M!D,J[+BX(&P*Q#X):1,<_B;9S3/:6+QN/M"P"^LYY $FM-0/<7,9,H@![@%^
M1\E?7<&Y12S_ "[.,,E&G74GRTE922[6244]]I=KJ[=OG>(LPJ8/$^U3<:?\
M_3\+O\#]R=RD## L3A8QDNP'\2@#:1[[OPJ%?GZ?K]<>]>6_!'QC<>-OAIH&
MKWBH]ZD=SI][<DCS?MEOP\G\68#@!68B0YYB7K7J<?R=?0]/KGVKY[$X7ZA6
MJ8:47"O15JM)ZRI_XN6\5KU4W?97/=BU.%.I!J5.M_"DMJG^'9_>D?L#_P $
MS/%-YJ'@GXA^")[MW@T/Q#+J>E1O<NS65KJ(_<I;?+E8P<>80 JD *'!./U+
MC/!]>_IR,?XU^1W_  3 TM?LGQ2\0(6D62]L=$C51(F1:99@?-2-#(Q0*N'.
M?XBIS7ZWQJQC)R.<8Y.3DGV_QXK^+..*%+#\9YUAJ3BZ5UK'X6W:[VU?1]>[
M9^Y<-3K5,DRR5:$HNE=5.97Y/*6K^25_O,_7X%N=.N !^\2'S$W=NO!QD@]>
MV,CJ.37'Z:Y/7O)Y0!Y!;U([+[CGMCO7H4J"5I8S]V2$QC/J21D^W3GKQ]*\
MXL7$3LC!MT=Z V #VSD9(XX[XKY@^F.XAD7R]N#D ^F.@]_Z5IP_ZO;W /TZ
M#_/2L.VD5F=0#E,YSC';IS_05M1G;CY68L"0 I! XZ[]H_7]* +-%-+J#CDG
M^Z 2>F>WMW.!3J "BBJ[W4<:EG$B@2"-L(S["<'+&/> N"#G/&0" >* +%%5
M1>6[':LB%PH)421$AB,^7Q)AI.N0A8 CEAE<SHX?H#^./;T)]: 'T444 %%%
M% !1110 4S>/0_I_C3&F5?X7/T /_LW/X5!+,(DWE'88SM386ZXQAG7G\>G-
M3*<8P=23]Q:N24I?^2PC.?7;DOY$J492Y4U?3?W5KHO>DHP_\G+6\>A_3_&G
MUGQW*2*&"2*&^[N"9?\ W=KM]?FQP>*MK*K= P^H _K_ #III]5VLVD_N=I?
M@#E&,N5M7WT]Y?\ @4>:'_DY+1113*"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OEWQ663]JKX82K@&7X<^*K4DY&5_M#[3MS@Y^0$8_
MOG'3##ZBKY:^(+BV_:3^"]S@_OO#_BFR)&,DD9 [9&3ZYX/% 'T[%\K%3UYY
M'3M]#^E6*BC0HF/EW>HZ?R'\O2I: "BBB@ HHHH I2H2+@\<[/7_  K O''E
M#@]#Z>I]ZZ"5P!<#G@)Z?XUS5Y_JA]#_ #- &'9&.37K0$$I(/E!QD=.O/'I
MP3Q7I&P^H_7_  KS;3HV&O60R/D'/7GZ<>W?%>G4 %%%% %5SOCP/1NOU_'T
MKY\_:'^ .A?'GP3>^&]1,&F:M#$6\.Z\L>ZZTVZ*]7?R7D6 E1D1^8<DL$)S
MGZ',;;-HVY]>?;/;OSGUIDV<#.,\8QT[_P">E5A,3B\OQD<RP56='$TW>'))
MQDFDU96:333::=TTVGT:PKT*&)HO#8FDJU*VMXJ2;T[OR[=3^);]KO\ 8 ^*
MOP:\5ZAJ5GH;A+N83S0VEM)-HMXA&0-.O?(CMG8CDBX:V R!DFOA=OAM\01,
ML"^"=;D<R&)6CLPT.[G)\[>(=O&<[_<"O]!OQ)X=\/\ B'2'LO%&D:3JVD11
MSS2P:E:P26%K' OS.T$P("E%)W&0X13G:H-?S\_$?Q1^SQ<?$/Q?:^'/AIJ$
M&B:=JHL]*UK2/$$[VUS+CYIH=$N/)M/(8Y8'[<7']WKC^P?"[Q[SG,<"\KQN
M55JV)25\?925VVDFW-SC=*4FM5I9;7?X+Q?X>Y?A<5S8?$4\/&6RV:OJUI'5
M*Y^-'PJ_98\4ZCJ6E>(?B/&^B^'[63[5!X>W-)?:E>$=)/+B:)(>1S/<Q-CC
M9CK^G'PUO%7XA>#(].TV2Y-AJYTXV%A;-+'::9_SVO!9"<V8[;KD1#IW(KIO
M[4^!-N[NO@OQGKJ2C-R][JATNWO2.?WIMKR[:T!_Z=TD&,],$"+5/BMJIMIM
M'\$Z1HGPPTB13"(]#,4FNSP==VI^('#76I2]/]9'".Q:OIL\XBS;B:C]5="M
M2I][:?A/?Y')@,IH97C/W;BNG3:S[&+\2]%NO#7Q"\>Z)J5NWVW3==U&XDA
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MQJT=8 8=.\5Z>WDZOHDBB.82\[KBWC9VFDL\ 'S94@;J?* X'!X#_2%S?BS
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M@@0G!K]P\$>-L-PWG#RW'U*<,)5;DIUFU#G<8J4;J,K.7*G&Z:DU*,;/EO\
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M)]IMK1%^?XO\3?\ !-#]M6;]C/Q[%X/\':';_'SX(_\ !63Q%^W;\(? .L7
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M5BL37S#&8K,<;S5<3F<G+%\^K4I7NYJ]E>[;2<K;+N2T445[)(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%,WCT/Z?XT /HJ#S#_>'Z57\P_WA^E
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MVIS:)X-L+H6=@+,^6^IR$<.;A'=C'W#'#\?=]/T4_:.TC6OA[H?QU\.LL?\
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ML#7X/F.'6"S*I@W[L:/\1.WN/^]9O37N^A^D8&I6Q&"O.$N5[[.^VVOE_P
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M_7_/^?TJ"%QSP><]OICOWQQWJU0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$@#)H 6H7G1.H;
M\ /?U(]*//3T;\A_C5*2174.,@9Q\PP>_ID<YXY_ID EWMZ_H/\ "J[.5ZL#
MTZ8/7IV_R>.M5V<KU8'ITP>O3M_D\=:QYKH_WLGZYZ_CW^O7CCH0#3:=EZLI
MZ=.>O3_/KQUJMY[?WE_2L*YOT0D&0%^I0<MSUXZ?K]/>"V2_N^;9'E!],K_Z
M&5H W3>S!MH8,?\ 9(Q_X\%_E7S-^T[=HOA/X>WK,5:U^*O@\%3@.HN+K[(A
M.">%EY?)R$Y4,PVCZ-A\/:A=/OGE^SC_ &&<'KCNB@^V"< _6OGC]JW0;73_
M (4VNHK++++8>._A[<(9"/EDG\2V=G&1R1GS;V-GZ8C5R S!5(!]#:E>!+V=
M%D&3R6!&U >F_N..?XOZU6^VK_ST3\U_^*KKI/#^F2O.[VX+7/\ K3O;\UXX
M.>>U1?\ "+Z-_P ^O_C[4 <^EX)/]6ZO_NXX_,BIS?1CI,C?[H8_S K5?PO8
M-_JWFB_W&Q_A6?-X3D_Y=[TC_KH"/_05;IVY[GV- $IN]OWV$?\ O@9_\=+5
M;6Z5NA(Z]0HZ=>_^3QUKFI]+U:U^\@N?<%S^I0#IU]L#FH!>- =MP)().T<@
MP_!P.%)7CTW9Z<<X !W4,GR[LC&,_P">W/?G@\\5;617Z9_'_P#6>O;_ !KD
MH+W<IC1B[9R=I&,Y.<9.?R&,$ 5J0W:^I[^G;KWQ]??&.>* +[%&^\#^0_EG
M%9MY#UZ=OU_#MV&/2KGF+MW\D9QP.?\ #COS_6HI?](SLXZ?>XZ?3=ZT <;<
MQ%',B[E:V_U)7'//\7YG[I)_E7:Z-JC7]NYE\OSX\AHE8;VXS]T^N<#WX/K6
M7=6JMYN /WGJ.GKGTQQG&?7IQ7/,DMA<K=VA*RQ_Z]6.$<Y_@ !S^..GO0!Z
MB&&=O0^AZXI:P=+U2#45# D7(R#'\JD 8Q@!B,=SSP.V<UN;USU ^I _F<_C
MC% #J*** "BBB@ JO5BHMA]1^O\ A0!^-G_!17]F9-5@UCXQ>'M,^TZ)JV@W
MFC^/],M[3S 8;@#9XEN%A#.P7H\G,HR-L1Z5_)A\0?!-]\._$FI>&K^&X%C!
M_I&DZM( EK=:=_S\6US.85NUXP(K03W!Z>3VK_1 O-'MM1M;BQOH8+BSO$$-
M];3Q+<07MKAE:TG@E'EB%E;!VY. 000QS^27[5/_  3%\,_$2TNM6^'=M8M:
M1R"9_!>KPH\%I=#&=0\.7\J?:-/DR1BRV"W8 MY@PV/Z.\'/&I\&K^R,WC%Y
M:W:-:LI>S44O=4FE4:Y=5S<CTLK7/R/CWP^>=5OK>7*4JO:DES7OYRAI\^K9
M_('@]6&U/^>AP4_\<W-_X[2V]E>:M?VNC:1:SZAJ%W<_9$M[6)I623/WI"H(
M6+G[R[G/!*BOUE\7?\$[9/"NJO%K7@+QYI*)C<MM#+>6IP/X60AL8Z9C!]ZZ
M[X>_!:R\&1PVW@GX=ZO<ZI"WFKJ-WH=TVH"3^]\\)7'OYGMCO7]6XCQ5X?Q.
M"Y\!CL!]8_DIUX<VNJN^6,=5UY[/N?C.%X4S&;:Q&'Q%._\ -3GKK?5J_P#6
M]SG_ (2_#X?#7P-H_AJ0>9JGDG4]15)(Y$.J]00^Y6,/NR(W'^KKWGX?>!]9
M^)/C;PU\//#MM/<ZMX@F^RW4T".8]-T4#/VS4Y8UD^RH.H.R1L8('3'M_P ,
M_P!C+X]_$>_B\_PVO@309$%U-K6N,MO(;8C(ABC"W,IGQD[2BQ\$^;@''[)?
M ']G#P9\ ?#WV'P_;0WWB2^0/KOBJ[7?J6IRYR;5)6C+VMEZ>40XQS&2<K_,
M?&_BC@L#2S+%9?B:.8X^NVJ=/#MU6O=;YIMQA&*>B2YN:3T2C[S7ZYPUPCBI
M5/8XF%2E0M\4TE&W]WWI:^=M#TGX5?#71?A/X(T'P-H,*?V;H]J$=V9O,GNL
M F4D("REBWS,0P 4[<YSZ;&5\K&-W?CGG)SG..,=/Q]*14+<;DR/3=@_3*_Y
M[5DZMJ\>FQ_(J!_[N<G\AQV.>_'X'^8J]6=>M+$U[U:TI.3D[2;<FFWKU>B;
MZ65M%8_8:5"&'H_5Z;O!:)I:;6T[:L76=4-G'Y5NRM.>=H(..<C)Z_A@9/&>
MU<996P^^X9Y1W))'U_O>O0>Q-2P(US<?:;@L[]U&"/7/.#[=/8\UT5K8[>H7
M\,Y/8<XZ]/<X)R>\FI8M8-O4#\.<]AVSSW'0\GL*V8D*L5.,\^N.WM3881[=
M_7V_GZ^G ]:LK&P?<2,8]\]![4 /1 OU_P _Y_2GT44 %%%% !1110 4444
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MUUX;(=<+^OX<X/Z]1GZUJPVJ]<#_ #TYP?UZC/UJU'"$ZX_#/]<=>Y].!ZT
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MK<JE:1B.TMX^,B 1\=,@8ZX!QGOC)'45=H **** "FMN_AQ^)/\ 0'_)IU%
M'(Z[J6C>&]*N]=UW5K'0M'TNW62ZU?5)_L.F65@V%\AS'=VD:Q1X7)F?*_+\
MK\5Y5\/OVC/@-\5]7NM ^&GQ7\!>,=?M6ADN='T#7K.:]>2T)WLJJYDEMV"J
MT;0I*VWD@ N1_/3_ ,'&?QD^)V@:9\ ?@SX>UGQ#X6^&_P 0-1\5ZAXOGTAK
MJWC\9ZE9J!9^%;G4;8*]J5.XI&6:/+-B0#&?YC?A1XU\5?"'XD^ _'OPPU^^
M\+^+-!\7>&K^SOM!N);:\:=\?;M*FL6N0FIVI_YY;I+@]&MUYH _T!?VK_\
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M2CE# ;B/?(G\[O\ P4+_ &1M)_;?_P""K/Q[^">F:A;Z!\:= _X)N> _B?\
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M5_VN_!GQ[\&:IX-\7ZW\5-<U#P=8>&]3^-7_  A4_P -Y/#\FJ?\(UJ_AO\
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M>H'I7UO++L_Z^9YY+1116X!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!'(H*DD=.3[__ %__ -59MU&S(%!&
M<=\XY)]JU'!92!U([U2F!XXZ8_KG\L\]Z .5O(QUQ^GY_E],#USFJ&F78TS4
M70L1:7O,F<'8W/(S@ CG/XG.,"NANH"_(P/K^O8]/3''!KGM0M(W$BD$*?\
M5$<,I[[O;CG!/?\   ]%5PV2H)4#(8;2K_[A#'/XXYKC/%MO/?>&?%&G6JM+
M>ZCX<OXK9(OOSW%SI[VT1@R1\HDQO)"L%.55L$"7P]JK&(6-VRB6$8A).,CG
M <G!SDYX5N/3;71E2S<((WV^6DP W0QXZ)@<G\AVYP* /\O;Q5I&K^&?&_CG
MPYXA_M)/$?ASQIXLTG6Y-2;R=3M+^/4/M9MKN"/S+=[N2/Y8TCN)0TF S*HW
M5C5^NG_!9_\ 8VUW]E_]I[Q)\9=/M=7O/@U^T#XH;Q'9:RUKYND>%_B-,2+O
M19[J-<QF4<I)-_HQ!P\R$E1^1195VEG51)_J2[",S_\ 7))-DA_X&B4 +12!
ME;.T[L>@;GZ9 _7%+0 444_8?4?K_A0 RBG[#ZC]?\*8-IW[G5"G57)!_# (
M/YB@ 19IIK.UM;>XO;W4)TM;"QM(S+=7EU+_ *BWMX\@/-<?\L5W#=W*U_6?
M_P $3O\ @F5XS^#U_>?M9?M#>&[WPQ\1=5LIM#^'OP\U VYE\-^'KY=U_P"(
M/$H<!+C4G)5;7[--,2I9S*FS:_X&?\$T_@WJGQU_;E_9[T"#3+G4- \)>,].
M\?>,Q:PPWEK8>&-(_P"/*6_VNY121^^CEC50,E6(YK_1!C@A,VX1@.J^4C%%
M94M3UM53(41<=E] 1P, &@B!?K_G_/Z4^BB@ HHHH *0D#K2UGWEPD$+7$TJ
M1Q #YB?O<9P@[G@X'&<9R: ,W7-2^QV9 =5FF.(U7ED&,_.N,@ #D@,?3M7+
M:=&Q?S#@MCC=DG/KT.>/9>I&>U-DN7U&\>[GB4Q?\L8\_,O&.0W XZD,<_RV
M=/M67KM_X"3G\3@'GCIUH T[5 O4?D,Y[#WY[CH>3V%:D"'GD=_7V]JBA1=N
M_'')QW_R?7/L,=:N1*5!)QW_ *4 2("J@'J!VIU%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4QT#?7_/^?TI]% &5(4?
MH#^/_P!8GIV/IP?6L6Z@WKN&!['KS^!Z=AZXKJ/)'M^9K,D17CVC@^_3'<=S
M_P#7Y- '#W,.R7[0NY)O]GA?\>,\' ]!DYKL-'UB.['V6Y<1W@&?*;"D@>G)
MYZ<=^V>:H7EJOH#V'7//4@X]SSC(/.017/75F=_VF%FCF'_+;)\P?@N1GW#<
M9P<<"@#.^-OP+^&_[0GPYU_X5_%;POIOBKP=XETU].U"SU"-)9+7<#B\TR22
M%WLK]3C;>PO%, %7<RY5OY2/VGO^#>_XT^$]8UG7?V4_&ND>.O!: '3?A]XT
MU"*#Q+ >21#K#VDL1&>A-RK'J5&<#^NK3-?##R-2D\J?N[?ZOMW+!CR/[O3/
M-;JP!U5VD,B(,K$QA:,D=-[K;"0J?H>V.M '^?%??\$G?^"DNDZ==ZEJW[+E
M];0:%:_:M42R\7Z!>3&/NEDEO?,NHRCNMB\ZCL]? ^J6.HZ#KFJ>&/$>F:CX
M;\3:++Y6K^'=>M)-,UG36_Z?+&X"RP ^K@?2O]1:.Q5 C0NT:1QB."%5A6*V
M0+L'V51 PA.  01(-HVC KX _:M_X)A?LH?M@RR:U\4/A_967CB:3S)?'GAA
MSI'B2<@#:-4NH(D&MCC&+M8=HQ@G:0P!_GN[UV@EHQGL9H..G5A(4[]F/YU6
M%U$3,/.C/V;_ (^G1TFAM?\ KYN83);0_P# YA7]D-G_ ,&X'[(UIJ]Q?GXM
M?'^?3Y,^5HLOBK3/LJ=^9O[),O7&<+[CGBOTD^$W_!,K]BCX-^ M:^''A;X%
M>#+[PYXF)/B,>)M.CU[4-4R, '4+O%Q; 'D?9V0G !)% '^=XES%(D<L=Q$\
M3_\ +0':$_WD=4F_[YC;\J[;X6_#?XG?'3QAI/@'X*^"-:^(7C'Q'>FSL++2
M+*::VB];K4KYE%MIEKWWWLD$G3,7%?WMWW_!(G_@GOJ&HV6IW'[.7A);FPP8
MC#<:G'%.<<BZ@6Y\MAG^[C(R>#7UY\*_V>/@U\$;.ZL/A3\,_!?@6WO5$5W)
MX=T>#3]0O(L89KS5(XVO+AR26"[HP#CY\J& !^??_!*__@F[HO["WPUO-7\7
MS6?B/X_?$BU34OB%KUO#$J:/'U'AK0I%52=.0[""T=LS.&3:#&V?UM5 K$\?
MU_P_QZU!]G<;P#&%8F3$:M TDN2<2R*7.P\9*KO[<@;6MT %%%% !3-X]#^G
M^-*S! 6()QV R?Z5FWE_:V(S/* ?[BD%OR8J!^)&.] %NXNX;6$SSMY<0QEF
MP.O08)S7GM_J,NK2JVPK!"<Q6[GY6..LFW/7'.T$# '' J*[N;K6)MUPVV #
MBW0DK]"..!@G/)SU()J_:V@7J/RZ\=.<9STSQGN3SR 6+"U#Q#  Y_BX[$]A
M[8]L]QTZ"U0+U'Y#.>P]^>XZ'D]A44$&U-J\'UYQC(]!GGWR36I"B^GK_3^?
MKZ<#UH ;"A\O;QD ^N.@]OZ5:4$#!]?\*9&A3.2._3/MZ@>E2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form424b5_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &S D # 2(  A$! Q$!_\0
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M\\?_ !T_XT>3#_SQ_P#'3_C5BB@"OY,/_/'_ ,=/^-'DP_\ /'_QT_XU8HH
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MT\*>+N/$RCP/K!T$ZKK"*F-%>0H6,9+.N2V<[%;Y:^.G_!2CQK\/?B-\9O\
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M+GQ7:ZA\+OAKX&T2[;P3XYUOP9C5]"T--"UIO[:\/,AD09;<JD,^5V$#)KH
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M_P 50!LT5C?V/:?\\I__  (;_P"*H_L>T_YY3_\ @0W_ ,50!LT5C?V/:?\
M/*?_ ,"&_P#BJ/['M/\ GE/_ .!#?_%4 ;-%8W]CVG_/*?\ \"&_^*H_L>T_
MYY3_ /@0W_Q5 &S16-_8]I_SRG_\"&_^*H_L>T_YY3_^!#?_ !5 &S16-_8]
MI_SRG_\  AO_ (JC^Q[3_GE/_P"!#?\ Q5 &S16-_8]I_P \I_\ P(;_ .*H
M_L>T_P">4_\ X$-_\50!LT5C?V/:?\\I_P#P(;_XJC^Q[3_GE/\ ^!#?_%4
M;-%8W]CVG_/*?_P(;_XJC^Q[3_GE/_X$-_\ %4 ;-%8W]CVG_/*?_P "&_\
MBJ/['M/^>4__ ($-_P#%4 ;-%8W]CVG_ #RG_P# AO\ XJC^Q[3_ )Y3_P#@
M0W_Q5 &S16-_8]I_SRG_ / AO_BJ/['M/^>4_P#X$-_\50!LT5C?V/:?\\I_
M_ AO_BJ/['M/^>4__@0W_P 50!LT5C?V/:?\\I__  (;_P"*H_L>T_YY3_\
M@0W_ ,50!LT5C?V/:?\ /*?_ ,"&_P#BJ/['M/\ GE/_ .!#?_%4 ;-%8W]C
MVG_/*?\ \"&_^*H_L>T_YY3_ /@0W_Q5 &S16-_8]I_SRG_\"&_^*H_L>T_Y
MY3_^!#?_ !5 &S16-_8]I_SRG_\  AO_ (JC^Q[3_GE/_P"!#?\ Q5 &S16-
M_8]I_P \I_\ P(;_ .*H_L>T_P">4_\ X$-_\50!LT5C?V/9?WKG_P "F_\
MBJ(M'LX9/.4W&[/4W3$?3J#^M &S1110 4444 %%%% !1110 4444 %%%% !
M1110!7HJQ10!7\CW_7_ZU+##Y7^>G^>>]3T4 ?GM^R]_R=7^W?\ ]C[X _\
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M+1V^?ZQZ'LYC_OF9MJS<VVKWL_>NKK1V[K1[HN4444S **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N<U*?58-/OI]+MUU'4+:S/V.TNC_9Z
MWVH@$\L54*"H'4;03A<X#5T=% 'Y9_L(ZO\ $#7?CC^V_J?Q5\%:;\-_'/\
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M<A"EL@@[CDC/!.0?HG2/CY\&/$&J66A:'\4_ASK.L:F!]ATO2O&&C:EJ-_\
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M7@7PUX3T#Q5XN\8>'/#FCZWI.G7MKJVKZOI6FZ=?&?2DF<I)(5#("2Q"EE7
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M#^G^->.^)?CG\'O!^JG1/%'Q,\!>&]9MU^V7>E:QXETC3=148X+1LRG(/#8
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M><'XE> HO#G_  G$WC#PT/"&TG_A*SK.CGPT!T_Y#08+G/&=_P"8YKE='_:
M^"6O:A8:1HOQ3^'.MZQJ?^BV6F6/B_1M0U"^(Z*$61I&/4E2NUB>,GBBPOJV
M*U^+2ZVZK=?\/:W4]MV+Z?J?\:?L3U'_ 'S7D7BGXP_"WP)?6^E>,OB)X+\*
M:C=6ANK2T\0>(M&TO42,X9@LC+\OJPW;A]TD8K1\-_$_P#XVM;^^\'>-O#OB
MN#3#B[NO#^KZ-J?V#O\ ,4W*H'J<@GC).!4NNGUMZ6_S8_J^)[O_ ,!_^U[Z
M>IZ;A?[W_CIHPO\ >_\ '37@/_#2WP"AD\F?XP_# 7%L?LA!\8Z,2.F1G=QT
MY ^7KV-=OKWQ*\#>#](@USQ3XP\.>'- N,?9-6UC6-)TW3+\L/X'? (('(4\
M="0<55@^K8K^]Y:;^G]7^X]%HKQKPY\;_A+XPU2'1/"OQ+\!>(M8G!(TKP_X
MET74]188)X1'+-CT*JQ. O:CQ%\=/@YX0U2XT/Q3\2_ ?AO7K90;O2M8\2Z/
MIVIV((S\R.0X/LR@CN0<@.W]:!]6Q-[>]?M9][7VVOI?;SU/9\+_ 'O_ !TT
M87^]_P".FO-],^(_@;7M!F\8:)XQ\-ZUX:M%/VOQ!I&LZ1J&DV(  ).L*Q0C
MYAR23R,&N2TW]HSX%:G>VVEZ3\8/AQJ&H78S9V=MXPT0F]_[Y8C(]B?QHL+Z
MMB?[W;;KV_%/T=]CW'8OI^I_QI^Q/4?]\UYAXJ^+GPV\!RVT'C;Q]X3\)W%W
MD6=KXB\0Z-I;7AQC.V1E)''7&.^"*?X5^*OP[\>?;_\ A"/'OASQ6=,/^F#P
M]K&CZG]@/N8]P''&22.G/(J773ZV]+?YL?L,3W?_ (#I]]K=?TW/3<+_ 'O_
M !TT87^]_P".FO"+S]I#X$Z;=7-C??&'X<6US:,+6]M+CQAHJ_8F'&""V#GH
M=QPV!D\5U^I?$CP#H_AV'QCJ?C'PWIOAF[0?9/$5]K6E:?I-]GH1JY94P<'.
MUE/'.<U5A?5L5I\6KLM.O;\/NUV/0PF"#GI[?_7JT1D$>M?!OQ!_:Y\*VGQ-
M^!/@'X:>-O 7C4_$;QCJ6A^)+32O$VBZEJ-GI:J&WJ@=]GS,5)(5R4Y!4*Q^
M\$("DGIG_"AMMZ[F#P[PRUOU_K_(?1112&%%%% !1110 4444 %%%% !1110
M 57\_P!OT_\ KU8KX*_;H_:0\9?LX?##P@OPTT/3_$?QA^,?Q5\+?!CX667B
M%S_PC5AXG\<2-Y>O:X5"_P#%/>& NYU)QC",I!.0#[M\_P!OT_\ KT>;#Z_J
M?\:_,O\ 9(_:(^..I_&GXR_LA_M/WOA/7/C!\)M)\+>-=(^(?@:U_LKPUX[\
M!^-]SY_L0<Z#XA\+,JHZ\AE;/ 5@WP;^U]_P4O\ C[\'_P!H#XW^%?"WB+X)
M^ =(_9XNO /_  CWP'\?R/\ \+<_:Q/CK52A;P#EP84P %,.PY;>1EG>@#^B
M;S8?7]3_ (T>?[?I_P#7K\+?C1^VK^UWJGC']I#QA\!-)^&^C?!_]B3PWX5U
MOXJ>%/'%EK&I>)_BWJVM^"QX]\<^#=$(V_\ "/-X1\.@$$8PP! ! K]3?"O[
M0OPRUCX2?#'XP^(_%'AWP%X9^)WA'PKXFT?_ (2K5M'TOCQ!HHUT:.K2,%?R
MXV!<JQ)(;:N\[* /"?V6?^3I?V[O^Q]^&'_J$M7Z!U^9O[&GC'PKXR_:%_;G
M\1^#_%.B^*_"]YX[^%_V37M!UA=4TWGP224;6U8JQ'((1F!P<$C!K]*/M=G_
M ,]X?^^EH \Y^*"P2?#?QM;R_P"HN/ _BK=Z;?['E^O9_P#]5?F'_P $8M,L
MM2_X)R_#C0]4M[;4=/N?$7QAL[K3+OYA?::?B?XC&"N1D 'G. =V 00"/U&\
M9VYUCPEXGTRSFMKBYU/P]K%E9VWKJ#:3)L7([8V-CJOMS7\U/[,'[</QA_X)
MP_LR^'OA;^T+^PS\=[3PSX"^)'B;1?$7Q9LCHP\-X\<^.-<?1-8R5.%D_MI5
MD &2G (8AAZ&'PSQF3YGA,)J^:+:NM+*HF]=_B6VK=M#P\1B%@\U6+Q>D5%I
M;Z>6EGTT>C1_01KO[,/P-\2_"(_ S4_ASH=Q\*=JK_PA15O[+P"3C&X#@D_3
M..1Q7CW@3_@G-^QO\,/%OA_Q_P" ?@7X1\.>,/"]X;WP[JME=:N'T_4CP&7=
M*0 IQU4@XQMK[&T;7;'6='TG5K>4"'4])TG5K4W&,E-:4R1[N!@@-MQ_M8SB
MML7,(()N+?CN1Q_6O(^KKNM.CU=O)V_1V/HL/F6,6%LLTE9MMM2LKNUVUU;L
MKO1OY7/D7XR?L._LP?M%>+;?QQ\7_A!H7C;Q39V)T6UU36+K5W9=,ZA?DD4
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M^#_A#P#KNO69M-6U?1[';J5^O(PQ+,#V.05Z#J,FOJ/[7 O2>WQ]>GYBD%Y
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M_@\7%K>&_4_:M8Q_:&1AS^].1_M#;V^7KG]$O-C_ .>T7_?2_P#Q=0_:HO\
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M_@O/_L^R_P"?>W_(_P"--_LRR_Y\+?\ (?\ Q-:5%<YZ1F_V99?\^%O^0_\
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MX[#1G6I=>,D<;+*I&0@8HH8\R.5V_JAS%%W./P./\<"N@">BBJ_G^WZ?_7H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.GZ=8KXZ^%Y%KI-BNGZ?N'@@_-A0%+G.,* #D@ "OT+\F'_GC_XZ?\: ,_\
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M/_GJ/\_C1_:=G_SU'^?QJ_Y4/I^A_P *3RQ_=@_6@"A_:]E_SW_G2_VG9_\
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MUW=].G+L1C,3=8M)/RVOT]?ZL:%%%%8'IA1110 4444 %%%% !1110 4444
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M.<$L223\Q)YK]0O[3F_Y\+C\A0!L45B_VC+_ - _4/\ /XT?VC+_ - _4/\
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M*&S_ -IO_@EQ^R?^U#I7A\^(_ 7A+1O&.F?$GP-\3]8\;:5X=C_M7Q7JF@N
MXUS;A2OB7.U^2PV@9=Z_46BJ _)CXY_\$T=*^*7Q&\<^(? WQA\6_"#X=?'7
M1?"WA?\ :/\ A5X6MHETOXF>'/ L8T+0DT<I\WAN0^&3_P (V^R$J(SO0$X2
MOTQ\(^%] \$^'?#W@[P]8KINA^%]'TS0-&L\[A9:9HB#1]%C7(7=F./(R!D#
MD#H>VHH _/W]EW_DZO\ ;P_['SX8?^H4U??7D>_Z_P#UJ^!?V7?^3J_V\/\
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MH\CW_7_ZU6** *_D>_Z__6H\CW_7_P"M5BB@"OY'O^O_ -:CR/?]?_K58HH
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M#U5B#C(!^7(((- 'P_\ LL_\G4_MW_\ 8]_#+_U"7K] Z_*[]A#X;>%O@_\
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M_8]_#+_U"7K] Z_/[]E[_DZ;]NW_ +'WX7?^H6U?H#0 4444 %%%% !1110
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M^"M/_2/GX?\ _AX%_P */^&L?^"M/_2/GX?_ /AX%_PKN^H8C^>G_P"#H?\
MR9S?VCA?/_P%_P"1^M'_  @7@+_H1O"?_A.:)_\ &ZF_X0'P3_T)'A/_ ,)K
M1O\ XW7Y#_\ #6W_  5I_P"D>WP]_P##OK_A1_PUM_P5I_Z1[?#W_P .^O\
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M_7[D%K72='N_!^IZI?;5)^2)0SOD@A5 +$\*,G!S[KXV_L86?B>X\':AX_\
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M=T7.X9QBOK#P=^SC\%?V=_V>-/\ B=^W7X/N&MK3Q[XJ\3? C]CL:R/$VEZ
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M7\5>(8?M/PW\"?ME_!SQ/\5+J[93I=AX$1O$"OK.N $_\4\K';)U )"DYXH
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M%% !1110 44S>/0_I_C3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#X3_X*#<_L[S_ /8^> __ $]&NI^/
M_P"S3HG[37PY\->#]9\;^/O 4.FG3-:&J?#W6?\ A&=3W!!\K, =J_+UVY&>
M 22*X?\ X*%WL&E_LTZMJ5Q%.;+3/%W@2^OC:68U!K/3$UI5=PF,D E02,A2
MR#D$&MC1OVZ?V8(='T@_\+-M>=(TSG^R-9)QM"C@I@$GJ-QXP=QSL#1OA:^,
MPF*6+P;:<=FNC::;ZK9];HX[X"?L!>%?@%X[A^(=E\8?CEXWU"WL6L?[(\<>
M+SJFF%2,$E0 2.>1N [ ^G/?%[_@G-X/^,_Q'\0_$S5/C=\>_"-[KRK]J\/>
M$_&;:=X<L21DC1D,8\O&" =S$]"H/!]E_P"&\/V7^/\ BYUMD],Z1K(Z=?X>
M*/\ AO#]E_G_ (N=;9'7&D:R>O3^'FN;ZKA+;+O:SWVO;TT_X&IT_P!MYM]=
M^O?VJ[VY;W5[<U[7MWU]=?,M^"/V6-!\#? G6/@7;?$;XDZEI6MC5E_X3?6/
M$3ZAXYL?[<(#[=;8#.TG ;;R3@'#$U\M>%?^"6/@?PIKWA_78?VA?VF-2GT&
M[-\;35?'I;3=0(&<:RBJ=_ /0AN.%/;Z9'[>'[,!Z?$VU_\ !1K7\]E._P"&
M[_V7S_S4ZV_'1]9'\UI/#Q=M=MM6]%?3;NQX7.LVP;;6:M<SYGLKMI*[[M\J
MO==#*_:6_8Y\._M-2>%[C4_B9\6? 0\,6AM+:T^'OB4^&S? @G_B=!58N<$
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M7BOP7X6\>>'=6\*>,=#TWQ+X6URS^Q:SH&O6RZCIFH:=SE&1CC:P.?O,V<'
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M^6  0&7:1@D'<":_4.LN>RMYI(9Y8+:>>U^:T-P #9Y &1U))& 3C=P.3UH
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M?]CS4O[ &LZ7HN-)^)&B:EJBZIKVMKH6B=!G+$AF)R<D$8R*_4N:;RO\]/\
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M]^SCK1T_4_"7CPZ*,_$[XI_V"2-?\.<<*N%'8#G'ZR?M?_\ !,G]F?\ :_\
M#GC\^*_ 'AS3?B1X\M-,L]9^)=L-5_M8?V*QV#*L$VJ 5'!9@ 2S$$MYSXI_
MX)S^*_"NM>'O$7[*_P :+;X%ZLWP?TOX%_$>VNO#:^)-+\5>%M"4 :UHV9-V
M@>(R=VTHI&,!L$;FYP/J;]ASQMXC^(7[)OP(\5>,O&6G>/O%VI^!-*;Q)XLM
M&&-1U0*0Q.6(&N@%01A?G!8@Y!;[,KYP_9J^ 'A;]F7X.>$?@MX/ENM2TCPQ
M9C[5JVJ,#J.NZIJLF[6=9=L\-(6R0%QMRA.5!;Z/KH **** "BBB@ K\M/\
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M_P"/]*L57BB Y/\ ^O\ SW/X"K% !1110 4444 %%%% !1110 4444 %%%%
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M'/6O._B1\5/A]\(?#%[XQ^)OB_1/!7A:T!-WK&OWBZ<B], $X)/! V@^^,T
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ML_I0 WRH?3]#_A5BH?WW^S^E34 %%%% !1110 4S8/4_I_A3Z* &;!ZG]/\
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M3#_9$\??\(P?%/@?6M2_L#P'I/PQNU/B_5]//B[P%H+-_8>C^-RLF/$*^&%
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M_"&Z=\(+#X7Z#K?]@CKGQ/\ \)&",Y/< ^]=]XP^/'[5WB/X2C]M#2?VIO\
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MJ=]X$T.9CX@TCP5+K\C0Z!XAE7R#;^)619(0)4C=E=DC_)8_\$U?VIM6M/\
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M-K>BZ[N&Y7W*!&R[5*;N<C;Z!\3O^"C_ .TS^S-K/[1_PF^.'@[X;^+?B?\
M#C]F35/VC_A9K_@"Y;_A&-0TOP_K9T+7-&\;JQ7_ (1TB0!Q)M(*@XR&5QG_
M +9__!-/19](_89^"/P#\$:W;?#;PS^U/J/Q/^+VO:1JVWQ*@_L0[O&FNZZ0
M'9RQ.XMM 0(HC5@[/Z1^U;_P3F\(>%_V//VQK/X >%?$GCWXZ_'#X5?\( /$
M'B+5V\1>*M1TIM97;HFBZRZJR8RVY" X*J#M)9* ,>P_;H_:U^"]W^RSXO\
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M7E?DY^WIIE[X;_:"_8:^.&K>>? O@3XQ'1/&!4YTW0QKBA=#UMSQ\VX,IZX
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M1XB\-_LR? '0_&7VC_A*-,^%7@2RU@774ZD-$4,3CG/0<=MHZ].@#Z:HHHH
M_/S]J']OKX5?LO\ Q,^#WP>U[2?$?B;QO\9/%VF>%]&M-*LB-,T,/@MK&O:R
MP^5<*OR\GCG'.[[[@[_C_2ORS_X*7^"-0UVV_9OO?"_A!M<U>T_:#\*W>KWF
ME:,NI:G9:8N=S\<@L2.I[9 &26_4JV^[^?\ ,5/_ #"+Y_HP+5%%%4 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
>"BBB@ HHHH **** "BBB@ JO_P M?\_WJ** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form424b5_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "? G # 2(  A$! Q$!_\0
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M\>7UX?[(.0="_P"$?_L/'/ /]MC(&%/((.3GN?\ A87BG_G_ +7_ ,!/_KT
M?2%%?-__  L+Q3_S_P!K_P" G_UZ/^%A>*?^?^U_\!/_ *] 'TA17S?_ ,+"
M\4_\_P#:_P#@)_\ 7H_X6%XI_P"?^U_\!/\ Z] 'T;O'H?T_QI]?&LWQ1\;?
M\+,MO#WVW33I-S\-M3\3_9?[(^8ZFOC/0M  )Y+ ;WQN) +$@9KNO^%A>*?^
M?^U_\!/_ *] 'TA17S?_ ,+"\4_\_P#:_P#@)_\ 7H_X6%XI_P"?^U_\!/\
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M +7_ ,!/_KT ?2%%?-__  L+Q3_S_P!K_P" G_UZ/^%A>*?^?^U_\!/_ *]
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M^P/C[_DGWQ!_[$/QW_Z9/$%<V)PWU6U]]+Z[.W?3KY"P^C7JW]VOF:_A4_\
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M9Z[_ "_KYC^LKNON]?/^OQ/T;F_Y+3IW_9'M5_\ 4S\/UZ/7G$W_ "6G3O\
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MT445^HGSP44S>/0_I_C3Z "BBB@#)O+VVL;6>]OIK>VLK>T^UW-W=,HL;54
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M>5_N_P#CQHRO]W_QXU\]_P 3N?2?_P"CC_\ E+AG_P"5'N?\2V^$W_1)2_\
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M"CX8^"M#T'PSXM_X5U)_PI71_BGX6'B7X5>#TE\&#7WPF$D"@']!?G^WZ?\
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M_P!)/HJ?1#ROP4P2XEXPMG_'CNN:4)2I\*--MQX9ER-QYW*TIJTG9)-ZQ?\
M)OC3XYXSQ,QKR?)W*EP3#7D=HRXGDKI5*L>9QY4M8TW>*WGKI'RKQ)_R7+X3
M_P#8H?%'_P!"\ U[?7BWB/\ Y+=\*/\ L4/BC_/P'7M-?W2?@H4444 %%%%
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M$WX?-_PD+:)XF\;_ !3_ &3_ !AXP\%[&\- [E)!_J"\CW_7_P"M1Y'O^O\
M]:@#^;3X1M^W1/\ &?X/ZY\1OA[^T'X"_9)_X1+]D[_A8_PS\.>.O&?C7XE:
M#\3DD\?C0]7_ +;U^1O%'B#]GI/$/]A>(_CCX8W?\+F$NO>&7\?1KX"\)>,X
M1]'_ +=W[4'[87P#^,?Q%NOAE_PD%Y\(/#'[,7COQM92Z/\ !T:EX8\"^/-#
M\%?$#75\;?%+QSXA\./X9\0>'!XAT;1 /"_A/QEX/\:;7('@CQD&-?MYY'O^
MO_UJRK[3;+5+.?3-5L[>_P!.NK0VE[IMW9B_T^[4@Y#*Z%2,<,)% '!P'4.
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MU/\ @F_/\7M2^%OQ6UKXJZY\8_%TWB#]IGXP:OX4\6?&[P#)\*O'.N> Y)-
M30-93P+]D\*'P/X9E<ZVGA3PN_A6(6\*1S-Y08N/TTJOY'O^O_UJL4 %%%%
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M7_P=^-__ )G:]JHH \5\S]H7_H%?!7_P=^-__F=H\S]H7_H%?!7_ ,'?C?\
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M&?&C:')\6-:\/Z#X'XT!) L4C^-]!E.P(1X2UH/A]VX 'T/YG[0O_0*^"O\
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M)XCX7\1>?;\"V'AW6,#'HV2#_0_6OY7PW[1_B[&?[GX%-^G%TG9_+A?U5O\
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MG[0O_0*^"O\ X._&_P#\SM'F?M"_] KX*_\ @[\;_P#S.U[510!XKYG[0O\
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M;U_2=5U;3QHTF@+K(<1RN"(AX@\/F5\F-1KOAZ3Y(W)0 Z[S/VA?^@5\%?\
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MS^$M6^%0T+^W571"B^)?$*QG7]%*_P#"+QR!R[$HISD ^O/,_:%_Z!7P5_\
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M:M9:GX ^+[^ OBG??!/X:^"/&&L:G\7/'7QX\/?M.:]\>/@9\3OBL=?\2?\
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MA\1]-^+UZOQ6^*H^*LOPU\=:)H7A](=GB===U[X;>.OBAX5\9"X/@;69!%X
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M C /J'6?^"4_@B\^)7QA^+<O[0GQ0A\<_$[5S>^$O$.JZ/X/U+4O >KCXS^
MOCQH*_VYKOAIS\0/#OA/Q+X&T3POX+\+>*]_@Z/P7M\#>6P?<OTQ^U#^Q?\
M#7]K/1M2L/BGXP\1P78^!'C_ .!5UJWAZ[TO2M0T'5?'>L^ O$$?Q,T1RL@\
M/?$/PIXB\#:%XG\%N@(1L 1\A:\._:8_8Q^+OQ9UW]CG6_ 7B+PC#XC_ &:=
M3T[3M8\0_$KQ#XQ\8:8=*+^ CK6L_P#""2: S?$+Q)'!X(#>#?%?_"8^#?&O
MA'QGK3SP^,UCE\6QM^?7P@_X)B?M&7GPX\/Z_P"*O"GP>\-ZC=W?AF\\8?LY
M^-?'GQ)U3PQ\==6T+6?BY_Q<S]H[QMX?9G7XC;?'6@MX(;PI'XQC"Z H9P61
M?!X!]J+_ ,$A/@SINI_$"YLOBEXCTZ;QYX2TT?;;GP?\--2\<^$_'6B>$? '
MAZ/XGZ!XWU[PY+XDT(>7\+=$9_"_F+X.+*/W2^9MC[#XA_\ !-/X+_&;P]K6
MA>/?B;XL\277CKQ%\7_&NM:]I7_"%Z;+KGBCXK^#_ WA_7M9T5-"T", >&?^
M$#T3Q';^&ERC2!GR\:BO M(_X)6^/M,L+W5=5^)6D>-_B=J]MXJ^'7B7XGW?
MB[XE^"/''BKX8:W^R7H7P&'@QO&VA'Q9)H"'XDZ#_P ).KQHZE2)LCQL#*..
M\!?\$POVC]#7X3/K/Q(^"D%_X._X1@:+XK\.W7C+3/$O[/6E^!OBAX@\=ZUH
MWPJT30O#7@_PO\0/$'Q<\/:SHGA;XT>+?%OA+P9%,-"#)X)=61J /L'PY_P3
M/^%ND>$?'/A'5?'UQ/J_Q-^$.J_!CQ'JWA7PC\-_ XU'2M<^)7B#XL:[K6C:
M'X>\- )XA#ZZ?FQ,FQ5D7E@4\W^%_P#P3G^ =O\ M%?$CQ5%^T'XM^(WQ$\,
M^._A?X_\1:#JDG@S4O%/A32]#^*'B/XL>!='\;ZY'X=/B;78W\0C6/#<+>*I
MFD_X0O10K)$R<^&W/_!)CQ]IWB']FB3P3XUA\+Z/\+OA9X%\+^/?[!^)7Q&\
M.:GH'QCT+7QK7C3]H3P1K:>'_&!^('B#QM\WAGQ?X8\5_P#"( CP]X:CF:'P
M8#"/H#]A/]BG]H3]DSQ#XYUJ>/\ 9Z@?XCW_ ,"_#'CA_#&K?$G4=3\6^&OA
M5HOQ"T7QS\9-;&N^&H@_QF^*7B#7M%\2;%/_  AXCB832&3>[ &YH7_!+WP-
MX6\2>';CPC\9?BI8>";75=(\:>+_ (?7WAKX<Z_I/COQWX,T;X@^'O#^LZ_K
MGB'PNS'0!H?Q/UB*?PGY9\'^*ET57E1%)#>A^ /^">O@#P3^RI\2/V6=:^)?
MQ'\<^&?B+XB?Q1I^J6=[I7AW_A6NK*WA[6O R_!'0XXY/#'P^\.^$O$W@C1/
M$W@SPPJR>#H?&89L,&=1^G%% 'X__&#_ ()?ZW^T;I_A&#X[?M=?&#XCW7AG
M6M5<FZ\$?"#0?#+:0^N^!/$).A^#-"\,#PUX?^(:>(O!3>7\3 /^$PA7Q!XC
MBC\N(H%Z?Q#_ ,$R_ASJ47AF;PS\5/'_ (3\8?#J[\2Z_P##SQ3:Z5X/U-]
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MH&A2>-O"D8 \&,K,0&DD<@'Z"?\ "V_%?_1"/BO_ -\^#O\ YIJ/^%M^*_\
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MH+_GKX>_\)R#_P")JO\ BHE]'3^?BS_Q%5_\D/\ XE:\4O\ GUPM_P")2_\
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M>U4 >"?\+@\5_P#1"?BS^7@[_P":>C_A<'BO_HA/Q9_+P=_\T]>]T4 >"?\
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M3_A<'BO_ *(3\6?R\'?_ #3T?\+@\5_]$)^+/Y>#O_FGKWNB@#P3_A<'BO\
MZ(3\6?R\'?\ S3T?\+@\5_\ 1"?BS^7@[_YIZ][HH \$_P"%P>*_^B$_%G\O
M!W_S3T?\+@\5_P#1"?BS^7@[_P":>O>Z* /!/^%P>*_^B$_%G\O!W_S3T?\
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MFJTOB>3Q0WAWPE\2M=T9D7_A$1XNA@5/&$< B4&OH"+_ ()Q?L7Q:?X?T?\
MX4OI]QI'ACQ"^LZ1I=SXM\8W^G63J-"5O!L22^)'Q\.D;0="(^%TJGP*W]B1
MD>"W'#>JWG[)W[.$UI>Q3?"3PL;74=+\5:'?6RG4=FH:5XY^)>A_%CQ!H\Q$
MO">)OB3H>B>)I@NV0W$0V*(@0P!P7[/'[:WPL_:5^*_QI^$G@VQ\3Z?XG^"O
M]E7>L76J+HFH>&M<\,Z[K'B/0-$U[P3K_AWQ)XK\.:_N\0^!]90LK!D\M-OW
MF!^YZ^2O@I^R1^SW^SCXB\7^(/@W\.;7PEK_ (\8V7B2\M-5UC5 FF#6_$'B
M2'2=&37_ !%./#7AV+Q'XSU_Q)_PCOAIH8_M.ML5BR\2#ZUH ^:/'7'QF^%
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M -#\!U[57BOBC_DN7PG_ .Q3^*7_ *'X#KVJ@ HHHH **** /%7_ .3A]/\
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M9\2ZV? $FA?&;2/'2>%?%L>M^)/"+>#M=$4;^$C),OB!I5#-YNWXS^'?B_\
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M^'/B\^'?#OPK&@ZX_@7Q2/&?B^9%90Z12>+O&B+^WE% !1110 4444 %%%%
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M#Q;_ /@HUO\ ^9ZO=** /"_^&@_@]_T/%O\ ^"C6_P#YGJ/^&@_@]_T/%O\
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MZ)_C7S'_ !!/PF_Z-OP3_P"(OPU_\J/?_P"(@\;_ /17\7?^)17_ ,C\_?\
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M .M>K_\ #0?P>_Z'BW_\%&M__,]7NE% 'A?_  T'\'O^AXM__!1K?_S/4?\
M#0?P>_Z'BW_\%&M__,]7NE% 'A?_  T'\'O^AXM__!1K?_S/4?\ #0?P>_Z'
MBW_\%&M__,]7NE% 'QK-\</A=_PNS3];_P"$L0Z/_P *LU6R^V?V+K>/[2_X
M330,#_D7L[L=6W?1>P]6_P"&@_@]_P!#Q;_^"C6__F>KW2B@#PO_ (:#^#W_
M $/%O_X*-;_^9ZC_ (:#^#W_ $/%O_X*-;_^9ZO=** /"_\ A?OP9BX/C*T'
M_<%UO_V70/\ ./:C_AH/X/?]#Q;_ /@HUO\ ^9ZO=** /"_^&@_@]_T/%O\
M^"C6_P#YGJ/^&@_@]_T/%O\ ^"C6_P#YGJ]THH \,_X:#^#'_0\6W_@FUK_Y
M14G_  T'\'O^AXM__!1K?_S/5[I10!X7_P -!_![_H>+?_P4:W_\SU'_  T'
M\'O^AXM__!1K?_S/5[I10!X7_P -!_![_H>+?_P4:W_\SU'_  T'\'O^AXM_
M_!1K?_S/5[I10!X7_P -!_![_H>+?_P4:W_\SU'_  T'\'O^AXM__!1K?_S/
M5[I10!X7_P -!_![_H>+?_P4:W_\SU'_  T'\'O^AXM__!1K?_S/5[I10!X7
M_P -!_![_H>+?_P4:W_\SU'_  T'\'O^AXM__!1K?_S/5[I10!X7_P -!_![
M_H>+?_P4:W_\SU'_  T'\'O^AXM__!1K?_S/5[I10!X7_P -!_![_H>+?_P4
M:W_\SU'_  T'\'O^AXM__!1K?_S/5[I10!X7_P -!_![_H>+?_P4:W_\SU'_
M  T'\'O^AXM__!1K?_S/5[I10!X7_P -!_![_H>+?_P4:W_\SU==X1^(WA#Q
EX]_#X7UV#6CIA O/L=IJM@(RW (:502,X' +$D #O7HU% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
